text,title,id,project_number,terms,administration,organization,mechanism,year,award_amount,cong_dist,score
"Predictive Modeling with Clinical and Genomic Data in COPD    DESCRIPTION (provided by applicant):  Candidate: Dr. Peter Castaldi is a physician completing a period of F32-funded support. On July 1st, 2009 he will begin a full-time position at Tufts Medical Center and the Institute for Clinical Research and Health Policy Studies (ICRHPS). This position involves a 25% clinical commitment. His principal research interests are the genetic epidemiology of COPD and the translation of genomic discoveries into clinical practice and public health. His particular interests are genetic meta-analysis, gene-environment interaction, and predictive modeling with regression-based and machine-learning methods.  His immediate goals are 1.) to identify novel genetic associations with COPD susceptibility and COPD- related phenotypes through the combined analysis of multiple genome-wide association (GWA) studies, 2.) to identify epistatic and gene-by-smoking interactions, and 3.) to develop accurate predictive models in chronic obstructive pulmonary disease (COPD) using clinical and genomic information. His long-term goal is to be an independent investigator with expertise in bioinformatics. His vision for achieving this goal involves developing expertise in bioinformatics so as to be able to participate in and eventually lead multidisciplinary teams in the application of computational methods to genomic datasets in order to answer important clinical questions that will improve the care of patients and population health. Environment: Dr. Castaldi will receive training in a rich, interdisciplinary environment. His principal mentor, Dr. Joseph Lau, is the head of the Center for Clinical Evidence Synthesis in the ICRHPS, and he is a worldwide leader in the field of meta-analysis and evidence synthesis. At Tufts, in addition to regular meetings with Dr. Lau, Peter will receive training in genetic evidence synthesis from leaders in the field, including Drs. John Ioannidis and Tom Trikalinos. The co-mentor of this application, Dr. Edwin Silverman, is a leading researcher in COPD genetics at the Channing Laboratory. At the Channing Laboratory, Peter will receive excellent training in respiratory genetics and genetic epidemiology, and he will have resources to state of the art high-throughput genotyping, next-generation sequencing technologies, and bioinformatics support. Dr. Castaldi will also continue his collaboration with Dr. Donna Slonim in the Tufts Computer Science Department, who will provide assistance with application of computational algorithms to genomic data and guidance as Dr. Castaldi continues to build a practical and theoretical foundation in Bioinformatics. Research: COPD is a major cause of morbidity and mortality that is of increasing public health importance. While the principal risk factor for COPD, smoking, is well-established, there is variable susceptibility in the general population to the lung damage caused by cigarette smoke. There is strong evidence supporting a genetic component to COPD susceptibility. Understanding how genes and environment interact to produce clinical COPD will allow for more accurate diagnostic tools and open new avenues of investigation for the development of COPD therapies. We propose to 1.) identify novel genetic associations with COPD susceptibility and 4 COPD-related phenotypes by performing meta-analysis on patient-level data from 4 large COPD GWA studies, 2.) identify gene-by-smoking and gene-gene interactions, and 3.) develop predictive models for COPD susceptibility and COPD-related phenotypes. In order to maximize the information obtained from genomic data, we will combine data from multiple studies (the National Emphysema Treatment Trial Genetics Ancillary Study, the Norway Case-Control Study, COPDGene, and ECLIPSE - total sample size=7,962) to increase power and employ regression-based and machine-learning methods to identify complex patterns of interaction in genotype data. Our study is designed to both explore and subsequently rigorously validate discovered main effect and interaction associations. Using predictive models, we will quantify the incremental predictive benefit of including genetic main effects and genetic interaction data to traditional clinical variables. Relevance: The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.      PUBLIC HEALTH RELEVANCE:  The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.           Project Narrative The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.",Predictive Modeling with Clinical and Genomic Data in COPD,7875053,K08HL102265,"['genetic epidemiology ', ' Genomics ', ' Clinical Research ', ' Clinical Study ', ' Meta-Analysis ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' treatment trial ', ' genome wide association study ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genetic variant ', ' predictive modeling ', ' computer based prediction ', ' design ', ' designing ', ' next generation ', ' Outcome ', ' Population ', ' multidisciplinary ', ' public health relevance ', ' clinical care ', ' patient population ', ' clinical practice ', ' population health ', ' Computational algorithm ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Bioinformatics ', ' Bio-Informatics ', ' Diabetes Mellitus ', ' diabetes ', ' Non-Insulin-Dependent Diabetes Mellitus ', ' type II DM ', ' type 2 DM ', ' maturity onset diabetes ', ' ketosis resistant diabetes ', ' adult onset diabetes ', ' Type II diabetes ', ' Type II Diabetes Mellitus ', ' Type 2 diabetes ', ' Type 2 Diabetes Mellitus ', ' T2DM ', ' T2D ', ' T2 DM ', ' Stable Diabetes Mellitus ', ' Slow-Onset Diabetes Mellitus ', ' Noninsulin Dependent Diabetes Mellitus ', ' Non-Insulin Dependent Diabetes ', ' NIDDM ', ' Maturity-Onset Diabetes Mellitus ', ' MODY ', ' Ketosis-Resistant Diabetes Mellitus ', ' Adult-Onset Diabetes Mellitus ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Disease susceptibility ', ' liability to disease ', ' disease/disorder proneness/risk ', ' Diathesis ', ' genetic association ', ' Environment ', ' Environmental Exposure ', ' Data Set ', ' Dataset ', ' Caring ', ' Data ', ' Disease Association ', ' Ancillary Study ', ' Validation ', ' Process ', ' Development ', ' developmental ', ' Foundations ', ' Future ', ' Pathway interactions ', ' pathway ', ' Affect ', ' Genes ', ' Epistatic Gene ', ' Genotype ', ' base ', ' Goals ', ' improved ', ' Head ', ' Health ', ' Health Policy ', ' healthcare policy ', ' health care policy ', ' Heart ', ' Hematological Disease ', ' blood disorder ', ' Hematological Disorder ', ' Hematologic Diseases ', ' Blood Diseases ', ' Hereditary Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Area ', ' Clinical ', ' Biological ', ' Link ', ' Institutes ', ' Predisposition ', ' Susceptibility ', ' prognostic ', ' Training ', ' Laboratories ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' insight ', ' Light ', ' Photoradiation ', ' Individual ', ' cigarette smoke ', ' smoke of cigarettes ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Sample Size ', ' Funding ', ' Mentors ', ' Methods ', ' Mission ', ' Morbidity - disease rate ', ' Morbidity ', ' Mortality Vital Statistics ', ' Mortality ', ' Persons ', ' Collaborations ', ' Norway ', ' Patients ', ' Phenotype ', ' Genetic ', ' Genetic Predisposition to Disease ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Physicians ', ' tool ', ' public health medicine (field) ', ' Public Health ', ' Pulmonary Emphysema ', ' Emphysema ', ' Diagnostic ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Risk Factors ', ' Sampling Studies ', ' Smoke ', ' Smoking ', ' Architecture ', ' Engineering / Architecture ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Life ', ' Arts ', ' Technology ', ' Testing ', ' Time ', ' Tobacco ', ' Training Programs ', ' Translating ', ' Translations ', ' Vision ', ' visual function ', ' Sight ', ' Investigation ', ' Work ', ' Frequencies (time pattern) ', ' Frequency ', ' Complex ', ' Pattern ', ' Techniques ', ' respiratory ', ' interest ', ' Biology ', ' Biomass ', ' meetings ', ' Medical center ', ' American ', ' gene environment interaction ', ' environment effect on gene ', ' gene interaction ', ' Performance ', ' success ', ' computer science ', ' cohort ', ' novel ', ' General Population ', ' General Public ', ' Prevention ', ' Case-Control Studies ', ' Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' Positioning Attribute ', ' Position ', ' Cause of Death ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' Relative (related person) ', ' Relative ', ' Pulmonary Function Test/Forced Expiratory Volume 1 ', ' PFT/FEV1 ', ' Forced Expiratory Volume in 1 Second ', ' Forced Expiratory Volume 1 Test ', ' FEV1%VC ', ' FEV1 ', ' African American ', ' black American ', ' Black or African American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' Modeling ', ' Sampling ', ' case control ', ' ']",NHLBI,TUFTS MEDICAL CENTER,K08,2010,128250,MA-07,0.4620681648984813
"Predictive Modeling with Clinical and Genomic Data in COPD    DESCRIPTION (provided by applicant):  Candidate: Dr. Peter Castaldi is a physician completing a period of F32-funded support. On July 1st, 2009 he will begin a full-time position at Tufts Medical Center and the Institute for Clinical Research and Health Policy Studies (ICRHPS). This position involves a 25% clinical commitment. His principal research interests are the genetic epidemiology of COPD and the translation of genomic discoveries into clinical practice and public health. His particular interests are genetic meta-analysis, gene-environment interaction, and predictive modeling with regression-based and machine-learning methods.  His immediate goals are 1.) to identify novel genetic associations with COPD susceptibility and COPD- related phenotypes through the combined analysis of multiple genome-wide association (GWA) studies, 2.) to identify epistatic and gene-by-smoking interactions, and 3.) to develop accurate predictive models in chronic obstructive pulmonary disease (COPD) using clinical and genomic information. His long-term goal is to be an independent investigator with expertise in bioinformatics. His vision for achieving this goal involves developing expertise in bioinformatics so as to be able to participate in and eventually lead multidisciplinary teams in the application of computational methods to genomic datasets in order to answer important clinical questions that will improve the care of patients and population health. Environment: Dr. Castaldi will receive training in a rich, interdisciplinary environment. His principal mentor, Dr. Joseph Lau, is the head of the Center for Clinical Evidence Synthesis in the ICRHPS, and he is a worldwide leader in the field of meta-analysis and evidence synthesis. At Tufts, in addition to regular meetings with Dr. Lau, Peter will receive training in genetic evidence synthesis from leaders in the field, including Drs. John Ioannidis and Tom Trikalinos. The co-mentor of this application, Dr. Edwin Silverman, is a leading researcher in COPD genetics at the Channing Laboratory. At the Channing Laboratory, Peter will receive excellent training in respiratory genetics and genetic epidemiology, and he will have resources to state of the art high-throughput genotyping, next-generation sequencing technologies, and bioinformatics support. Dr. Castaldi will also continue his collaboration with Dr. Donna Slonim in the Tufts Computer Science Department, who will provide assistance with application of computational algorithms to genomic data and guidance as Dr. Castaldi continues to build a practical and theoretical foundation in Bioinformatics. Research: COPD is a major cause of morbidity and mortality that is of increasing public health importance. While the principal risk factor for COPD, smoking, is well-established, there is variable susceptibility in the general population to the lung damage caused by cigarette smoke. There is strong evidence supporting a genetic component to COPD susceptibility. Understanding how genes and environment interact to produce clinical COPD will allow for more accurate diagnostic tools and open new avenues of investigation for the development of COPD therapies. We propose to 1.) identify novel genetic associations with COPD susceptibility and 4 COPD-related phenotypes by performing meta-analysis on patient-level data from 4 large COPD GWA studies, 2.) identify gene-by-smoking and gene-gene interactions, and 3.) develop predictive models for COPD susceptibility and COPD-related phenotypes. In order to maximize the information obtained from genomic data, we will combine data from multiple studies (the National Emphysema Treatment Trial Genetics Ancillary Study, the Norway Case-Control Study, COPDGene, and ECLIPSE - total sample size=7,962) to increase power and employ regression-based and machine-learning methods to identify complex patterns of interaction in genotype data. Our study is designed to both explore and subsequently rigorously validate discovered main effect and interaction associations. Using predictive models, we will quantify the incremental predictive benefit of including genetic main effects and genetic interaction data to traditional clinical variables. Relevance: The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.      PUBLIC HEALTH RELEVANCE:  The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.          Project Narrative  The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.    Relevance: The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.",Predictive Modeling with Clinical and Genomic Data in COPD,8063638,K08HL102265,"['respiratory ', ' multidisciplinary ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' clinical care ', ' Vision ', ' visual function ', ' Sight ', ' Environmental Exposure ', ' genetic association ', ' Genotype ', ' Smoking ', ' next generation ', ' Head ', ' Bioinformatics ', ' Bio-Informatics ', ' Institutes ', ' case control ', ' Sample Size ', ' Non-Insulin-Dependent Diabetes Mellitus ', ' type II DM ', ' type 2 DM ', ' maturity onset diabetes ', ' ketosis resistant diabetes ', ' adult onset diabetes ', ' Type II diabetes ', ' Type II Diabetes Mellitus ', ' Type 2 diabetes ', ' Type 2 Diabetes Mellitus ', ' T2DM ', ' T2D ', ' T2 DM ', ' Stable Diabetes Mellitus ', ' Slow-Onset Diabetes Mellitus ', ' Noninsulin Dependent Diabetes Mellitus ', ' Non-Insulin Dependent Diabetes ', ' NIDDM ', ' Maturity-Onset Diabetes Mellitus ', ' MODY ', ' Ketosis-Resistant Diabetes Mellitus ', ' Adult-Onset Diabetes Mellitus ', ' Lung diseases ', ' lung disorder ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Mission ', ' Translating ', ' Training Programs ', ' Smoke ', ' prognostic ', ' Cause of Death ', ' patient population ', ' Future ', ' Predisposition ', ' Susceptibility ', ' Caring ', ' Individual ', ' Medical center ', ' Training ', ' Translations ', ' Performance ', ' Validation ', ' Hereditary Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Life ', ' genetic variant ', ' Diabetes Mellitus ', ' diabetes ', ' Mortality Vital Statistics ', ' Mortality ', ' improved ', ' Population ', ' Data Set ', ' Dataset ', ' Prevention ', ' interest ', ' Heart Diseases ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Work ', ' Patients ', ' design ', ' designing ', ' Development ', ' developmental ', ' Pattern ', ' Morbidity - disease rate ', ' Morbidity ', ' General Population ', ' General Public ', ' insight ', ' American ', ' Investigation ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Relative (related person) ', ' Relative ', ' Mentors ', ' Environment ', ' Genomics ', ' Diagnostic ', ' clinical practice ', ' Risk Factors ', ' Case-Control Studies ', ' Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' Persons ', ' Time ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Genes ', ' Area ', ' Laboratories ', ' Modeling ', ' Frequencies (time pattern) ', ' Frequency ', ' Pulmonary Emphysema ', ' Emphysema ', ' Techniques ', ' Data ', ' public health medicine (field) ', ' Public Health ', ' cohort ', ' public health relevance ', ' success ', ' Affect ', ' Research ', ' genome wide association study ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' Link ', ' Outcome ', ' Architecture ', ' Engineering / Architecture ', ' Resources ', ' Research Resources ', ' Goals ', ' Positioning Attribute ', ' Position ', ' novel ', ' Pathway interactions ', ' pathway ', ' Clinical ', ' base ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Physicians ', ' Complex ', ' Technology ', ' Collaborations ', ' Sampling ', ' Testing ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Biology ', ' gene environment interaction ', ' environment effect on gene ', ' Genetic ', ' Phenotype ', ' tool ', ' Funding ', ' Foundations ', ' Clinical Research ', ' Clinical Study ', ' meetings ', ' Methods ', ' Health ', ' Biological ', ' Disease susceptibility ', ' liability to disease ', ' disease/disorder proneness/risk ', ' Diathesis ', ' Hematological Disease ', ' blood disorder ', ' Hematological Disorder ', ' Hematologic Diseases ', ' Blood Diseases ', ' cigarette smoke ', ' smoke of cigarettes ', ' treatment trial ', ' Computational algorithm ', ' computer algorithm ', ' Epistatic Gene ', ' computer science ', ' Biomass ', ' Norway ', ' population health ', ' Tobacco ', ' predictive modeling ', ' computer based prediction ', ' Genetic Predisposition to Disease ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' genetic epidemiology ', ' Pulmonary Function Test/Forced Expiratory Volume 1 ', ' PFT/FEV1 ', ' Forced Expiratory Volume in 1 Second ', ' Forced Expiratory Volume 1 Test ', ' FEV1%VC ', ' FEV1 ', ' Meta-Analysis ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Ancillary Study ', ' Disease Association ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Health Policy ', ' healthcare policy ', ' health care policy ', ' gene interaction ', ' ']",NHLBI,TUFTS MEDICAL CENTER,K08,2011,128250,MA-07,0.45027842128766965
"Predictive Modeling with Clinical and Genomic Data in COPD Candidate: Dr. Peter Castaldi is a physician completing a period of F32-funded support. On July 1st, 2009 he will begin a full-time position at Tufts Medical Center and the Institute for Clinical Research and Health Policy Studies (ICRHPS). This position involves a 25% clinical commitment. His principal research interests are the genetic epidemiology of COPD and the translation of genomic discoveries into clinical practice and public health. His particular interests are genetic meta-analysis, gene-environment interaction, and predictive modeling with regression-based and machine-learning methods.  His immediate goals are 1.) to identify novel genetic associations with COPD susceptibility and COPD- related phenotypes through the combined analysis of multiple genome-wide association (GWA) studies, 2.) to identify epistatic and gene-by-smoking interactions, and 3.) to develop accurate predictive models in chronic obstructive pulmonary disease (COPD) using clinical and genomic information. His long-term goal is to be an independent investigator with expertise in bioinformatics. His vision for achieving this goal involves developing expertise in bioinformatics so as to be able to participate in and eventually lead multidisciplinary teams in the application of computational methods to genomic datasets in order to answer important clinical questions that will improve the care of patients and population health.    Environment: Dr. Castaldi will receive training in a rich, interdisciplinary environment. His principal mentor, Dr. Joseph Lau, is the head of the Center for Clinical Evidence Synthesis in the ICRHPS, and he is a worldwide leader in the field of meta-analysis and evidence synthesis. At Tufts, in addition to regular meetings with Dr. Lau, Peter will receive training in genetic evidence synthesis from leaders in the field, including Drs. John Ioannidis and Tom Trikalinos. The co-mentor of this application, Dr. Edwin Silverman, is a leading researcher in COPD genetics at the Channing Laboratory. At the Channing Laboratory, Peter will receive excellent training in respiratory genetics and genetic epidemiology, and he will have resources to state of the art high-throughput genotyping, next-generation sequencing technologies, and bioinformatics support. Dr. Castaldi will also continue his collaboration with Dr. Donna Slonim in the Tufts Computer Science Department, who will provide assistance with application of computational algorithms to genomic data and guidance as Dr. Castaldi continues to build a practical and theoretical foundation in Bioinformatics.    Research: COPD is a major cause of morbidity and mortality that is of increasing public health importance. While the principal risk factor for COPD, smoking, is well-established, there is variable susceptibility in the general population to the lung damage caused by cigarette smoke. There is strong evidence supporting a genetic component to COPD susceptibility. Understanding how genes and environment interact to produce clinical COPD will allow for more accurate diagnostic tools and open new avenues of investigation for the development of COPD therapies. We propose to 1.) identify novel genetic associations with COPD susceptibility and 4 COPD-related phenotypes by performing meta-analysis on patient-level data from 4 large COPD GWA studies, 2.) identify gene-by-smoking and gene-gene interactions, and 3.) develop predictive models for COPD susceptibility and COPD-related phenotypes. In order to maximize the information obtained from genomic data, we will combine data from multiple studies (the National Emphysema Treatment Trial Genetics Ancillary Study, the Norway Case-Control Study, COPDGene, and ECLIPSE - total sample size=7,962) to increase power and employ regression-based and machine-learning methods to identify complex patterns of interaction in genotype data. Our study is designed to both explore and subsequently rigorously validate discovered main effect and interaction associations. Using predictive models, we will quantify the incremental predictive benefit of including genetic main effects and genetic interaction data to traditional clinical variables.    Relevance: The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. Project Narrative  The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.    Relevance: The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.",Predictive Modeling with Clinical and Genomic Data in COPD,8261100,K08HL102265,"['Affect ', ' Engineering / Architecture ', ' Architecture ', ' Biology ', ' Biomass ', ' Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' Case-Control Studies ', ' Cause of Death ', ' Clinical Study ', ' Clinical Research ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' type II DM ', ' type 2 DM ', ' maturity onset diabetes ', ' ketosis resistant diabetes ', ' adult onset diabetes ', ' Type II diabetes ', ' Type II Diabetes Mellitus ', ' Type 2 diabetes ', ' Type 2 Diabetes Mellitus ', ' T2DM ', ' T2D ', ' T2 DM ', ' Stable Diabetes Mellitus ', ' Slow-Onset Diabetes Mellitus ', ' Noninsulin Dependent Diabetes Mellitus ', ' Non-Insulin Dependent Diabetes ', ' NIDDM ', ' Maturity-Onset Diabetes Mellitus ', ' MODY ', ' Ketosis-Resistant Diabetes Mellitus ', ' Adult-Onset Diabetes Mellitus ', ' Non-Insulin-Dependent Diabetes Mellitus ', ' disease/disorder ', ' Disorder ', ' Disease ', ' liability to disease ', ' disease/disorder proneness/risk ', ' Diathesis ', ' Disease susceptibility ', ' Environment ', ' Environmental Exposure ', ' Foundations ', ' Future ', ' Genes ', ' Epistatic Gene ', ' Genotype ', ' Goals ', ' Head ', ' Health ', ' healthcare policy ', ' health care policy ', ' Health Policy ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' blood disorder ', ' Hematological Disorder ', ' Hematologic Diseases ', ' Blood Diseases ', ' Hematological Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Institutes ', ' Laboratories ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' lung disorder ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Lung diseases ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Chronic Obstructive Airway Disease ', ' Mentors ', ' Methods ', ' Mission ', ' Morbidity ', ' Morbidity - disease rate ', ' Mortality ', ' Mortality Vital Statistics ', ' Persons ', ' Norway ', ' Patients ', ' Phenotype ', ' Physicians ', ' Public Health ', ' public health medicine (field) ', ' Emphysema ', ' Pulmonary Emphysema ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Risk Factors ', ' Smoke ', ' Smoking ', ' Technology ', ' Testing ', ' Time ', ' Tobacco ', ' Training Programs ', ' Translating ', ' Translations ', ' visual function ', ' Sight ', ' Vision ', ' Work ', ' Relative ', ' Relative (related person) ', ' Dataset ', ' Data Set ', ' Caring ', ' base ', ' improved ', ' Area ', ' Clinical ', ' Biological ', ' Link ', ' Susceptibility ', ' Predisposition ', ' prognostic ', ' Training ', ' insight ', ' Individual ', ' smoke of cigarettes ', ' cigarette smoke ', ' Sample Size ', ' Funding ', ' Collaborations ', ' Genetic ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Genetic Predisposition to Disease ', ' tool ', ' Diagnostic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Life ', ' Investigation ', ' Frequency ', ' Frequencies (time pattern) ', ' Complex ', ' Pattern ', ' Techniques ', ' respiratory ', ' interest ', ' meetings ', ' Medical center ', ' American ', ' environment effect on gene ', ' gene environment interaction ', ' gene interaction ', ' Performance ', ' success ', ' computer science ', ' cohort ', ' novel ', ' General Public ', ' General Population ', ' Prevention ', ' Position ', ' Positioning Attribute ', ' Single Base Polymorphism ', ' Single Nucleotide Polymorphism ', ' PFT/FEV1 ', ' Forced Expiratory Volume in 1 Second ', ' Forced Expiratory Volume 1 Test ', ' FEV1%VC ', ' FEV1 ', ' Pulmonary Function Test/Forced Expiratory Volume 1 ', ' Modeling ', ' Sampling ', ' case control ', ' genetic epidemiology ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' Bio-Informatics ', ' Bioinformatics ', ' genetic association ', ' Data ', ' Disease Association ', ' Ancillary Study ', ' Validation ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' treatment trial ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' genetic variant ', ' computer based prediction ', ' predictive modeling ', ' designing ', ' design ', ' next generation ', ' Outcome ', ' Population ', ' multidisciplinary ', ' computer algorithm ', ' Computational algorithm ', ' clinical care ', ' patient population ', ' clinical practice ', ' population health ', ' ']",NHLBI,TUFTS MEDICAL CENTER,K08,2012,128250,MA-07,0.4620681648984813
"Predictive Modeling with Clinical and Genomic Data in COPD Candidate: Dr. Peter Castaldi is a physician completing a period of F32-funded support. On July 1st, 2009 he will begin a full-time position at Tufts Medical Center and the Institute for Clinical Research and Health Policy Studies (ICRHPS). This position involves a 25% clinical commitment. His principal research interests are the genetic epidemiology of COPD and the translation of genomic discoveries into clinical practice and public health. His particular interests are genetic meta-analysis, gene-environment interaction, and predictive modeling with regression-based and machine-learning methods.  His immediate goals are 1.) to identify novel genetic associations with COPD susceptibility and COPD- related phenotypes through the combined analysis of multiple genome-wide association (GWA) studies, 2.) to identify epistatic and gene-by-smoking interactions, and 3.) to develop accurate predictive models in chronic obstructive pulmonary disease (COPD) using clinical and genomic information. His long-term goal is to be an independent investigator with expertise in bioinformatics. His vision for achieving this goal involves developing expertise in bioinformatics so as to be able to participate in and eventually lead multidisciplinary teams in the application of computational methods to genomic datasets in order to answer important clinical questions that will improve the care of patients and population health.    Environment: Dr. Castaldi will receive training in a rich, interdisciplinary environment. His principal mentor, Dr. Joseph Lau, is the head of the Center for Clinical Evidence Synthesis in the ICRHPS, and he is a worldwide leader in the field of meta-analysis and evidence synthesis. At Tufts, in addition to regular meetings with Dr. Lau, Peter will receive training in genetic evidence synthesis from leaders in the field, including Drs. John Ioannidis and Tom Trikalinos. The co-mentor of this application, Dr. Edwin Silverman, is a leading researcher in COPD genetics at the Channing Laboratory. At the Channing Laboratory, Peter will receive excellent training in respiratory genetics and genetic epidemiology, and he will have resources to state of the art high-throughput genotyping, next-generation sequencing technologies, and bioinformatics support. Dr. Castaldi will also continue his collaboration with Dr. Donna Slonim in the Tufts Computer Science Department, who will provide assistance with application of computational algorithms to genomic data and guidance as Dr. Castaldi continues to build a practical and theoretical foundation in Bioinformatics.    Research: COPD is a major cause of morbidity and mortality that is of increasing public health importance. While the principal risk factor for COPD, smoking, is well-established, there is variable susceptibility in the general population to the lung damage caused by cigarette smoke. There is strong evidence supporting a genetic component to COPD susceptibility. Understanding how genes and environment interact to produce clinical COPD will allow for more accurate diagnostic tools and open new avenues of investigation for the development of COPD therapies. We propose to 1.) identify novel genetic associations with COPD susceptibility and 4 COPD-related phenotypes by performing meta-analysis on patient-level data from 4 large COPD GWA studies, 2.) identify gene-by-smoking and gene-gene interactions, and 3.) develop predictive models for COPD susceptibility and COPD-related phenotypes. In order to maximize the information obtained from genomic data, we will combine data from multiple studies (the National Emphysema Treatment Trial Genetics Ancillary Study, the Norway Case-Control Study, COPDGene, and ECLIPSE - total sample size=7,962) to increase power and employ regression-based and machine-learning methods to identify complex patterns of interaction in genotype data. Our study is designed to both explore and subsequently rigorously validate discovered main effect and interaction associations. Using predictive models, we will quantify the incremental predictive benefit of including genetic main effects and genetic interaction data to traditional clinical variables.    Relevance: The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. Project Narrative  The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.    Relevance: The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.",Predictive Modeling with Clinical and Genomic Data in COPD,8500430,K08HL102265,"['Affect ', ' Engineering / Architecture ', ' Architecture ', ' Biology ', ' Biomass ', ' Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' Case-Control Studies ', ' Cause of Death ', ' Clinical Study ', ' Clinical Research ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' type II DM ', ' type 2 DM ', ' maturity onset diabetes ', ' ketosis resistant diabetes ', ' adult onset diabetes ', ' Type II diabetes ', ' Type II Diabetes Mellitus ', ' Type 2 diabetes ', ' Type 2 Diabetes Mellitus ', ' T2DM ', ' T2D ', ' T2 DM ', ' Stable Diabetes Mellitus ', ' Slow-Onset Diabetes Mellitus ', ' Noninsulin Dependent Diabetes Mellitus ', ' Non-Insulin Dependent Diabetes ', ' NIDDM ', ' Maturity-Onset Diabetes Mellitus ', ' MODY ', ' Ketosis-Resistant Diabetes Mellitus ', ' Adult-Onset Diabetes Mellitus ', ' Non-Insulin-Dependent Diabetes Mellitus ', ' disease/disorder ', ' Disorder ', ' Disease ', ' liability to disease ', ' disease/disorder proneness/risk ', ' Diathesis ', ' Disease susceptibility ', ' Environment ', ' Environmental Exposure ', ' Foundations ', ' Future ', ' Genes ', ' Epistatic Gene ', ' Genotype ', ' Goals ', ' Head ', ' Health ', ' healthcare policy ', ' health care policy ', ' Health Policy ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' blood disorder ', ' Hematological Disorder ', ' Hematologic Diseases ', ' Blood Diseases ', ' Hematological Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Institutes ', ' Laboratories ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' lung disorder ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Lung diseases ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Chronic Obstructive Airway Disease ', ' Mentors ', ' Methods ', ' Mission ', ' Morbidity ', ' Morbidity - disease rate ', ' Mortality ', ' Mortality Vital Statistics ', ' Persons ', ' Norway ', ' Patients ', ' Phenotype ', ' Physicians ', ' Public Health ', ' public health medicine (field) ', ' Emphysema ', ' Pulmonary Emphysema ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Risk Factors ', ' Smoke ', ' Smoking ', ' Technology ', ' Testing ', ' Time ', ' Tobacco ', ' Training Programs ', ' Translating ', ' Translations ', ' visual function ', ' Sight ', ' Vision ', ' Work ', ' Relative ', ' Relative (related person) ', ' Dataset ', ' Data Set ', ' Caring ', ' base ', ' improved ', ' Area ', ' Clinical ', ' Biological ', ' Link ', ' Susceptibility ', ' Predisposition ', ' prognostic ', ' Training ', ' insight ', ' Individual ', ' smoke of cigarettes ', ' cigarette smoke ', ' Sample Size ', ' Funding ', ' Collaborations ', ' Genetic ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Genetic Predisposition to Disease ', ' tool ', ' Diagnostic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Life ', ' Investigation ', ' Frequency ', ' Frequencies (time pattern) ', ' Complex ', ' Pattern ', ' Techniques ', ' respiratory ', ' interest ', ' meetings ', ' Medical center ', ' American ', ' environment effect on gene ', ' gene environment interaction ', ' gene interaction ', ' Performance ', ' success ', ' computer science ', ' cohort ', ' novel ', ' General Public ', ' General Population ', ' Prevention ', ' Position ', ' Positioning Attribute ', ' Single Base Polymorphism ', ' Single Nucleotide Polymorphism ', ' PFT/FEV1 ', ' Forced Expiratory Volume in 1 Second ', ' Forced Expiratory Volume 1 Test ', ' FEV1%VC ', ' FEV1 ', ' Pulmonary Function Test/Forced Expiratory Volume 1 ', ' Modeling ', ' Sampling ', ' case control ', ' genetic epidemiology ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' Bio-Informatics ', ' Bioinformatics ', ' genetic association ', ' Data ', ' Disease Association ', ' Ancillary Study ', ' Validation ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' treatment trial ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' genetic variant ', ' computer based prediction ', ' predictive modeling ', ' designing ', ' design ', ' Outcome ', ' Population ', ' multidisciplinary ', ' computer algorithm ', ' Computational algorithm ', ' clinical care ', ' patient population ', ' clinical practice ', ' population health ', ' next generation sequencing ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K08,2013,128250,MA-07,0.4620681648984813
"Predictive Modeling with Clinical and Genomic Data in COPD Candidate: Dr. Peter Castaldi is a physician completing a period of F32-funded support. On July 1st, 2009 he will begin a full-time position at Tufts Medical Center and the Institute for Clinical Research and Health Policy Studies (ICRHPS). This position involves a 25% clinical commitment. His principal research interests are the genetic epidemiology of COPD and the translation of genomic discoveries into clinical practice and public health. His particular interests are genetic meta-analysis, gene-environment interaction, and predictive modeling with regression-based and machine-learning methods.  His immediate goals are 1.) to identify novel genetic associations with COPD susceptibility and COPD- related phenotypes through the combined analysis of multiple genome-wide association (GWA) studies, 2.) to identify epistatic and gene-by-smoking interactions, and 3.) to develop accurate predictive models in chronic obstructive pulmonary disease (COPD) using clinical and genomic information. His long-term goal is to be an independent investigator with expertise in bioinformatics. His vision for achieving this goal involves developing expertise in bioinformatics so as to be able to participate in and eventually lead multidisciplinary teams in the application of computational methods to genomic datasets in order to answer important clinical questions that will improve the care of patients and population health.    Environment: Dr. Castaldi will receive training in a rich, interdisciplinary environment. His principal mentor, Dr. Joseph Lau, is the head of the Center for Clinical Evidence Synthesis in the ICRHPS, and he is a worldwide leader in the field of meta-analysis and evidence synthesis. At Tufts, in addition to regular meetings with Dr. Lau, Peter will receive training in genetic evidence synthesis from leaders in the field, including Drs. John Ioannidis and Tom Trikalinos. The co-mentor of this application, Dr. Edwin Silverman, is a leading researcher in COPD genetics at the Channing Laboratory. At the Channing Laboratory, Peter will receive excellent training in respiratory genetics and genetic epidemiology, and he will have resources to state of the art high-throughput genotyping, next-generation sequencing technologies, and bioinformatics support. Dr. Castaldi will also continue his collaboration with Dr. Donna Slonim in the Tufts Computer Science Department, who will provide assistance with application of computational algorithms to genomic data and guidance as Dr. Castaldi continues to build a practical and theoretical foundation in Bioinformatics.    Research: COPD is a major cause of morbidity and mortality that is of increasing public health importance. While the principal risk factor for COPD, smoking, is well-established, there is variable susceptibility in the general population to the lung damage caused by cigarette smoke. There is strong evidence supporting a genetic component to COPD susceptibility. Understanding how genes and environment interact to produce clinical COPD will allow for more accurate diagnostic tools and open new avenues of investigation for the development of COPD therapies. We propose to 1.) identify novel genetic associations with COPD susceptibility and 4 COPD-related phenotypes by performing meta-analysis on patient-level data from 4 large COPD GWA studies, 2.) identify gene-by-smoking and gene-gene interactions, and 3.) develop predictive models for COPD susceptibility and COPD-related phenotypes. In order to maximize the information obtained from genomic data, we will combine data from multiple studies (the National Emphysema Treatment Trial Genetics Ancillary Study, the Norway Case-Control Study, COPDGene, and ECLIPSE - total sample size=7,962) to increase power and employ regression-based and machine-learning methods to identify complex patterns of interaction in genotype data. Our study is designed to both explore and subsequently rigorously validate discovered main effect and interaction associations. Using predictive models, we will quantify the incremental predictive benefit of including genetic main effects and genetic interaction data to traditional clinical variables.    Relevance: The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. Project Narrative  The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.    Relevance: The proposed work will identify new genes associated with COPD and place them in a multivariate context so as to develop a better understanding of how genetic differences and environmental exposures contribute to the development of COPD. The models generated by this work will facilitate the translation of genomic discoveries to clinical practice and public health, in keeping with the NHLBI's mission to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.",Predictive Modeling with Clinical and Genomic Data in COPD,8668035,K08HL102265,"['Affect ', ' Engineering / Architecture ', ' Architecture ', ' Biology ', ' Biomass ', ' Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' Case-Control Studies ', ' Cause of Death ', ' Clinical Study ', ' Clinical Research ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' type II DM ', ' type 2 DM ', ' maturity onset diabetes ', ' ketosis resistant diabetes ', ' adult onset diabetes ', ' Type II diabetes ', ' Type II Diabetes Mellitus ', ' Type 2 diabetes ', ' Type 2 Diabetes Mellitus ', ' T2DM ', ' T2D ', ' T2 DM ', ' Stable Diabetes Mellitus ', ' Slow-Onset Diabetes Mellitus ', ' Noninsulin Dependent Diabetes Mellitus ', ' Non-Insulin Dependent Diabetes ', ' NIDDM ', ' Maturity-Onset Diabetes Mellitus ', ' MODY ', ' Ketosis-Resistant Diabetes Mellitus ', ' Adult-Onset Diabetes Mellitus ', ' Non-Insulin-Dependent Diabetes Mellitus ', ' disease/disorder ', ' Disorder ', ' Disease ', ' liability to disease ', ' disease/disorder proneness/risk ', ' Diathesis ', ' Disease susceptibility ', ' Environment ', ' Environmental Exposure ', ' Foundations ', ' Future ', ' Genes ', ' Epistatic Gene ', ' Genotype ', ' Goals ', ' Head ', ' Health ', ' healthcare policy ', ' health care policy ', ' Health Policy ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' blood disorder ', ' Hematological Disorder ', ' Hematologic Diseases ', ' Blood Diseases ', ' Hematological Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Institutes ', ' Laboratories ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' lung disorder ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Lung diseases ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Chronic Obstructive Airway Disease ', ' Mentors ', ' Methods ', ' Mission ', ' Morbidity ', ' Morbidity - disease rate ', ' Mortality ', ' Mortality Vital Statistics ', ' Persons ', ' Norway ', ' Patients ', ' Phenotype ', ' Physicians ', ' Public Health ', ' public health medicine (field) ', ' Emphysema ', ' Pulmonary Emphysema ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Risk Factors ', ' Smoke ', ' Smoking ', ' Technology ', ' Testing ', ' Time ', ' Tobacco ', ' Training Programs ', ' Translating ', ' Translations ', ' visual function ', ' Sight ', ' Vision ', ' Work ', ' Relative ', ' Relative (related person) ', ' Dataset ', ' Data Set ', ' Caring ', ' base ', ' improved ', ' Area ', ' Clinical ', ' Biological ', ' Link ', ' Susceptibility ', ' Predisposition ', ' prognostic ', ' Training ', ' insight ', ' Individual ', ' smoke of cigarettes ', ' cigarette smoke ', ' Sample Size ', ' Funding ', ' Collaborations ', ' Genetic ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Genetic Predisposition to Disease ', ' tool ', ' Diagnostic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Life ', ' Investigation ', ' Frequency ', ' Frequencies (time pattern) ', ' Complex ', ' Pattern ', ' Techniques ', ' respiratory ', ' interest ', ' meetings ', ' Medical center ', ' American ', ' environment effect on gene ', ' gene environment interaction ', ' gene interaction ', ' Performance ', ' success ', ' computer science ', ' cohort ', ' novel ', ' General Public ', ' General Population ', ' Prevention ', ' Position ', ' Positioning Attribute ', ' Single Base Polymorphism ', ' Single Nucleotide Polymorphism ', ' PFT/FEV1 ', ' Forced Expiratory Volume in 1 Second ', ' Forced Expiratory Volume 1 Test ', ' FEV1%VC ', ' FEV1 ', ' Pulmonary Function Test/Forced Expiratory Volume 1 ', ' Modeling ', ' Sampling ', ' case control ', ' genetic epidemiology ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' Bio-Informatics ', ' Bioinformatics ', ' genetic association ', ' Data ', ' Disease Association ', ' Ancillary Study ', ' Validation ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' treatment trial ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' computer based prediction ', ' predictive modeling ', ' designing ', ' design ', ' Outcome ', ' Population ', ' multidisciplinary ', ' computer algorithm ', ' Computational algorithm ', ' clinical care ', ' patient population ', ' clinical practice ', ' population health ', ' next generation sequencing ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K08,2014,128250,MA-07,0.4620681648984813
"Autoimmunity as a Mechanism for Atherosclerosis in COPD     DESCRIPTION (provided by applicant): This project will facilitate the development of the principal investigator into an independent translational researcher investigating systemic vascular injury in Chronic obstructive pulmonary disease (COPD). This will be accomplished in the rich academic environment at the University of Pittsburgh, under the guidance of a highly accomplished team of mentors, and in the conduct of multidisciplinary research project that will develop autoimmunity as a novel mechanism for atherosclerosis in COPD. The increased risk of atherosclerosis in COPD is not explained by smoking, age, hypertension, and other established vascular disease risk factors. Chronic inflammation has recently been implicated as an atherogenic mechanism in COPD. We and others have reported that chronic inflammation in COPD may be propagated by humoral autoimmunity. Specifically, smokers with COPD have greatly increased levels of circulating autoantibodies that demonstrate in vitro pathogenic effects. Our subsequent studies also show that these autoantibodies target at least 50 different autoantigens and consistently target glucose regulated protein 78 (GRP78), particularly in patients with parenchymal lung destruction, i.e. emphysema. GRP78 is present in the endoplasmic reticulum, where it regulates the unfolded protein response, and is also a multifunction cell surface receptor. Studies in cancer patients suggest that ligation of the N-terminus of cell surface GRP78 by anti-GRP78 IgG transduces pro-inflammatory and pro-proliferative signals by activation of the AKT pathway, followed by NFB activation. Additional in vivo studies have identified anti-GRP78 IgG with affinity for the C-terminus of cell surface GRP78 that produce counteracting anti-inflammatory effects by suppressing AKT activation. Our preliminary work shows that circulating anti-GRP78 IgG in COPD patients binds to macrophages and leads to increased NFB activation and production of atherogenic inflammatory mediators by them. The macrophage is critical in the development of both atherosclerosis and COPD. Also, cross-sectional studies in our cohort find that levels of circulating anti-GRP78 IgG are strongly associated with carotid atherosclerosis in patients with emphysema, independent of established vascular risk factors. Therefore, we hypothesize that autoimmune responses against GRP78 are a mechanism for atherosclerosis in COPD. During this award, we will: (1) Test the hypothesis that elevated levels of circulating anti-GRP78 IgG predict progression of carotid atherosclerosis in patients with emphysema independent of established risk factors over 4 year follow up; (2) Test the hypothesis that anti-GRP78 IgG binds to the N-terminus of cell surface GRP78 and activates the AKT pathway followed by NFB activation and production of inflammatory mediators using a variety of cell function assays, and provide proof of concept for two potential therapeutic strategies; (3) Test the hypothesis that there are other antigen-specific immune responses associated with atherosclerosis in COPD by using machine learning to analyze high-throughput data on a large number of circulating autoantibody levels.         PUBLIC HEALTH RELEVANCE: Chronic obstructive pulmonary disease (COPD) is a lung disease caused by smoking that kills more and more Americans each year, and is now the third leading cause of death in the US. Although it is largely viewed as a disease of the lungs, the most common cause of death in patients with COPD are blockages in blood vessels. This research project will investigate why patients with COPD are so prone to develop these blood vessel blockages.            ",Autoimmunity as a Mechanism for Atherosclerosis in COPD,8860899,K23HL126912,"['Age ', ' Algorithms ', ' Antiinflammatory Agents ', ' Antiinflammatories ', ' Anti-Inflammatories ', ' Anti-Inflammatory Agents ', ' Antibodies ', ' immunogen ', ' ATGN ', ' Antigens ', ' atherosclerotic vascular disease ', ' atheromatosis ', ' Atherosclerotic Cardiovascular Disease ', ' Atheroscleroses ', ' Atherosclerosis ', ' self reactive antibody ', ' autoimmune antibody ', ' Autoantibodies ', ' Self-Antigens ', ' Autologous Antigens ', ' Autoantigens ', ' autoimmune disorder ', ' Autoimmune Diseases ', ' Autoimmune Responses ', ' self recognition (immune) ', ' Autoimmune Status ', ' Autoimmunity ', ' Award ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' vascular ', ' Blood Vessels ', ' protein blotting ', ' Western Immunoblotting ', ' Western Blotting ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cause of Death ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Disease Frequency Surveys ', ' Cross-Sectional Survey ', ' Cross-Sectional Analyses ', ' Cross Sectional Analysis ', ' Cross-Sectional Studies ', ' Ergastoplasm ', ' Endoplasmic Reticulum ', ' Environment ', ' ELISA ', ' Enzyme-Linked Immunosorbent Assay ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Flow Cytometry ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' hypertensive disease ', ' hyperpiesis ', ' hyperpiesia ', ' high blood pressure ', ' Vascular Hypertensive Disorder ', ' Vascular Hypertensive Disease ', ' Hypertension ', ' IgG ', ' 7S Gamma Globulin ', ' Immunoglobulin G ', ' In Vitro ', ' Inflammation ', ' Closure by Ligation ', ' Ligation ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' lung disorder ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Lung diseases ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Chronic Obstructive Airway Disease ', ' macrophage ', ' Mentors ', ' Mentorship ', ' Morbidity ', ' Morbidity - disease rate ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Patients ', ' Peptides ', ' Phenotype ', ' Protein Phosphorylation ', ' Phosphorylation ', ' Production ', ' gene product ', ' Proteins ', ' Emphysema ', ' Pulmonary Emphysema ', ' Cell Surface Receptors ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Risk ', ' Risk Factors ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Smoking ', ' Testing ', ' ultrasound scanning ', ' ultrasound imaging ', ' ultrasound ', ' sound measurement ', ' sonography ', ' sonogram ', ' diagnostic ultrasound ', ' Ultrasound Test ', ' Ultrasound Medical Imaging ', ' Ultrasound Diagnosis ', ' Ultrasonogram ', ' Ultrasonic Imaging ', ' Medical Ultrasound ', ' Echotomography ', ' Echography ', ' Ultrasonography ', ' Universities ', ' vasculopathy ', ' vascular dysfunction ', ' blood vessel disorder ', ' Vascular Disorder ', ' Vascular Diseases ', ' Work ', ' glucose-regulated proteins ', ' Measures ', ' Killings ', ' related to A and C-protein ', ' rac protein kinase ', ' proto-oncogene protein akt ', ' proto-oncogene protein RAC ', ' protein-serine-threonine kinase (rac) ', ' c-akt protein ', ' RAC-PK protein ', ' Protein Kinase B ', ' Akt protein ', ' AKT ', ' Proto-Oncogene Proteins c-akt ', ' Injury ', ' Chronic ', ' Clinical ', ' Link ', ' Fostering ', ' Multidisciplinary Research ', ' Multidisciplinary Collaboration ', ' Interdisciplinary Research ', ' Interdisciplinary Study ', ' inflammatory mediator ', ' Inflammation Mediators ', ' Funding ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Research Project Grants ', ' immunoresponse ', ' host response ', ' Immune response ', ' Therapeutic ', ' Therapeutic Agents ', ' Inflammatory ', ' Smoker ', ' Figs ', ' Figs - dietary ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Investigation ', ' Event ', ' Carotid Atheroscleroses ', ' Carotid Atherosclerotic Disease ', ' American ', ' cohort ', ' novel ', ' disease risk ', ' disorder risk ', ' Cell surface ', ' Reporting ', ' carotid plaque ', ' Carotid Artery Plaque ', ' Carotid Artery Plaques ', ' response ', ' Molecular Interaction ', ' Binding ', ' Binding (Molecular Function) ', ' preventing ', ' prevent ', ' Affinity ', ' Data ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' K-Series Research Career Programs ', ' in vivo ', ' Anti-inflammatory ', ' Cancer Patient ', ' Principal Investigator ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' public health relevance ', ' biomarker ', ' biologic marker ', ' Biological Markers ', ' in vitro testing ', ' ']",NHLBI,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,K23,2015,132192,PA-18,0.4664874579589209
"INTEGRATIVE GENOMICS OF CLINICAL SUBTYPES IN COPDGENE     DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, which is not captured by the degree of airflow limitation measured by spirometry. One of the goals of the Genetic Epidemiology of COPD Study (COPDGene) is to define meaningful subgroups of COPD, leading to a new disease classification. These clinical and statistical approaches are utilizing the extensive phenotype data collected in COPDGene, including chest CT scans. The ""Integrative Genomics of Clinical Subtypes in COPDGene"" study will use RNA sequencing and miRNA for subtyping, different from the main COPDGene study. The hypothesis is that different COPD subtypes will have distinct pathophysiology, which can be identified through gene expression signatures, miRNA profiling and integrative genomics studies. Genomewide genotyping data can be used to test for associations with the subtypes. However, traditional genomewide association studies may be underpowered to detect subtype effects. Gene expression is an important intermediate phenotype between genotypes and complex traits, and can be easily assayed in peripheral blood. In this proposal, we will use expression quantitative trait locus (eQTL) analysis to identify functional single nucleotide polymorphisms (SNPs) affecting expression of differentially expressed genes and miRNAs. We will address the following Specific Aims: (1) Gene expression profiling in COPD subtypes: We will collect peripheral blood RNA samples from subjects in COPDGene, perform RNA sequencing and miRNA profiling and test for differentially expressed transcripts and miRNAs for two clinical subtype comparisons: (A) emphysema-predominant vs. airway-predominant COPD and (B) frequent vs. infrequent acute exacerbations. We will validate the blood associations by RNA-sequencing in COPD lung tissue samples. (2) Molecular subtypes of COPD: We will use statistical and machine learning methods to define molecular subtypes based on the RNA sequencing and miRNA data. We will validate the molecular subtypes with the clinical, imaging and longitudinal follow-up data. (3) Integrative genomics of COPD subtypes: We will integrate the gene and miRNA expression data with genomewide SNP data to identify eQTL SNPs associated with transcript levels of the differentially expressed and subtype-defining genes and miRNAs from Aims 1 and Aim 2. The eQTL SNPs will be tested for association with the clinical subtypes in the full COPDGene Study population. This proposal will be distinct yet complement the parent COPDGene Study by using mRNA and miRNA expression data to identify genetic influences on COPD subtypes, which could identify biomarkers of disease subtypes or novel pathways and targets, moving towards the goal of precision medicine in COPD. The gene expression, miRNA and eQTL datasets will serve as resources for COPDGene and the community of COPD investigators.         PUBLIC HEALTH RELEVANCE: The ""Integrative Genomics of Clinical Subtypes in COPDGene"" study will allow us to find genes that are responsible for the specific type of COPD experienced by a patient. The information we learn may eventually lead to a more personalized approach to the diagnosis and treatment of COPD patients.            ",INTEGRATIVE GENOMICS OF CLINICAL SUBTYPES IN COPDGENE,8965166,R01HL125583,"['Affect ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Blood Reticuloendothelial System ', ' Blood ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Communities ', ' Complement Proteins ', ' Complement ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Environmental Exposure ', ' Gene Expression ', ' Genes ', ' Genotype ', ' Goals ', ' Heterogeneity ', ' History ', ' Recording of previous events ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Chronic Obstructive Airway Disease ', ' Methods ', ' Parents ', ' Patients ', ' Phenotype ', ' Emphysema ', ' Pulmonary Emphysema ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' mRNA ', ' Messenger RNA ', ' Spirometry ', ' Testing ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computerized Axial Tomography (Computerized Tomography) ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' X-Ray Computed Tomography ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Measures ', ' Dataset ', ' Data Set ', ' RNA Sequences ', ' Guidelines ', ' base ', ' Blood Sample ', ' Blood specimen ', ' improved ', ' Acute ', ' Clinical ', ' Phase ', ' Biological ', ' peripheral blood ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Complex ', ' Techniques ', ' experience ', ' QTL ', ' Quantitative Trait Loci ', ' small airways disease ', ' disease natural history ', ' trait ', ' novel ', ' Population Study ', ' nosology ', ' disorder classification ', ' disease classification ', ' Single Base Polymorphism ', ' Single Nucleotide Polymorphism ', ' gene expression analysis ', ' Transcript Expression Analysis ', ' Transcript Expression Analyses ', ' Gene Expression Pattern Analysis ', ' Gene Expression Monitoring ', ' Gene Expression Profiling ', ' Thorax ', ' Thoracic ', ' Thorace ', ' Chest ', ' Lung Tissue ', ' Lung Parenchyma ', ' Structure of parenchyma of lung ', ' Sampling ', ' response ', ' genetic epidemiology ', ' disease subtype ', ' disorder subtype ', ' Genomics ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Tissue Sample ', ' genome sequencing ', ' Address ', ' Symptoms ', ' Data ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Signature ', ' Expression Profiling ', ' Molecular Profiling ', ' Subgroup ', ' nonmalignant ', ' Non-Malignant ', ' Transcript ', ' Molecular ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' transcriptome ', ' gene expression signature ', ' gene expression pattern ', ' Gene Expression Profile ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' bloodstream infection ', ' Sepsis ', ' clinical relevance ', ' clinically relevant ', ' public health relevance ', ' biomarker ', ' biologic marker ', ' Biological Markers ', ' genomewide ', ' genome-wide ', ' exomes ', ' exome ', ' RNAseq ', ' RNA-seq ', ' transcriptome sequencing ', ' rare allele ', ' rare variant ', ' precision medicine ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,R01,2015,911563,MA-07,0.4106033809787729
"Machine Learning Development for Subtyping COPD Project Summary Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by progressive loss of lung function with subsequent increasing breathlessness and worsening quality of life. This heterogeneity makes it difficult to predict health decline and develop targeted treatments for better patient care. To date, researchers have attempted to use standard machine learning methodology to identify more meaningful subtypes of COPD, but these methods often make general assumptions about the data, limiting their ability to penetrate more complex patterns in some data sets. Thus, a meaningful reclassification of COPD subtypes that could lead to more targeted therapies and interventions has been elusive. The applicant introduces a new way of looking at the COPD subtyping problem by recasting it in terms of discovering associations of individuals to disease trajectories  i.e., grouping individuals based on their similarity in response to environmental and/or disease causing variables. The machine learning methods proposed build on the most recent advances in Bayesian nonparametrics, a collection of theoretical ideas and techniques that permit very flexible data representations. In this career development proposal, the applicant hypothesizes that these machine learning methods and extensions thereof  together with data sources not previously leveraged for COPD subtyping  will produce more biologically meaningful sub-groupings of patients, leading to a better understanding of the genetic and biological underpinnings of the disease and ultimately improved patient management. Aim 1 of this application involves evaluating the utility of CT-assessed lung mass  a potentially more discriminative measure of emphysema than conventionally used measures  for defining COPD subtypes using both K-means clustering and our disease trajectory algorithm. The goal of Aim 2 is to evaluate the utility of comorbidity data for defining COPD subtypes using our trajectory clustering algorithm. Novel computed tomography based measures of muscle wasting (cachexia) and pulmonary vascular pruning will be explored to determine their efficacy in subtype determination. Additionally, we will extend and test the trajectory algorithm in order to model discrete outputs (such as physician-diagnosed comorbidities), count data (e.g. exacerbations), and time-to-event data (death). In Aim 3, the applicant will extend our trajectory clustering algorithms to directly incorporate genetic and omics data for subtype discovery. Together, the research proposed in the aims of this award will take full advantage of the comprehensive data set available through the COPDGene study. Execution of the aims in this proposal will be possible through active collaboration with Dr. Ron Kikinis, M.D., a renowned leader in the field of medical image analysis, and Dr. Ed Silverman, an internationally recognized expert in the genetic epidemiology of COPD. Project Narrative Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by progressive loss of lung function with subsequent increasing breathlessness and worsening quality of life. This heterogeneity makes it difficult to predict health decline and develop targeted treatments for better patient care. In carrying out the research outlined in the following proposal, we plan to develop and apply machine learning methods to better identify subpopulations of individuals who have similar forms of COPD, potentially enabling better, targeted therapies.",Machine Learning Development for Subtyping COPD,9180344,K25HL130637,"['Affect ', ' Algorithms ', ' Award ', ' vascular ', ' Blood Vessels ', ' Cachectic ', ' Cachexia ', ' Cause of Death ', ' co-morbidity ', ' Comorbidity ', ' data representation ', ' Data Reporting ', ' Data Sources ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' Disorder ', ' Disease ', ' liability to disease ', ' Diathesis ', ' Disease susceptibility ', ' Breathlessness ', ' Dyspnea ', ' Environment ', ' Patient Care Delivery ', ' Patient Care ', ' Goals ', ' Health ', ' Heterogeneity ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Chronic Obstructive Airway Disease ', ' Medical Imaging ', ' Methods ', ' Methodology ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' mortality ', ' muscle wasting ', ' muscle loss ', ' muscle deterioration ', ' muscle degradation ', ' muscle breakdown ', ' Muscle Atrophy ', ' Muscular Atrophy ', ' Patients ', ' Physicians ', ' Publishing ', ' emphysematous ', ' Emphysema ', ' Pulmonary Emphysema ', ' QOL ', ' Quality of life ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' respiratory function ', ' lung function ', ' Respiratory physiology ', ' Smoke ', ' Syndrome ', ' Testing ', ' Time ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' X-Ray Computed Tomography ', ' Measures ', ' Pulmonary Mass ', ' Lung Mass ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Clinical ', ' Biological ', ' peripheral blood ', ' Failure ', ' Individual ', ' smoke of cigarettes ', ' cigarette smoke ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Disease Progression ', ' Collaborations ', ' Descriptor ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Complex ', ' Event ', ' Pattern ', ' Techniques ', ' particle ', ' novel ', ' disorder model ', ' Disease model ', ' environmental risk ', ' Environmental Factor ', ' Environmental Risk Factor ', ' Modeling ', ' career development ', ' response ', ' genetic epidemiologic study ', ' genetic epidemiology ', ' disease subtype ', ' disorder subtype ', ' interventional strategy ', ' Intervention Strategies ', ' Intervention ', ' Inflammatory Response ', ' genetic association ', ' Data ', ' M.D. ', ' Doctor of Medicine ', ' Subgroup ', ' Collection ', ' Physiologic Imaging ', ' Functional Imaging ', ' Scheme ', ' Characteristics ', ' Process ', ' groupings ', ' Grouping ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' Output ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' designing ', ' design ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' flexibility ', ' flexible ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' learning strategy ', ' learning method ', ' learning activity ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K25,2016,188040,MA-07,0.44476189124601284
"INTEGRATIVE GENOMICS OF CLINICAL SUBTYPES IN COPDGENE     DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, which is not captured by the degree of airflow limitation measured by spirometry. One of the goals of the Genetic Epidemiology of COPD Study (COPDGene) is to define meaningful subgroups of COPD, leading to a new disease classification. These clinical and statistical approaches are utilizing the extensive phenotype data collected in COPDGene, including chest CT scans. The ""Integrative Genomics of Clinical Subtypes in COPDGene"" study will use RNA sequencing and miRNA for subtyping, different from the main COPDGene study. The hypothesis is that different COPD subtypes will have distinct pathophysiology, which can be identified through gene expression signatures, miRNA profiling and integrative genomics studies. Genomewide genotyping data can be used to test for associations with the subtypes. However, traditional genomewide association studies may be underpowered to detect subtype effects. Gene expression is an important intermediate phenotype between genotypes and complex traits, and can be easily assayed in peripheral blood. In this proposal, we will use expression quantitative trait locus (eQTL) analysis to identify functional single nucleotide polymorphisms (SNPs) affecting expression of differentially expressed genes and miRNAs. We will address the following Specific Aims: (1) Gene expression profiling in COPD subtypes: We will collect peripheral blood RNA samples from subjects in COPDGene, perform RNA sequencing and miRNA profiling and test for differentially expressed transcripts and miRNAs for two clinical subtype comparisons: (A) emphysema-predominant vs. airway-predominant COPD and (B) frequent vs. infrequent acute exacerbations. We will validate the blood associations by RNA-sequencing in COPD lung tissue samples. (2) Molecular subtypes of COPD: We will use statistical and machine learning methods to define molecular subtypes based on the RNA sequencing and miRNA data. We will validate the molecular subtypes with the clinical, imaging and longitudinal follow-up data. (3) Integrative genomics of COPD subtypes: We will integrate the gene and miRNA expression data with genomewide SNP data to identify eQTL SNPs associated with transcript levels of the differentially expressed and subtype-defining genes and miRNAs from Aims 1 and Aim 2. The eQTL SNPs will be tested for association with the clinical subtypes in the full COPDGene Study population. This proposal will be distinct yet complement the parent COPDGene Study by using mRNA and miRNA expression data to identify genetic influences on COPD subtypes, which could identify biomarkers of disease subtypes or novel pathways and targets, moving towards the goal of precision medicine in COPD. The gene expression, miRNA and eQTL datasets will serve as resources for COPDGene and the community of COPD investigators. PUBLIC HEALTH RELEVANCE: The ""Integrative Genomics of Clinical Subtypes in COPDGene"" study will allow us to find genes that are responsible for the specific type of COPD experienced by a patient. The information we learn may eventually lead to a more personalized approach to the diagnosis and treatment of COPD patients.",INTEGRATIVE GENOMICS OF CLINICAL SUBTYPES IN COPDGENE,9133462,R01HL125583,"['Affect ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Blood Reticuloendothelial System ', ' Blood ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Communities ', ' Complement Proteins ', ' Complement ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Environmental Exposure ', ' Gene Expression ', ' Genes ', ' Genotype ', ' Goals ', ' Health ', ' Heterogeneity ', ' History ', ' Recording of previous events ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Chronic Obstructive Airway Disease ', ' Parents ', ' Patients ', ' Phenotype ', ' emphysematous ', ' Emphysema ', ' Pulmonary Emphysema ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' mRNA ', ' Messenger RNA ', ' Spirometry ', ' Testing ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' X-Ray Computed Tomography ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Measures ', ' Data Set ', ' Dataset ', ' Guidelines ', ' base ', ' Blood Sample ', ' Blood specimen ', ' improved ', ' Acute ', ' Clinical ', ' Phase ', ' Biological ', ' peripheral blood ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Complex ', ' Techniques ', ' experience ', ' QTL ', ' Quantitative Trait Loci ', ' small airways disease ', ' disease natural history ', ' trait ', ' novel ', ' nosology ', ' disorder classification ', ' disease classification ', ' Single Base Polymorphism ', ' Single Nucleotide Polymorphism ', ' gene expression assay ', ' gene expression analysis ', ' Transcript Expression Analysis ', ' Transcript Expression Analyses ', ' Gene Expression Pattern Analysis ', ' Gene Expression Monitoring ', ' Gene Expression Profiling ', ' Thorax ', ' Thoracic ', ' Thorace ', ' Chest ', ' Lung Tissue ', ' Lung Parenchyma ', ' Structure of parenchyma of lung ', ' Sampling ', ' genetic epidemiologic study ', ' genetic epidemiology ', ' disease subtype ', ' disorder subtype ', ' Genomics ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Tissue Sample ', ' genome sequencing ', ' Address ', ' Symptoms ', ' Data ', ' Subgroup ', ' nonmalignant ', ' Non-Malignant ', ' Transcript ', ' Molecular ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' transcriptional signature ', ' gene expression signature ', ' gene expression pattern ', ' Expression Signature ', ' Gene Expression Profile ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' bloodstream infection ', ' Sepsis ', ' clinically relevant ', ' clinical relevance ', ' treatment response ', ' therapeutic response ', ' response to treatment ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' rare variant ', ' rare allele ', ' precision medicine ', ' differential expression ', ' transcriptional differences ', ' differentially expressed ', ' learning strategy ', ' learning method ', ' learning activity ', ' personalized approach ', ' tailored approach ', ' precision approach ', ' individualized approach ', ' Personalized medical approach ', ' molecular subtypes ', ' molecular subsets ', ' molecular sub-types ', ' disease heterogeneity ', ' study population ', ' whole genome ', ' entire genome ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,R01,2016,891352,MA-07,0.4106033809787729
"Autoimmunity as a Mechanism for Atherosclerosis in COPD     DESCRIPTION (provided by applicant): This project will facilitate the development of the principal investigator into an independent translational researcher investigating systemic vascular injury in Chronic obstructive pulmonary disease (COPD). This will be accomplished in the rich academic environment at the University of Pittsburgh, under the guidance of a highly accomplished team of mentors, and in the conduct of multidisciplinary research project that will develop autoimmunity as a novel mechanism for atherosclerosis in COPD. The increased risk of atherosclerosis in COPD is not explained by smoking, age, hypertension, and other established vascular disease risk factors. Chronic inflammation has recently been implicated as an atherogenic mechanism in COPD. We and others have reported that chronic inflammation in COPD may be propagated by humoral autoimmunity. Specifically, smokers with COPD have greatly increased levels of circulating autoantibodies that demonstrate in vitro pathogenic effects. Our subsequent studies also show that these autoantibodies target at least 50 different autoantigens and consistently target glucose regulated protein 78 (GRP78), particularly in patients with parenchymal lung destruction, i.e. emphysema. GRP78 is present in the endoplasmic reticulum, where it regulates the unfolded protein response, and is also a multifunction cell surface receptor. Studies in cancer patients suggest that ligation of the N-terminus of cell surface GRP78 by anti-GRP78 IgG transduces pro-inflammatory and pro-proliferative signals by activation of the AKT pathway, followed by NFB activation. Additional in vivo studies have identified anti-GRP78 IgG with affinity for the C-terminus of cell surface GRP78 that produce counteracting anti-inflammatory effects by suppressing AKT activation. Our preliminary work shows that circulating anti-GRP78 IgG in COPD patients binds to macrophages and leads to increased NFB activation and production of atherogenic inflammatory mediators by them. The macrophage is critical in the development of both atherosclerosis and COPD. Also, cross-sectional studies in our cohort find that levels of circulating anti-GRP78 IgG are strongly associated with carotid atherosclerosis in patients with emphysema, independent of established vascular risk factors. Therefore, we hypothesize that autoimmune responses against GRP78 are a mechanism for atherosclerosis in COPD. During this award, we will: (1) Test the hypothesis that elevated levels of circulating anti-GRP78 IgG predict progression of carotid atherosclerosis in patients with emphysema independent of established risk factors over 4 year follow up; (2) Test the hypothesis that anti-GRP78 IgG binds to the N-terminus of cell surface GRP78 and activates the AKT pathway followed by NFB activation and production of inflammatory mediators using a variety of cell function assays, and provide proof of concept for two potential therapeutic strategies; (3) Test the hypothesis that there are other antigen-specific immune responses associated with atherosclerosis in COPD by using machine learning to analyze high-throughput data on a large number of circulating autoantibody levels. PUBLIC HEALTH RELEVANCE: Chronic obstructive pulmonary disease (COPD) is a lung disease caused by smoking that kills more and more Americans each year, and is now the third leading cause of death in the US. Although it is largely viewed as a disease of the lungs, the most common cause of death in patients with COPD are blockages in blood vessels. This research project will investigate why patients with COPD are so prone to develop these blood vessel blockages.",Autoimmunity as a Mechanism for Atherosclerosis in COPD,9024612,K23HL126912,"['Age ', ' Algorithms ', ' Antiinflammatory Agents ', ' Antiinflammatories ', ' Anti-Inflammatories ', ' Anti-Inflammatory Agents ', ' Antibodies ', ' immunogen ', ' ATGN ', ' Antigens ', ' atherosclerotic vascular disease ', ' atherosclerotic disease ', ' atheromatosis ', ' Atherosclerotic Cardiovascular Disease ', ' Atheroscleroses ', ' Atherosclerosis ', ' self reactive antibody ', ' autoimmune antibody ', ' Autoantibodies ', ' Self-Antigens ', ' Autologous Antigens ', ' Autoantigens ', ' autoimmune disorder ', ' Autoimmune Diseases ', ' Autoimmune Responses ', ' Autoimmune Status ', ' Autoimmunity ', ' Award ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' vascular ', ' Blood Vessels ', ' protein blotting ', ' Western Immunoblotting ', ' Western Blotting ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cause of Death ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Disease Frequency Surveys ', ' Cross-Sectional Survey ', ' Cross-Sectional Analyses ', ' Cross Sectional Analysis ', ' Cross-Sectional Studies ', ' Ergastoplasm ', ' Endoplasmic Reticulum ', ' Environment ', ' ELISA ', ' Enzyme-Linked Immunosorbent Assay ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Flow Cytometry ', ' Health ', ' Modern Man ', ' Human ', ' hypertensive disease ', ' hyperpiesis ', ' hyperpiesia ', ' high blood pressure ', ' Vascular Hypertensive Disorder ', ' Vascular Hypertensive Disease ', ' Hypertension ', ' IgG ', ' 7S Gamma Globulin ', ' Immunoglobulin G ', ' In Vitro ', ' Inflammation ', ' Closure by Ligation ', ' Ligation ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' lung disorder ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Lung diseases ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Chronic Obstructive Airway Disease ', ' macrophage ', ' Mentors ', ' Mentorship ', ' Morbidity ', ' Morbidity - disease rate ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Patients ', ' Phenotype ', ' Protein Phosphorylation ', ' Phosphorylation ', ' Production ', ' Proteins ', ' emphysematous ', ' Emphysema ', ' Pulmonary Emphysema ', ' Cell Surface Receptors ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Risk ', ' Risk Factors ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Smoking ', ' Testing ', ' Ultrasonography ', ' ultrasound scanning ', ' ultrasound imaging ', ' ultrasound ', ' sound measurement ', ' sonography ', ' sonogram ', ' diagnostic ultrasound ', ' Ultrasound Test ', ' Ultrasound Medical Imaging ', ' Ultrasound Diagnosis ', ' Ultrasonogram ', ' Ultrasonic Imaging ', ' Medical Ultrasound ', ' Echotomography ', ' Echography ', ' Universities ', ' Vascular Diseases ', ' vasculopathy ', ' vascular dysfunction ', ' blood vessel disorder ', ' Vascular Disorder ', ' Work ', ' glucose-regulated proteins ', ' Measures ', ' Killings ', ' related to A and C-protein ', ' rac protein kinase ', ' proto-oncogene protein akt ', ' proto-oncogene protein RAC ', ' c-akt protein ', ' RAC-PK protein ', ' Protein Kinase B ', ' Akt protein ', ' AKT ', ' Proto-Oncogene Proteins c-akt ', ' Injury ', ' Chronic ', ' Clinical ', ' Link ', ' Fostering ', ' Multidisciplinary Research ', ' Multidisciplinary Collaboration ', ' Interdisciplinary Research ', ' Interdisciplinary Study ', ' inflammatory mediator ', ' Inflammation Mediators ', ' Funding ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Research Project Grants ', ' immunoresponse ', ' host response ', ' Immune response ', ' Therapeutic ', ' Therapeutic Agents ', ' Inflammatory ', ' Smoker ', ' Figs ', ' Figs - dietary ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Investigation ', ' Event ', ' Carotid Atheroscleroses ', ' Carotid Atherosclerotic Disease ', ' American ', ' cohort ', ' novel ', ' disease risk ', ' disorder risk ', ' Cell surface ', ' Reporting ', ' carotid plaque ', ' Carotid Artery Plaque ', ' Carotid Artery Plaques ', ' response ', ' Molecular Interaction ', ' Binding ', ' preventing ', ' prevent ', ' Affinity ', ' Data ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' K-Series Research Career Programs ', ' in vivo ', ' Anti-inflammatory ', ' Cancer Patient ', ' Principal Investigator ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' peptidomimetics ', ' peptide mimic ', ' peptide mimetic ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' in vitro testing ', ' predictive marker ', ' predictive molecular biomarker ', ' predictive biomarkers ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' ']",NHLBI,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,K23,2016,166104,PA-18,0.4664874579589209
"Machine Learning Development for Subtyping COPD Project Summary Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by progressive loss of lung function with subsequent increasing breathlessness and worsening quality of life. This heterogeneity makes it difficult to predict health decline and develop targeted treatments for better patient care. To date, researchers have attempted to use standard machine learning methodology to identify more meaningful subtypes of COPD, but these methods often make general assumptions about the data, limiting their ability to penetrate more complex patterns in some data sets. Thus, a meaningful reclassification of COPD subtypes that could lead to more targeted therapies and interventions has been elusive. The applicant introduces a new way of looking at the COPD subtyping problem by recasting it in terms of discovering associations of individuals to disease trajectories  i.e., grouping individuals based on their similarity in response to environmental and/or disease causing variables. The machine learning methods proposed build on the most recent advances in Bayesian nonparametrics, a collection of theoretical ideas and techniques that permit very flexible data representations. In this career development proposal, the applicant hypothesizes that these machine learning methods and extensions thereof  together with data sources not previously leveraged for COPD subtyping  will produce more biologically meaningful sub-groupings of patients, leading to a better understanding of the genetic and biological underpinnings of the disease and ultimately improved patient management. Aim 1 of this application involves evaluating the utility of CT-assessed lung mass  a potentially more discriminative measure of emphysema than conventionally used measures  for defining COPD subtypes using both K-means clustering and our disease trajectory algorithm. The goal of Aim 2 is to evaluate the utility of comorbidity data for defining COPD subtypes using our trajectory clustering algorithm. Novel computed tomography based measures of muscle wasting (cachexia) and pulmonary vascular pruning will be explored to determine their efficacy in subtype determination. Additionally, we will extend and test the trajectory algorithm in order to model discrete outputs (such as physician-diagnosed comorbidities), count data (e.g. exacerbations), and time-to-event data (death). In Aim 3, the applicant will extend our trajectory clustering algorithms to directly incorporate genetic and omics data for subtype discovery. Together, the research proposed in the aims of this award will take full advantage of the comprehensive data set available through the COPDGene study. Execution of the aims in this proposal will be possible through active collaboration with Dr. Ron Kikinis, M.D., a renowned leader in the field of medical image analysis, and Dr. Ed Silverman, an internationally recognized expert in the genetic epidemiology of COPD. Project Narrative Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by progressive loss of lung function with subsequent increasing breathlessness and worsening quality of life. This heterogeneity makes it difficult to predict health decline and develop targeted treatments for better patient care. In carrying out the research outlined in the following proposal, we plan to develop and apply machine learning methods to better identify subpopulations of individuals who have similar forms of COPD, potentially enabling better, targeted therapies.",Machine Learning Development for Subtyping COPD,9316700,K25HL130637,"['Affect ', ' Algorithms ', ' Award ', ' vascular ', ' Blood Vessels ', ' Cachectic ', ' Cachexia ', ' Cause of Death ', ' co-morbidity ', ' Comorbidity ', ' data representation ', ' Data Reporting ', ' Data Sources ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' Disorder ', ' Disease ', ' liability to disease ', ' Diathesis ', ' Disease susceptibility ', ' Breathlessness ', ' Dyspnea ', ' Environment ', ' Patient Care Delivery ', ' Patient Care ', ' Goals ', ' Health ', ' Heterogeneity ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Medical Imaging ', ' Methods ', ' Methodology ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' mortality ', ' Muscular Atrophy ', ' muscle wasting ', ' muscle loss ', ' muscle deterioration ', ' muscle degradation ', ' muscle breakdown ', ' Muscle Atrophy ', ' Patients ', ' Physicians ', ' Publishing ', ' Pulmonary Emphysema ', ' emphysematous ', ' Emphysema ', ' Quality of life ', ' QOL ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Respiratory physiology ', ' respiratory function ', ' lung function ', ' Smoke ', ' Syndrome ', ' Testing ', ' Time ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' X-Ray Computed Tomography ', ' Measures ', ' Lung Mass ', ' Pulmonary Mass ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Clinical ', ' Biological ', ' peripheral blood ', ' Failure ', ' Individual ', ' smoke of cigarettes ', ' cigarette smoke ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Disease Progression ', ' Collaborations ', ' Descriptor ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Event ', ' Pattern ', ' Techniques ', ' particle ', ' novel ', ' Disease model ', ' disorder model ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Modeling ', ' career development ', ' response ', ' genetic epidemiology ', ' genetic epidemiologic study ', ' disorder subtype ', ' disease subtype ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Inflammatory Response ', ' genetic association ', ' Data ', ' Doctor of Medicine ', ' M.D. ', ' International ', ' Subgroup ', ' Collection ', ' physiological imaging ', ' Physiologic Imaging ', ' Functional Imaging ', ' Scheme ', ' Characteristics ', ' Process ', ' groupings ', ' Grouping ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' Output ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' designing ', ' design ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' flexibility ', ' flexible ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' learning strategy ', ' learning method ', ' learning activity ', ' clinical imaging ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K25,2017,187400,MA-07,0.44476189124601284
"Omics Data Integration to Identify Disease Pathways in COPD Project Summary Although chronic obstructive pulmonary disease (COPD) occurs predominantly in smokers, it is unknown why only a minority of smokers (~20-40%) develops chronic airflow limitation and/or destruction of distal airspaces (emphysema). Using several NIH and foundation grants, we have systematically generated genetic, genomics, proteomic, and metabolomics profiles from the NHLBI supported COPDGene cohort, which includes 10,300 current and former smokers age 45-80. This proposal will focus on integrating the omics data generated in the five-year followup (Phase II) of the COPDgene study to identify molecular subtypes of COPD across a broad range of blood profiles (Specific Aim 1). Biomarkers and pathways discriminating the molecular subtypes, in addition to other COPD phenotypes will then be identified (Specific Aim 2). These results will identify markers that are specific to smoking-related lung disease and can be used to develop novel diagnostic tests and therapies for early prevention and treatment of COPD. Relevance to Public Health Chronic obstructive pulmonary disease (COPD) is the third most common cause of death in the United States. The major risk factor is smoking; however, most smokers do not develop COPD and the factors that identify who goes from normal to abnormal lung function are unknown. This proposal will use already collected data on existing NHLBI cohorts to identify blood signatures that can identify who will be at risk for developing smoking related lung disease. The knowledge gained will help guide treatment strategies and improve prognosis assessments.",Omics Data Integration to Identify Disease Pathways in COPD,9440672,R21HL140376,"['ages ', ' Age ', ' Biology ', ' Blood Reticuloendothelial System ', ' Blood ', ' Cause of Death ', ' Complement Proteins ', ' Complement ', ' Computers ', ' Disorder ', ' Disease ', ' Foundations ', ' Gene Expression ', ' Goals ', ' Grant ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' blood disorder ', ' Hematological Disorder ', ' Hematologic Diseases ', ' Blood Diseases ', ' Hematological Disease ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lung diseases ', ' lung disorder ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Methods ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Phenotype ', ' outcome forecast ', ' Prognosis ', ' Proteins ', ' Public Health ', ' Pulmonary Emphysema ', ' emphysematous ', ' Emphysema ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Respiratory physiology ', ' respiratory function ', ' lung function ', ' Risk ', ' Risk Factors ', ' Smoking ', ' Supervision ', ' Time ', ' United States ', ' Work ', ' Diagnostic tests ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Distal ', ' Chronic ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Individual ', ' Sample Size ', ' Disease Progression ', ' Funding ', ' Genetic ', ' Smoker ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Investigation ', ' Complex ', ' Source ', ' System ', ' Severity of illness ', ' disease severity ', ' cohort ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' novel ', ' Prevention ', ' Sleep Disorders ', ' sleep problem ', ' Sampling ', ' response ', ' Proteomics ', ' disorder subtype ', ' disease subtype ', ' Genomics ', ' disorder control ', ' disease control ', ' computerized data processing ', ' data processing ', ' metabolomics ', ' metabonomics ', ' metabolism measurement ', ' data mining ', ' datamining ', ' Data ', ' Disease Pathway ', ' Molecular Profiling ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Profiling ', ' Molecular Target ', ' Classification Scheme ', ' Preparation ', ' Characteristics ', ' Molecular ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' clinical phenotype ', ' disease phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' data integration ', ' Minority ', ' multidisciplinary ', ' Early treatment ', ' early therapy ', ' data space ', ' human disease ', ' novel diagnostics ', ' next generation diagnostics ', ' new diagnostics ', ' new therapeutic target ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel druggable target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new druggable target ', ' new drug target ', ' novel therapeutic intervention ', ' novel therapy approach ', ' novel therapeutic approach ', ' new therapy approaches ', ' new therapeutic strategies ', ' new therapeutic intervention ', ' new therapeutic approach ', ' treatment strategy ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' learning strategy ', ' learning method ', ' learning activity ', ' multiple omics ', ' molecular subtypes ', ' molecular subsets ', ' molecular sub-types ', ' secondary analysis ', ' Disease stratification ', ' high dimensionality ', ' ']",NHLBI,UNIVERSITY OF COLORADO DENVER,R21,2017,117278,CO-06,0.4244675570074906
"Systems Level Causal Discovery in Heterogeneous TOPMed Data SYSTEMS LEVEL CAUSAL DISCOVERY IN HETEROGENEOUS TOPMED DATA ABSTRACT The advent of new technologies for collecting and analyzing multiple heterogeneous data streams from the same individual makes possible the detailed phenotypic characterization of diseases and paves the way for the development of individualized precision therapies. A major bottleneck in this process is the lack of robust, efficient and truly integrative analytic methods for such multi-modal data. This proposal builds on the ongoing efforts of our group in the area of causal learning in biomedicine. The objective of this application is to extend, modify and tailor our causal probabilistic graphical models to data typically collected by TOPMed projects, such as omics data (SNPs, metabolomics, RNA-seq, etc), imaging, patients' history, and clinical data. COPDGene is one of the TOPMed projects and has generated datasets with those modalities for 10,000 patients with chronic obstructive pulmonary disease (COPD), the third leading cause of death and a major cause of disability and health care costs in the US. The prevailing view is that COPD is a syndrome, consisting of multiple diseases with different characteristics. There is currently no satisfactory method for COPD subtyping or prediction of disease progression. In this project we will apply, test and validate our approaches on COPDGene and another large independent COPD cohort. The extension and application of our methods to cross-sectional and longitudinal data will also allow us to investigate a number of important questions and aspects related to COPD. Mechanistically, we will investigate how SNPs, genes and their networks are causally linked to disease phenotypes. In pathology, we will identify conditional biomarkers, which will lead to disease sub-classification and identification of causal components in each subtype. In pathophysiology, we will identify features that are directly linked to lung function decline and outcome. We will make all our algorithms and results available to the community through web and public cloud interfaces. The deliverables will be (1) new probabilistic approaches for integration and analysis of multi-modal cross-sectional and longitudinal data, including SNPs, blood biomarkers, CT scans and clinical data; (2) new cloud-based server to make these approaches available to the research community; (3) results on the mechanism, pathology and pathophysiology of COPD facilitation and progression. To guarantee the success of the project we have assembled a team of experts in genomics, machine learning, cloud computing and COPD. This cross- disciplinary team project will have a positive impact beyond the above deliverables, since the generality of our approaches makes them applicable to any disease. We expect that during this U01 we will have the opportunity to collaborate with other teams in the TOPMed consortium to help them investigate the causes of their corresponding disease phenotypes. We do believe that data integration in a single probabilistic framework will be in the heart of precision medicine strategies in the future, when massive high-throughput data collection will become a routine diagnostic and prognostic procedure in all hospitals. PROJECT NARRATIVE Current technologies for high-throughput biomedical data collection allow the interrogation of multiple modalities from a single patient. New promising analytical methods started emerging, which can analyze those multi-modal data in a holistic way. Chronic obstructive pulmonary disease (COPD) constitutes the third leading cause of death and a major cause of disability and health care costs in the US. The prevailing view is that COPD is a syndrome, consisting of multiple diseases with their own characteristics. There is currently no satisfactory method for COPD subtyping. We will apply, test and validate new probabilistic approaches on two cohorts of COPD patients. We will investigate the mechanisms of disease facilitation; we will identify patient cohorts with specific characteristics (disease subtypes); and investigate risk factors and causal variants for the disease progression in each subtype. ",Systems Level Causal Discovery in Heterogeneous TOPMed Data,9310591,U01HL137159,"['Algorithms ', ' Blood Reticuloendothelial System ', ' Blood ', ' Cause of Death ', ' Systematics ', ' Classification ', ' Communities ', ' Data Collection ', ' Disorder ', ' Disease ', ' liability to disease ', ' Diathesis ', ' Disease susceptibility ', ' Future ', ' Genes ', ' Genotype ', ' Goals ', ' Heart ', ' History ', ' Recording of previous events ', ' Hospitals ', ' Learning ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Methods ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' mortality ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Pathology ', ' Patients ', ' Phenotype ', ' outcome forecast ', ' Prognosis ', ' Pulmonology ', ' Pulmonary Medicine ', ' Pneumonology ', ' Pneumology ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Respiratory physiology ', ' respiratory function ', ' lung function ', ' Risk ', ' Risk Factors ', ' medical schools ', ' school of medicine ', ' medical college ', ' Science ', ' Computer software ', ' Software ', ' Syndrome ', ' Technology ', ' Testing ', ' Tissues ', ' Body Tissues ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' X-Ray Computed Tomography ', ' Universities ', ' Healthcare Costs ', ' Health Costs ', ' Health Care Costs ', ' Outcome Assessment ', ' Dataset ', ' Data Set ', ' analytical method ', ' base ', ' Procedures ', ' Area ', ' Clinical ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Lifting ', ' Link ', ' prognostic ', ' disability ', ' Individual ', ' Disease Progression ', ' Funding ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Morphology ', ' tool ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Computational Biology ', ' computer biology ', ' Stream ', ' System ', ' Visit ', ' success ', ' computer science ', ' cohort ', ' Peripheral Blood Mononuclear Cell ', ' PBMC ', ' novel ', ' Graph ', ' new technology ', ' novel technologies ', ' Disease model ', ' disorder model ', ' Modality ', ' Modeling ', ' high throughput technology ', ' repository ', ' disorder subtype ', ' disease subtype ', ' Genomics ', ' Genetic Determinism ', ' genetic determinant ', ' metabolomics ', ' metabonomics ', ' metabolism measurement ', ' Address ', ' Data ', ' Subgroup ', ' Clinical Data ', ' physiological imaging ', ' Physiologic Imaging ', ' Functional Imaging ', ' Characteristics ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' disease phenotype ', ' data integration ', ' Outcome ', ' cost effective ', ' cost-effective ', ' innovation ', ' innovative ', ' innovate ', ' clinically relevant ', ' clinical relevance ', ' user-friendly ', ' graphical user interface ', ' graphic user interface ', ' Graphical interface ', ' multimodality ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' The Cancer Genome Atlas ', ' TCGA ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' Cloud Computing ', ' cloud computer ', ' Cloud Infrastructure ', ' cloud based ', ' precision medicine ', ' Precision therapeutics ', ' precision treatment ', ' precision therapies ', ' Genomic medicine ', ' precision genomic medicine ', ' Trans-Omics for Precision Medicine ', ' TOPMed ', ' longitudinal dataset ', ' longitudinal data set ', ' clinical imaging ', ' ']",NHLBI,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,U01,2017,607934,PA-18,0.41662108031881584
"INTEGRATIVE GENOMICS OF CLINICAL SUBTYPES IN COPDGENE     DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, which is not captured by the degree of airflow limitation measured by spirometry. One of the goals of the Genetic Epidemiology of COPD Study (COPDGene) is to define meaningful subgroups of COPD, leading to a new disease classification. These clinical and statistical approaches are utilizing the extensive phenotype data collected in COPDGene, including chest CT scans. The ""Integrative Genomics of Clinical Subtypes in COPDGene"" study will use RNA sequencing and miRNA for subtyping, different from the main COPDGene study. The hypothesis is that different COPD subtypes will have distinct pathophysiology, which can be identified through gene expression signatures, miRNA profiling and integrative genomics studies. Genomewide genotyping data can be used to test for associations with the subtypes. However, traditional genomewide association studies may be underpowered to detect subtype effects. Gene expression is an important intermediate phenotype between genotypes and complex traits, and can be easily assayed in peripheral blood. In this proposal, we will use expression quantitative trait locus (eQTL) analysis to identify functional single nucleotide polymorphisms (SNPs) affecting expression of differentially expressed genes and miRNAs. We will address the following Specific Aims: (1) Gene expression profiling in COPD subtypes: We will collect peripheral blood RNA samples from subjects in COPDGene, perform RNA sequencing and miRNA profiling and test for differentially expressed transcripts and miRNAs for two clinical subtype comparisons: (A) emphysema-predominant vs. airway-predominant COPD and (B) frequent vs. infrequent acute exacerbations. We will validate the blood associations by RNA-sequencing in COPD lung tissue samples. (2) Molecular subtypes of COPD: We will use statistical and machine learning methods to define molecular subtypes based on the RNA sequencing and miRNA data. We will validate the molecular subtypes with the clinical, imaging and longitudinal follow-up data. (3) Integrative genomics of COPD subtypes: We will integrate the gene and miRNA expression data with genomewide SNP data to identify eQTL SNPs associated with transcript levels of the differentially expressed and subtype-defining genes and miRNAs from Aims 1 and Aim 2. The eQTL SNPs will be tested for association with the clinical subtypes in the full COPDGene Study population. This proposal will be distinct yet complement the parent COPDGene Study by using mRNA and miRNA expression data to identify genetic influences on COPD subtypes, which could identify biomarkers of disease subtypes or novel pathways and targets, moving towards the goal of precision medicine in COPD. The gene expression, miRNA and eQTL datasets will serve as resources for COPDGene and the community of COPD investigators. PUBLIC HEALTH RELEVANCE: The ""Integrative Genomics of Clinical Subtypes in COPDGene"" study will allow us to find genes that are responsible for the specific type of COPD experienced by a patient. The information we learn may eventually lead to a more personalized approach to the diagnosis and treatment of COPD patients.",INTEGRATIVE GENOMICS OF CLINICAL SUBTYPES IN COPDGENE,9281906,R01HL125583,"['Affect ', ' Atrophic Arthritis ', ' Rheumatoid Arthritis ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Blood Reticuloendothelial System ', ' Blood ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Communities ', ' Complement Proteins ', ' Complement ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Environmental Exposure ', ' Gene Expression ', ' Genes ', ' Genotype ', ' Goals ', ' Heterogeneity ', ' History ', ' Recording of previous events ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Learning ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Lung diseases ', ' lung disorder ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Parents ', ' Patients ', ' Phenotype ', ' Pulmonary Emphysema ', ' emphysematous ', ' Emphysema ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Respiratory physiology ', ' respiratory function ', ' lung function ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' Messenger RNA ', ' mRNA ', ' Spirometry ', ' Testing ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' X-Ray Computed Tomography ', ' Genetic Diversity ', ' Genetic Variation ', ' Measures ', ' Dataset ', ' Data Set ', ' Guidelines ', ' base ', ' Blood Sample ', ' Blood specimen ', ' improved ', ' Acute ', ' Clinical ', ' Phase ', ' Biological ', ' peripheral blood ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Techniques ', ' experience ', ' Quantitative Trait Loci ', ' QTL ', ' small airways disease ', ' disease natural history ', ' trait ', ' novel ', ' Study Subject ', ' disease classification ', ' nosology ', ' disorder classification ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' Gene Expression Profiling ', ' gene expression assay ', ' gene expression analysis ', ' Transcript Expression Analysis ', ' Transcript Expression Analyses ', ' Gene Expression Pattern Analysis ', ' Gene Expression Monitoring ', ' Structure of parenchyma of lung ', ' Lung Tissue ', ' Lung Parenchyma ', ' Sampling ', ' genetic epidemiology ', ' genetic epidemiologic study ', ' disorder subtype ', ' disease subtype ', ' Genomics ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Tissue Sample ', ' genome sequencing ', ' Address ', ' Symptoms ', ' Data ', ' Subgroup ', ' nonmalignant ', ' Non-Malignant ', ' Transcript ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' pathway ', ' Pathway interactions ', ' transcriptional signature ', ' gene expression signature ', ' gene expression pattern ', ' Expression Signature ', ' Gene Expression Profile ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' bloodstream infection ', ' blood infection ', ' Sepsis ', ' clinically relevant ', ' clinical relevance ', ' public health relevance ', ' treatment response ', ' therapeutic response ', ' response to treatment ', ' molecular phenotype ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' rare variant ', ' rare allele ', ' precision medicine ', ' differential expression ', ' transcriptional differences ', ' differentially expressed ', ' learning strategy ', ' learning method ', ' learning activity ', ' personalized approach ', ' tailored approach ', ' precision approach ', ' individualized approach ', ' Personalized medical approach ', ' phenotypic data ', ' molecular subtypes ', ' molecular subsets ', ' molecular sub-types ', ' disease heterogeneity ', ' study population ', ' whole genome ', ' entire genome ', ' chest computed tomography ', ' chest CT ', ' clinical imaging ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,R01,2017,859987,MA-07,0.4106033809787729
"Autoimmunity as a Mechanism for Atherosclerosis in COPD     DESCRIPTION (provided by applicant): This project will facilitate the development of the principal investigator into an independent translational researcher investigating systemic vascular injury in Chronic obstructive pulmonary disease (COPD). This will be accomplished in the rich academic environment at the University of Pittsburgh, under the guidance of a highly accomplished team of mentors, and in the conduct of multidisciplinary research project that will develop autoimmunity as a novel mechanism for atherosclerosis in COPD. The increased risk of atherosclerosis in COPD is not explained by smoking, age, hypertension, and other established vascular disease risk factors. Chronic inflammation has recently been implicated as an atherogenic mechanism in COPD. We and others have reported that chronic inflammation in COPD may be propagated by humoral autoimmunity. Specifically, smokers with COPD have greatly increased levels of circulating autoantibodies that demonstrate in vitro pathogenic effects. Our subsequent studies also show that these autoantibodies target at least 50 different autoantigens and consistently target glucose regulated protein 78 (GRP78), particularly in patients with parenchymal lung destruction, i.e. emphysema. GRP78 is present in the endoplasmic reticulum, where it regulates the unfolded protein response, and is also a multifunction cell surface receptor. Studies in cancer patients suggest that ligation of the N-terminus of cell surface GRP78 by anti-GRP78 IgG transduces pro-inflammatory and pro-proliferative signals by activation of the AKT pathway, followed by NFB activation. Additional in vivo studies have identified anti-GRP78 IgG with affinity for the C-terminus of cell surface GRP78 that produce counteracting anti-inflammatory effects by suppressing AKT activation. Our preliminary work shows that circulating anti-GRP78 IgG in COPD patients binds to macrophages and leads to increased NFB activation and production of atherogenic inflammatory mediators by them. The macrophage is critical in the development of both atherosclerosis and COPD. Also, cross-sectional studies in our cohort find that levels of circulating anti-GRP78 IgG are strongly associated with carotid atherosclerosis in patients with emphysema, independent of established vascular risk factors. Therefore, we hypothesize that autoimmune responses against GRP78 are a mechanism for atherosclerosis in COPD. During this award, we will: (1) Test the hypothesis that elevated levels of circulating anti-GRP78 IgG predict progression of carotid atherosclerosis in patients with emphysema independent of established risk factors over 4 year follow up; (2) Test the hypothesis that anti-GRP78 IgG binds to the N-terminus of cell surface GRP78 and activates the AKT pathway followed by NFB activation and production of inflammatory mediators using a variety of cell function assays, and provide proof of concept for two potential therapeutic strategies; (3) Test the hypothesis that there are other antigen-specific immune responses associated with atherosclerosis in COPD by using machine learning to analyze high-throughput data on a large number of circulating autoantibody levels. PUBLIC HEALTH RELEVANCE: Chronic obstructive pulmonary disease (COPD) is a lung disease caused by smoking that kills more and more Americans each year, and is now the third leading cause of death in the US. Although it is largely viewed as a disease of the lungs, the most common cause of death in patients with COPD are blockages in blood vessels. This research project will investigate why patients with COPD are so prone to develop these blood vessel blockages.",Autoimmunity as a Mechanism for Atherosclerosis in COPD,9238793,K23HL126912,"['ages ', ' Age ', ' Algorithms ', ' Antiinflammatory Agents ', ' Antiinflammatories ', ' Anti-Inflammatories ', ' Anti-Inflammatory Agents ', ' Antibodies ', ' immunogen ', ' ATGN ', ' Antigens ', ' atherosclerotic vascular disease ', ' atherosclerotic disease ', ' atheromatosis ', ' Atherosclerotic Cardiovascular Disease ', ' Atheroscleroses ', ' Atherosclerosis ', ' self reactive antibody ', ' autoimmune antibody ', ' Autoantibodies ', ' Self-Antigens ', ' Autologous Antigens ', ' Autoantigens ', ' autoimmune disorder ', ' auto-immune disorder ', ' auto-immune disease ', ' Autoimmune Diseases ', ' Autoimmune Responses ', ' Autoimmune Status ', ' Autoimmunity ', ' Award ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' vascular ', ' Blood Vessels ', ' protein blotting ', ' Western Immunoblotting ', ' Western Blotting ', ' Cause of Death ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Disease Frequency Surveys ', ' Cross-Sectional Survey ', ' Cross-Sectional Analyses ', ' Cross Sectional Analysis ', ' Cross-Sectional Studies ', ' Ergastoplasm ', ' Endoplasmic Reticulum ', ' Environment ', ' ELISA ', ' Enzyme-Linked Immunosorbent Assay ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Flow Cytometry ', ' Modern Man ', ' Human ', ' hypertensive disease ', ' hyperpiesis ', ' hyperpiesia ', ' high blood pressure ', ' Vascular Hypertensive Disorder ', ' Vascular Hypertensive Disease ', ' Hypertension ', ' Immunoglobulin G ', ' IgG ', ' 7S Gamma Globulin ', ' In Vitro ', ' Inflammation ', ' Ligation ', ' Closure by Ligation ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Lung diseases ', ' lung disorder ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' macrophage ', ' Mentors ', ' Mentorship ', ' Morbidity - disease rate ', ' Morbidity ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Patients ', ' Phenotype ', ' Phosphorylation ', ' Protein Phosphorylation ', ' Production ', ' Proteins ', ' Pulmonary Emphysema ', ' emphysematous ', ' Emphysema ', ' Cell Surface Receptors ', ' Risk ', ' Risk Factors ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Smoking ', ' Testing ', ' ultrasound scanning ', ' ultrasound imaging ', ' ultrasound ', ' sound measurement ', ' sonography ', ' sonogram ', ' diagnostic ultrasound ', ' Ultrasound Test ', ' Ultrasound Medical Imaging ', ' Ultrasound Diagnosis ', ' Ultrasonogram ', ' Ultrasonic Imaging ', ' Medical Ultrasound ', ' Echotomography ', ' Echography ', ' Ultrasonography ', ' Universities ', ' vasculopathy ', ' vascular dysfunction ', ' blood vessel disorder ', ' Vascular Disorder ', ' Vascular Diseases ', ' Work ', ' glucose-regulated proteins ', ' Measures ', ' Killings ', ' related to A and C-protein ', ' rac protein kinase ', ' proto-oncogene protein akt ', ' proto-oncogene protein RAC ', ' c-akt protein ', ' RAC-PK protein ', ' Protein Kinase B ', ' Akt protein ', ' AKT ', ' Proto-Oncogene Proteins c-akt ', ' Injury ', ' Chronic ', ' Link ', ' Fostering ', ' Multidisciplinary Research ', ' Multidisciplinary Collaboration ', ' Interdisciplinary Research ', ' Interdisciplinary Study ', ' inflammatory mediator ', ' Inflammation Mediators ', ' Funding ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Research Project Grants ', ' Immune response ', ' immunoresponse ', ' host response ', ' Immunological response ', ' Therapeutic ', ' Therapeutic Agents ', ' Inflammatory ', ' Smoker ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Investigation ', ' Event ', ' Carotid Atherosclerotic Disease ', ' Carotid Atheroscleroses ', ' American ', ' cohort ', ' novel ', ' Cell surface ', ' Reporting ', ' Carotid Artery Plaques ', ' carotid plaque ', ' Carotid Artery Plaque ', ' response ', ' Pathogenicity ', ' Binding ', ' Molecular Interaction ', ' prevent ', ' preventing ', ' Affinity ', ' Data ', ' K-Series Research Career Programs ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' in vivo ', ' Anti-inflammatory ', ' Cancer Patient ', ' Principal Investigator ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' peptidomimetics ', ' peptide mimic ', ' peptide mimetic ', ' public health relevance ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' in vitro testing ', ' predictive marker ', ' predictive molecular biomarker ', ' predictive biomarkers ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' cancer clinical trial ', ' translational scientist ', ' translational researcher ', ' translational investigator ', ' ']",NHLBI,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,K23,2017,166104,PA-18,0.4664874579589209
"Multi-omic Subtyping of Chronic Obstructive Pulmonary Disease PROJECT SUMMARY/ABSTRACT Chronic obstructive pulmonary disease (COPD) is the leading cause of respiratory mortality in the United States. COPD is a highly heterogeneous disease and some COPD therapies are only applied to specific clinically defined subtypes. With the advent of multiple high-throughput biological assays and machine learning approaches, data-driven subtypes are increasingly being recognized. We hypothesize that such subtypes exist in COPD and that they can be identified using an integrative, multi-'omic approach. To accomplish this goal, we first propose to complement existing RNA and whole genome sequencing data in the well-phenotyped COPDGene study with peripheral blood microRNA sequencing. We will study the relationship of microRNA to genetic variation and gene expression in COPD. Next, we will apply a patient-based network similarity method to these three data types to identify COPD molecular subtypes. Finally, we will associate these subtypes with important clinical phenotypes and outcomes, and validate these subtypes in an independent subset of subjects. Our analysis targets a key clinical problem in COPD management, and will allow the mentee to become an independent investigator, applying bioinformatic and machine learning methods to genomic data in respiratory diseases. PROJECT NARRATIVE Chronic obstructive pulmonary disease (COPD) is a leading cause of death in the United States. Patients with COPD may have very similar lung function but differ in many other characteristics. We propose to use multiple types of biologic data to identify different COPD subtypes, which may be important for disease prognosis and treatment.",Multi-omic Subtyping of Chronic Obstructive Pulmonary Disease,9295208,K08HL136928,"['Affect ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Blood Reticuloendothelial System ', ' Blood ', ' Cause of Death ', ' Complement Proteins ', ' Complement ', ' Disorder ', ' Disease ', ' Gene Expression ', ' Genes ', ' Goals ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Lung diseases ', ' lung disorder ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Methods ', ' mortality ', ' Muscular Atrophy ', ' muscle wasting ', ' muscle loss ', ' muscle deterioration ', ' muscle degradation ', ' muscle breakdown ', ' Muscle Atrophy ', ' Patients ', ' Phenotype ', ' outcome forecast ', ' Prognosis ', ' Pulmonary Emphysema ', ' emphysematous ', ' Emphysema ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Respiratory physiology ', ' respiratory function ', ' lung function ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' Spirometry ', ' Testing ', ' United States ', ' Genetic Diversity ', ' Genetic Variation ', ' X-Ray Medical Imaging ', ' X-Ray Imaging ', ' Roentgenography ', ' Radiography ', ' Diagnostic X-Ray Radiology ', ' Diagnostic X-Ray ', ' Diagnostic Radiology ', ' Conventional X-Ray ', ' Diagnostic radiologic examination ', ' Measures ', ' base ', ' Chronic ', ' Clinical ', ' Training ', ' peripheral blood ', ' Individual ', ' Genetic ', ' Lung volume reduction surgery ', ' LVRS ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Disease Management ', ' Disorder Management ', ' programs ', ' Severities ', ' Complex ', ' respiratory ', ' cohort ', ' Expert Opinion ', ' novel ', ' Participant ', ' disorder subtype ', ' disease subtype ', ' Genomics ', ' Genetic Determinism ', ' genetic determinant ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Bioinformatics ', ' Bio-Informatics ', ' genome sequencing ', ' Data ', ' Molecular Profiling ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Profiling ', ' Genetic Risk ', ' Principal Investigator ', ' Characteristics ', ' Molecular ', ' pathway ', ' Pathway interactions ', ' clinical phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' Outcome ', ' Impairment ', ' transcriptomics ', ' clinically relevant ', ' clinical relevance ', ' Network-based ', ' exome ', ' exomes ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' quantitative imaging ', ' learning strategy ', ' learning method ', ' learning activity ', ' personalized approach ', ' tailored approach ', ' precision approach ', ' individualized approach ', ' Personalized medical approach ', ' multiple omics ', ' SNP array ', ' SNP chip ', ' molecular subtypes ', ' molecular subsets ', ' molecular sub-types ', ' whole genome ', ' entire genome ', ' patient subsets ', ' patient subtypes ', ' genomic data ', ' Trans-Omics for Precision Medicine ', ' TOPMed ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K08,2017,172800,MA-07,0.4806416259634665
"Clinical significance and genetic determinants of novel imaging measures of emphysema distribution in 9,743 smokers PROJECT SUMMARY/ABSTRACT Candidate: Dr. Adel El Boueiz is a pulmonary and critical care physician-scientist completing a period of T32- funded support at the Channing Division of Network Medicine (CDNM) and Harvard Medical School (HMS). He received a Master's of Medical Science in Biomedical Informatics from HMS in May 2016. He will be promoted to Instructor of Medicine at the CDNM and HMS on July 1, 2017. His principal research interests are the genetic epidemiology of chronic obstructive pulmonary disease (COPD) and the translation of genomic discoveries into clinical practice and public health. His long-term goal is to be an independent investigator with expertise in imaging phenotyping, genomics, and predictive analytics of the regional heterogeneity of the various aspects of COPD (emphysema, airway disease, and pulmonary vascular remodeling). Environment: Dr. El Boueiz will continue to pursue his research and career development in the rich and multidisciplinary environment of the CDNM and the Brigham and Women's Hospital Applied Chest Imaging Lab (ACIL). He will be mentored by Drs. Edwin K. Silverman, Peter J. Castaldi, and Ral San Jos Estpar, leaders in the field of COPD quantitative imaging, genetic epidemiology, and predictive analytics with excellent track records of mentoring young investigators towards independent research careers. His career development will also be overseen by an advisory committee with expertise related to key areas of his proposal. Research: COPD is a major cause of morbidity and mortality that is of increasing public health importance. COPD is a heterogeneous disease and this heterogeneity complicates the identification of the predictors of disease progression and consequently, the development of effective therapies. Emphysema distribution is an important COPD-related phenotype that emerged as a strong predictor of the response to lung volume reduction procedures. Despite the availability of advanced texture-based CT quantification methods, global threshold-based quantitative metrics have to date been the cornerstone for the radiological characterization of emphysema distribution with inability to differentiate centrilobular, panlobular, and paraseptal emphysema patterns. In this project, we will apply a texture-based CT quantification method to discover novel imaging biomarkers of the regional heterogeneity of centrilobular, panlobular, and paraseptal emphysema in a large cohort of well-characterized smokers and identify their genetic determinants using whole genome sequencing and integrative genomics analyses. The results will be considered for inclusion along with other rich phenotypic and imaging data in COPD disease progression machine learning predictive models. Relevance: Through improved radiographic phenotyping of emphysema distribution, better understanding of disease pathobiology, and more accurate prediction of disease progression, the proposed work will open new avenues of investigation for the development of personalized and improved COPD therapeutic strategies. PROJECT NARRATIVE Chronic obstructive pulmonary disease (COPD) is a common disease that affects up to 24 million people in the United States, is associated with considerable and increasing morbidity and mortality, and for which there is no available disease-modifying therapy. COPD is associated with significant variation in radiographic, symptomatic and physiologic presentation and exhibits variability in progression. Currently, there is no satisfactory method for progression prediction. This project will identify novel imaging biomarkers of the regional distribution of centrilobular, panlobular, and paraseptal emphysema with particular emphasis on their associations with clinical relevant COPD-related outcomes, their genetic determinants, and their ability to improve prediction of COPD disease progression, above and beyond that provided by the traditional clinical, radiographic, and genetic features. This is an important area of research as predicting those patients who will remain stable from those who will have rapid disease progression is critical in defining prognosis and selecting patients for specific therapeutic interventions.","Clinical significance and genetic determinants of novel imaging measures of emphysema distribution in 9,743 smokers",9503881,K08HL141601,"['Accounting ', ' Affect ', ' Automobile Driving ', ' driving ', ' Clinical Trials ', ' Cohort Studies ', ' Concurrent Studies ', ' Comorbidity ', ' co-morbidity ', ' Computers ', ' Computing Methodologies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Critical Care ', ' Disease ', ' Disorder ', ' Dyspnea ', ' Breathlessness ', ' Environment ', ' Exhibits ', ' Genes ', ' Medical Genetics ', ' Clinical genetics ', ' Goals ', ' Heterogeneity ', ' Hospitals ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Lung diseases ', ' lung disorder ', ' disorder of the lung ', ' disease of the lung ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Medicine ', ' Mentors ', ' Mentorship ', ' Methods ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Patients ', ' Phenotype ', ' Physicians ', ' Genetic Polymorphism ', ' polymorphism ', ' outcome forecast ', ' Prognosis ', ' Public Health ', ' Pulmonary Emphysema ', ' emphysematous ', ' Emphysema ', ' Radiology Specialty ', ' Radiology ', ' General Radiology ', ' Records ', ' Research ', ' research and development ', ' R&D ', ' R & D ', ' Development and Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Respiratory physiology ', ' respiratory function ', ' lung function ', ' medical schools ', ' school of medicine ', ' medical college ', ' Science ', ' Technology ', ' Testing ', ' Tissues ', ' Body Tissues ', ' tomography ', ' Translations ', ' United States ', ' Woman ', ' Work ', ' Diagnostic radiologic examination ', ' X-Ray Medical Imaging ', ' X-Ray Imaging ', ' Roentgenography ', ' Radiography ', ' Diagnostic X-Ray Radiology ', ' Diagnostic X-Ray ', ' Diagnostic Radiology ', ' Conventional X-Ray ', ' Generations ', ' Measures ', ' Medical Research ', ' Walking ', ' advisory team ', ' Task Forces ', ' Advisory Committees ', ' base ', ' career ', ' improved ', ' Procedures ', ' Area ', ' Clinical ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Medical ', ' Evaluation ', ' prognostic ', ' Visual ', ' Disease Progression ', ' Funding ', ' Biological Function ', ' Biological Process ', ' Therapeutic ', ' Genetic ', ' Smoker ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Scientist ', ' Investigation ', ' Complex ', ' Texture ', ' Pattern ', ' respiratory ', ' Lung Volume Reductions ', ' interest ', ' instructor ', ' Quantitative Trait Loci ', ' QTL ', ' cohort ', ' attenuation ', ' novel ', ' disorder risk ', ' disease risk ', ' Positioning Attribute ', ' Position ', ' Lobe ', ' lobes ', ' Therapeutic Intervention ', ' intervention therapy ', ' Chest ', ' Thorax ', ' Thoracic ', ' Thorace ', ' Structure of parenchyma of lung ', ' Lung Tissue ', ' Lung Parenchyma ', ' Pulmonary Function Test/Forced Expiratory Volume 1 ', ' PFT/FEV1 ', ' Forced Expiratory Volume in 1 Second ', ' Forced Expiratory Volume 1 Test ', ' FEV1%VC ', ' FEV1 ', ' Modeling ', ' career development ', ' genetic epidemiology ', ' genetic epidemiologic study ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Genomics ', ' Genetic Determinism ', ' genetic determinant ', ' Bioinformatics ', ' Bio-Informatics ', ' data mining ', ' datamining ', ' genetic association ', ' genome sequencing ', ' ACVR1B gene ', ' Type IB Gene Activin A Receptor ', ' Activin Receptor-Like Kinase 4 Gene ', ' Activin A Receptor, Type II-Like Kinase 4 Gene ', ' ALK4 Gene ', ' ACVRLK4 Gene ', ' ACVR1B ', ' Data ', ' Detection ', ' Subgroup ', ' Clinical/Radiologic ', ' Collection ', ' Pathologic ', ' Lobar ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' disease phenotype ', ' biomed informatics ', ' biomedical informatics ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' Outcome ', ' Vascular remodeling ', ' clinical relevance ', ' clinically relevant ', ' clinical significance ', ' clinically significant ', ' multidisciplinary ', ' effective treatment ', ' effective therapy ', ' genomewide ', ' genome scale ', ' genome-wide ', ' clinical practice ', ' rare allele ', ' rare variant ', ' genetic predictors ', ' personalized patient care ', ' individualized patient care ', ' individualized care ', ' Precision care ', ' personalized care ', ' genomic strategy ', ' genomic effort ', ' Genomic approach ', ' quantitative imaging ', ' imaging marker ', ' imaging biomarker ', ' learning method ', ' learning activity ', ' learning strategy ', ' Predictive Analytics ', ' response prediction ', ' predictor of response ', ' predictive response ', ' prediction of response ', ' predicting response ', ' disease heterogeneity ', ' full genome ', ' entire genome ', ' whole genome ', ' genomic predictors ', ' imaging genetics ', ' Airway Disease ', ' genetic architecture ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K08,2018,170640,MA-07,0.37436875921610646
"An Integrative Radiogenomic Approach to Design Genetically-Informed Image Biomarker for Characterizing COPD ! Abstract  Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of death worldwide with a devastating socio-economic burden impacting more than three million individuals per year in the US. The primary environmental risk factor in the susceptible population is smoking, which causes an exaggerated inflammatory response. However, many factors including several genetic risk variants substantially influence the susceptibility. Twin-based studies show that families with emphysema have a higher risk for the disease. The two different major phenotypes of COPD are small airway remodeling (airway disease) and alveolar destruction (emphysema). Although these two major phenotypes result in a similar deficiency in global lung function, the relationship between them is complicated and likely involves feedback mechanisms. Developing an objective method to characterize lung phenotypes is critical since treatment candidates vary based on phenotype. Measurements from High-Resolution Computed Tomography (HRCT) images are increasingly used to describe COPD since they can quantitatively describe the contribution of the phenotypes. To discover the genetic risk variants, Genome-Association Studies (GWAS) have focused on either the physiological lung function or a simple threshold-based measurement from lung CT, neither of which fully characterizes phenotypic subtypes or the distribution pattern of disease. The proposed studies will take advantage of the rich image and genetic data jointly to build a genetically-informed imaging biomarker to characterize each patient. For each patient, our method summarizes the CT image to a vector representation that accurately describes the severity of the disease. Also, a method to link the representation back to the genetic risk variants will be developed. If successful, these methods can be used to monitor the efficacy of treatment or progression of the disease using imaging data. Successful execution of the second aim will result in better understanding of the etiology of different disease subtypes and discovery of novel genetic pathways that could be used as potential drug targets. Furthermore, the patient representation enables the use of image data to construct a more powerful model to predict the so-called acute exacerbation event. Predicting the exacerbations is clinically important since they cause further damage to the lung.  In Aim 1, we develop and implement a novel image biomarker that is mutually informed by imaging and genetic data from each patient. Our statistical method in Aim 2 elucidates the underlying genetic pathways behind the abnormal anatomical variations explained by the biomarker. We validate our method on data from 10,300 patients in the COPDGene dataset. ! Narrative  Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of death worldwide with a devastating socio-economic burden impacting more than three million individuals per year in the US. Measurements from High-Resolution Computed Tomography (HRCT) images are increasingly used to describe COPD. Many factors including several genetic risk variants substantially influence the susceptibility. We propose to take advantage of the rich image and genetic data jointly to understand the underlying biological causes of the disease and discovery of novel genetic pathways that could be used as potential drug targets.",An Integrative Radiogenomic Approach to Design Genetically-Informed Image Biomarker for Characterizing COPD,9499218,R01HL141813,"['Affect ', "" Alzheimer's Disease "", ' senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', ' Anatomy ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Back ', ' Dorsum ', ' Cause of Death ', ' Chronic Bronchitis ', ' Computers ', ' Disease ', ' Disorder ', ' Disease Vectors ', ' Family ', ' Feedback ', ' Genes ', ' Genetic Markers ', ' genetic biomarker ', ' Genome ', ' Genotype ', ' Goals ', ' Joints ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Mathematics ', ' Math ', ' Methods ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Obstruction ', ' Patients ', ' Phenotype ', ' Pulmonary Emphysema ', ' emphysematous ', ' Emphysema ', ' Respiratory physiology ', ' respiratory function ', ' lung function ', ' Risk Factors ', ' Smoking ', ' Spirometry ', ' Time ', ' tomography ', ' X-Ray Computed Tomography ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' Twin Multiple Birth ', ' Twins ', ' Measures ', ' Data Set ', ' Dataset ', ' Caring ', ' base ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Area ', ' Acute ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Physiologic ', ' Physiological ', ' Link ', ' Susceptibility ', ' Predisposition ', ' lung lobe ', ' Individual ', ' Measurement ', ' Disease Progression ', ' Descriptor ', ' Deformity ', ' Anatomical Abnormality ', ' Anatomic Abnormality ', ' Genetic ', ' clinical Diagnosis ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Pollution ', ' Dimensions ', ' Complex ', ' Event ', ' Pattern ', ' Severity of illness ', ' disease severity ', ' small airways disease ', ' Biological Neural Networks ', ' neural network ', ' attenuation ', ' novel ', ' economic cost ', ' disorder risk ', ' disease risk ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Reporting ', ' Statistical Methods ', ' Pulmonary Function Test/Forced Expiratory Volume 1 ', ' PFT/FEV1 ', ' Forced Expiratory Volume in 1 Second ', ' Forced Expiratory Volume 1 Test ', ' FEV1%VC ', ' FEV1 ', ' Modeling ', ' drug development ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Pathogenicity ', ' Inflammatory Response ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' Address ', ' Data ', ' Economic Burden ', ' High Resolution Computed Tomography ', ' high resolution CT ', ' Resolution ', ' Genetic Risk ', ' Pathologic ', ' Monitor ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' socioeconomically ', ' socio-economically ', ' socio-economic ', ' socioeconomics ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' vector ', ' designing ', ' design ', ' airway remodeling ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Treatment Efficacy ', ' Population ', ' alveolar destruction ', ' Heritability ', ' endophenotype ', ' high risk ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' risk variant ', ' Drug Targeting ', ' Radiogenomics ', ' noninvasive imaging ', ' non-invasive imaging ', ' Lung CT scan ', ' Lung CT ', ' CT Lung Screening ', ' Lung CAT Scan ', ' imaging marker ', ' imaging biomarker ', ' genotyped patients ', ' imaging genetics ', ' high dimensionality ', ' Airway Disease ', ' deep learning ', ' ']",NHLBI,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,R01,2018,570906,PA-18,0.281208006586705
"Machine Learning Development for Subtyping COPD Project Summary Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by progressive loss of lung function with subsequent increasing breathlessness and worsening quality of life. This heterogeneity makes it difficult to predict health decline and develop targeted treatments for better patient care. To date, researchers have attempted to use standard machine learning methodology to identify more meaningful subtypes of COPD, but these methods often make general assumptions about the data, limiting their ability to penetrate more complex patterns in some data sets. Thus, a meaningful reclassification of COPD subtypes that could lead to more targeted therapies and interventions has been elusive. The applicant introduces a new way of looking at the COPD subtyping problem by recasting it in terms of discovering associations of individuals to disease trajectories  i.e., grouping individuals based on their similarity in response to environmental and/or disease causing variables. The machine learning methods proposed build on the most recent advances in Bayesian nonparametrics, a collection of theoretical ideas and techniques that permit very flexible data representations. In this career development proposal, the applicant hypothesizes that these machine learning methods and extensions thereof  together with data sources not previously leveraged for COPD subtyping  will produce more biologically meaningful sub-groupings of patients, leading to a better understanding of the genetic and biological underpinnings of the disease and ultimately improved patient management. Aim 1 of this application involves evaluating the utility of CT-assessed lung mass  a potentially more discriminative measure of emphysema than conventionally used measures  for defining COPD subtypes using both K-means clustering and our disease trajectory algorithm. The goal of Aim 2 is to evaluate the utility of comorbidity data for defining COPD subtypes using our trajectory clustering algorithm. Novel computed tomography based measures of muscle wasting (cachexia) and pulmonary vascular pruning will be explored to determine their efficacy in subtype determination. Additionally, we will extend and test the trajectory algorithm in order to model discrete outputs (such as physician-diagnosed comorbidities), count data (e.g. exacerbations), and time-to-event data (death). In Aim 3, the applicant will extend our trajectory clustering algorithms to directly incorporate genetic and omics data for subtype discovery. Together, the research proposed in the aims of this award will take full advantage of the comprehensive data set available through the COPDGene study. Execution of the aims in this proposal will be possible through active collaboration with Dr. Ron Kikinis, M.D., a renowned leader in the field of medical image analysis, and Dr. Ed Silverman, an internationally recognized expert in the genetic epidemiology of COPD. Project Narrative Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by progressive loss of lung function with subsequent increasing breathlessness and worsening quality of life. This heterogeneity makes it difficult to predict health decline and develop targeted treatments for better patient care. In carrying out the research outlined in the following proposal, we plan to develop and apply machine learning methods to better identify subpopulations of individuals who have similar forms of COPD, potentially enabling better, targeted therapies.",Machine Learning Development for Subtyping COPD,9480874,K25HL130637,"['Affect ', ' Algorithms ', ' Award ', ' Blood Vessels ', ' vascular ', ' Cachexia ', ' Cachectic ', ' Cause of Death ', ' Comorbidity ', ' co-morbidity ', ' Data Reporting ', ' data representation ', ' Data Sources ', ' Cessation of life ', ' Death ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Disease susceptibility ', ' liability to disease ', ' Diathesis ', ' Dyspnea ', ' Breathlessness ', ' Environment ', ' Patient Care ', ' Patient Care Delivery ', ' Goals ', ' Health ', ' Heterogeneity ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Medical Imaging ', ' Methods ', ' Methodology ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' mortality ', ' Muscular Atrophy ', ' muscle wasting ', ' muscle loss ', ' muscle deterioration ', ' muscle degradation ', ' muscle breakdown ', ' Muscle Atrophy ', ' Patients ', ' Physicians ', ' Publishing ', ' Pulmonary Emphysema ', ' emphysematous ', ' Emphysema ', ' Quality of life ', ' QOL ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Respiratory physiology ', ' respiratory function ', ' lung function ', ' Smoke ', ' Syndrome ', ' Testing ', ' Time ', ' X-Ray Computed Tomography ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' Measures ', ' Pulmonary Mass ', ' Lung Mass ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Clinical ', ' Biological ', ' peripheral blood ', ' Failure ', ' Individual ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Disease Progression ', ' Collaborations ', ' Descriptor ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Event ', ' Pattern ', ' Techniques ', ' particle ', ' novel ', ' Disease model ', ' disorder model ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Modeling ', ' career development ', ' response ', ' genetic epidemiology ', ' genetic epidemiologic study ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Inflammatory Response ', ' genetic association ', ' Data ', ' Doctor of Medicine ', ' M.D. ', ' International ', ' Subgroup ', ' Collection ', ' physiological imaging ', ' Physiologic Imaging ', ' Functional Imaging ', ' Scheme ', ' Characteristics ', ' Process ', ' groupings ', ' Grouping ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' Output ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' designing ', ' design ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' flexible ', ' flexibility ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' targeted treatment ', ' learning method ', ' learning activity ', ' learning strategy ', ' cigarette smoke ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K25,2018,187699,MA-07,0.44476189124601284
"Multi-omic Subtyping of Chronic Obstructive Pulmonary Disease PROJECT SUMMARY/ABSTRACT Chronic obstructive pulmonary disease (COPD) is the leading cause of respiratory mortality in the United States. COPD is a highly heterogeneous disease and some COPD therapies are only applied to specific clinically defined subtypes. With the advent of multiple high-throughput biological assays and machine learning approaches, data-driven subtypes are increasingly being recognized. We hypothesize that such subtypes exist in COPD and that they can be identified using an integrative, multi-'omic approach. To accomplish this goal, we first propose to complement existing RNA and whole genome sequencing data in the well-phenotyped COPDGene study with peripheral blood microRNA sequencing. We will study the relationship of microRNA to genetic variation and gene expression in COPD. Next, we will apply a patient-based network similarity method to these three data types to identify COPD molecular subtypes. Finally, we will associate these subtypes with important clinical phenotypes and outcomes, and validate these subtypes in an independent subset of subjects. Our analysis targets a key clinical problem in COPD management, and will allow the mentee to become an independent investigator, applying bioinformatic and machine learning methods to genomic data in respiratory diseases. PROJECT NARRATIVE Chronic obstructive pulmonary disease (COPD) is a leading cause of death in the United States. Patients with COPD may have very similar lung function but differ in many other characteristics. We propose to use multiple types of biologic data to identify different COPD subtypes, which may be important for disease prognosis and treatment.",Multi-omic Subtyping of Chronic Obstructive Pulmonary Disease,9479280,K08HL136928,"['Affect ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Blood ', ' Blood Reticuloendothelial System ', ' Cause of Death ', ' Complement ', ' Complement Proteins ', ' Disease ', ' Disorder ', ' Gene Expression ', ' Genes ', ' Goals ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Lung diseases ', ' lung disorder ', ' disorder of the lung ', ' disease of the lung ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Methods ', ' mortality ', ' Muscular Atrophy ', ' muscle wasting ', ' muscle loss ', ' muscle deterioration ', ' muscle degradation ', ' muscle breakdown ', ' Muscle Atrophy ', ' Patients ', ' Phenotype ', ' outcome forecast ', ' Prognosis ', ' Pulmonary Emphysema ', ' emphysematous ', ' Emphysema ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Respiratory physiology ', ' respiratory function ', ' lung function ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' Spirometry ', ' Testing ', ' United States ', ' Genetic Variation ', ' Genetic Diversity ', ' Diagnostic radiologic examination ', ' X-Ray Medical Imaging ', ' X-Ray Imaging ', ' Roentgenography ', ' Radiography ', ' Diagnostic X-Ray Radiology ', ' Diagnostic X-Ray ', ' Diagnostic Radiology ', ' Conventional X-Ray ', ' Measures ', ' base ', ' Chronic ', ' Clinical ', ' Training ', ' peripheral blood ', ' Individual ', ' Genetic ', ' Lung volume reduction surgery ', ' LVRS ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Disease Management ', ' Disorder Management ', ' programs ', ' Severities ', ' Complex ', ' respiratory ', ' cohort ', ' Expert Opinion ', ' novel ', ' Participant ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Genomics ', ' Genetic Determinism ', ' genetic determinant ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Bioinformatics ', ' Bio-Informatics ', ' genome sequencing ', ' Data ', ' Molecular Profiling ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Genetic Risk ', ' Principal Investigator ', ' Characteristics ', ' Molecular ', ' pathway ', ' Pathway interactions ', ' clinical phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' Outcome ', ' Impairment ', ' transcriptomics ', ' clinical relevance ', ' clinically relevant ', ' Network-based ', ' exomes ', ' exome ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' transcriptome sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' risk variant ', ' quantitative imaging ', ' microRNA sequencing ', ' micro RNA expression profiling ', ' miRNA-seq ', ' miRNA sequencing ', ' global miRNA profiling ', ' MicroRNA Expression Profiling ', ' miRNA expression profiling ', ' learning method ', ' learning activity ', ' learning strategy ', ' tailored approach ', ' precision approach ', ' individualized approach ', ' Personalized medical approach ', ' personalized approach ', ' multi-omics ', ' multiple omics ', ' SNP chip ', ' SNP array ', ' molecular subsets ', ' molecular sub-types ', ' expression subtypes ', ' molecular subtypes ', ' full genome ', ' entire genome ', ' whole genome ', ' patient subtypes ', ' patient subpopulations ', ' patient subgroups ', ' patient subsets ', ' genomic data ', ' TOPMed ', ' Trans-Omics for Precision Medicine ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K08,2018,172800,MA-07,0.4806416259634665
"Autoimmunity as a Mechanism for Atherosclerosis in COPD     DESCRIPTION (provided by applicant): This project will facilitate the development of the principal investigator into an independent translational researcher investigating systemic vascular injury in Chronic obstructive pulmonary disease (COPD). This will be accomplished in the rich academic environment at the University of Pittsburgh, under the guidance of a highly accomplished team of mentors, and in the conduct of multidisciplinary research project that will develop autoimmunity as a novel mechanism for atherosclerosis in COPD. The increased risk of atherosclerosis in COPD is not explained by smoking, age, hypertension, and other established vascular disease risk factors. Chronic inflammation has recently been implicated as an atherogenic mechanism in COPD. We and others have reported that chronic inflammation in COPD may be propagated by humoral autoimmunity. Specifically, smokers with COPD have greatly increased levels of circulating autoantibodies that demonstrate in vitro pathogenic effects. Our subsequent studies also show that these autoantibodies target at least 50 different autoantigens and consistently target glucose regulated protein 78 (GRP78), particularly in patients with parenchymal lung destruction, i.e. emphysema. GRP78 is present in the endoplasmic reticulum, where it regulates the unfolded protein response, and is also a multifunction cell surface receptor. Studies in cancer patients suggest that ligation of the N-terminus of cell surface GRP78 by anti-GRP78 IgG transduces pro-inflammatory and pro-proliferative signals by activation of the AKT pathway, followed by NFB activation. Additional in vivo studies have identified anti-GRP78 IgG with affinity for the C-terminus of cell surface GRP78 that produce counteracting anti-inflammatory effects by suppressing AKT activation. Our preliminary work shows that circulating anti-GRP78 IgG in COPD patients binds to macrophages and leads to increased NFB activation and production of atherogenic inflammatory mediators by them. The macrophage is critical in the development of both atherosclerosis and COPD. Also, cross-sectional studies in our cohort find that levels of circulating anti-GRP78 IgG are strongly associated with carotid atherosclerosis in patients with emphysema, independent of established vascular risk factors. Therefore, we hypothesize that autoimmune responses against GRP78 are a mechanism for atherosclerosis in COPD. During this award, we will: (1) Test the hypothesis that elevated levels of circulating anti-GRP78 IgG predict progression of carotid atherosclerosis in patients with emphysema independent of established risk factors over 4 year follow up; (2) Test the hypothesis that anti-GRP78 IgG binds to the N-terminus of cell surface GRP78 and activates the AKT pathway followed by NFB activation and production of inflammatory mediators using a variety of cell function assays, and provide proof of concept for two potential therapeutic strategies; (3) Test the hypothesis that there are other antigen-specific immune responses associated with atherosclerosis in COPD by using machine learning to analyze high-throughput data on a large number of circulating autoantibody levels. PUBLIC HEALTH RELEVANCE: Chronic obstructive pulmonary disease (COPD) is a lung disease caused by smoking that kills more and more Americans each year, and is now the third leading cause of death in the US. Although it is largely viewed as a disease of the lungs, the most common cause of death in patients with COPD are blockages in blood vessels. This research project will investigate why patients with COPD are so prone to develop these blood vessel blockages.",Autoimmunity as a Mechanism for Atherosclerosis in COPD,9460547,K23HL126912,"['Age ', ' ages ', ' Algorithms ', ' Antibodies ', ' Antigens ', ' immunogen ', ' ATGN ', ' Atherosclerosis ', ' atherosclerotic vascular disease ', ' atherosclerotic disease ', ' atheromatosis ', ' Atherosclerotic Cardiovascular Disease ', ' Atheroscleroses ', ' Autoantibodies ', ' self reactive antibody ', ' autoimmune antibody ', ' Autoantigens ', ' Self-Antigens ', ' Autologous Antigens ', ' Autoimmune Diseases ', ' autoimmune disorder ', ' Autoimmune Responses ', ' Autoimmunity ', ' Autoimmune Status ', ' Award ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Blood Vessels ', ' vascular ', ' Western Blotting ', ' Western Immunoblotting ', ' protein blotting ', ' Cause of Death ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cross-Sectional Studies ', ' Disease Frequency Surveys ', ' Cross-Sectional Survey ', ' Cross-Sectional Analyses ', ' Cross Sectional Analysis ', ' Endoplasmic Reticulum ', ' Ergastoplasm ', ' Environment ', ' Enzyme-Linked Immunosorbent Assay ', ' ELISA ', ' Flow Cytometry ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Human ', ' Modern Man ', ' Hypertension ', ' hypertensive disease ', ' hyperpiesis ', ' hyperpiesia ', ' high blood pressure ', ' Vascular Hypertensive Disorder ', ' Vascular Hypertensive Disease ', ' Immunoglobulin G ', ' IgG ', ' 7S Gamma Globulin ', ' In Vitro ', ' Inflammation ', ' Ligation ', ' Closure by Ligation ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Lung diseases ', ' lung disorder ', ' disorder of the lung ', ' disease of the lung ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' macrophage ', ' Mentors ', ' Mentorship ', ' Morbidity - disease rate ', ' Morbidity ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Patients ', ' Phenotype ', ' Phosphorylation ', ' Protein Phosphorylation ', ' Production ', ' Proteins ', ' Pulmonary Emphysema ', ' emphysematous ', ' Emphysema ', ' Cell Surface Receptors ', ' Risk ', ' Risk Factors ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Smoking ', ' Testing ', ' Ultrasonography ', ' ultrasound scanning ', ' ultrasound imaging ', ' ultrasound ', ' sound measurement ', ' sonography ', ' sonogram ', ' diagnostic ultrasound ', ' Ultrasound Test ', ' Ultrasound Medical Imaging ', ' Ultrasound Diagnosis ', ' Ultrasonogram ', ' Ultrasonic Imaging ', ' Medical Ultrasound ', ' Echotomography ', ' Echography ', ' Universities ', ' Vascular Diseases ', ' vasculopathy ', ' vascular dysfunction ', ' blood vessel disorder ', ' Vascular Disorder ', ' Work ', ' glucose-regulated proteins ', ' Measures ', ' related to A and C-protein ', ' rac protein kinase ', ' proto-oncogene protein akt ', ' proto-oncogene protein RAC ', ' c-akt protein ', ' RAC-PK protein ', ' Protein Kinase B ', ' Akt protein ', ' AKT ', ' Proto-Oncogene Proteins c-akt ', ' Injury ', ' Chronic ', ' Link ', ' Fostering ', ' Multidisciplinary Research ', ' Multidisciplinary Collaboration ', ' Interdisciplinary Research ', ' Interdisciplinary Study ', ' inflammatory mediator ', ' Inflammation Mediators ', ' Funding ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Research Project Grants ', ' Immune response ', ' immunoresponse ', ' host response ', ' Immunological response ', ' Therapeutic ', ' Therapeutic Agents ', ' Exposure to ', ' Inflammatory ', ' Smoker ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Investigation ', ' Event ', ' Carotid Atherosclerotic Disease ', ' Carotid Atheroscleroses ', ' American ', ' cohort ', ' novel ', ' Cell surface ', ' Reporting ', ' Carotid Artery Plaques ', ' carotid plaque ', ' Carotid Artery Plaque ', ' response ', ' Pathogenicity ', ' Binding ', ' Molecular Interaction ', ' prevent ', ' preventing ', ' Affinity ', ' Data ', ' K-Series Research Career Programs ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' in vivo ', ' anti-inflammatory effect ', ' Antiinflammatory Effect ', ' Cancer Patient ', ' Principal Investigator ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' peptide mimic ', ' peptide mimetic ', ' peptidomimetics ', ' public health relevance ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' in vitro testing ', ' vascular risk factor ', ' predictive molecular biomarker ', ' predictive biomarkers ', ' predictive marker ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' targeted treatment ', ' cancer clinical trial ', ' translational researcher ', ' translational investigator ', ' translational scientist ', ' atherosclerotic risk ', ' atherosclerosis risk ', ' ']",NHLBI,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,K23,2018,166104,PA-18,0.4664874579589209
"Omics Data Integration to Identify Disease Pathways in COPD Project Summary Although chronic obstructive pulmonary disease (COPD) occurs predominantly in smokers, it is unknown why only a minority of smokers (~20-40%) develops chronic airflow limitation and/or destruction of distal airspaces (emphysema). Using several NIH and foundation grants, we have systematically generated genetic, genomics, proteomic, and metabolomics profiles from the NHLBI supported COPDGene cohort, which includes 10,300 current and former smokers age 45-80. This proposal will focus on integrating the omics data generated in the five-year followup (Phase II) of the COPDgene study to identify molecular subtypes of COPD across a broad range of blood profiles (Specific Aim 1). Biomarkers and pathways discriminating the molecular subtypes, in addition to other COPD phenotypes will then be identified (Specific Aim 2). These results will identify markers that are specific to smoking-related lung disease and can be used to develop novel diagnostic tests and therapies for early prevention and treatment of COPD. Relevance to Public Health Chronic obstructive pulmonary disease (COPD) is the third most common cause of death in the United States. The major risk factor is smoking; however, most smokers do not develop COPD and the factors that identify who goes from normal to abnormal lung function are unknown. This proposal will use already collected data on existing NHLBI cohorts to identify blood signatures that can identify who will be at risk for developing smoking related lung disease. The knowledge gained will help guide treatment strategies and improve prognosis assessments.",Omics Data Integration to Identify Disease Pathways in COPD,9562961,R21HL140376,"['Age ', ' ages ', ' Biology ', ' Blood ', ' Blood Reticuloendothelial System ', ' Cause of Death ', ' Complement ', ' Complement Proteins ', ' Computers ', ' Disease ', ' Disorder ', ' Foundations ', ' Gene Expression ', ' Goals ', ' Grant ', ' Heart Diseases ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Hematological Disease ', ' blood disorder ', ' Hematological Disorder ', ' Hematologic Diseases ', ' Blood Diseases ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lung diseases ', ' lung disorder ', ' disorder of the lung ', ' disease of the lung ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Methods ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Phenotype ', ' outcome forecast ', ' Prognosis ', ' Proteins ', ' Public Health ', ' Pulmonary Emphysema ', ' emphysematous ', ' Emphysema ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Respiratory physiology ', ' respiratory function ', ' lung function ', ' Risk ', ' Risk Factors ', ' Smoking ', ' Supervision ', ' Time ', ' United States ', ' Work ', ' Diagnostic tests ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Distal ', ' Chronic ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Individual ', ' Sample Size ', ' Disease Progression ', ' Funding ', ' Genetic ', ' Smoker ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Investigation ', ' Complex ', ' Source ', ' System ', ' Severity of illness ', ' disease severity ', ' cohort ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' novel ', ' Prevention ', ' Sleep Disorders ', ' sleep problem ', ' Sampling ', ' response ', ' Proteomics ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Genomics ', ' disorder control ', ' disease control ', ' computerized data processing ', ' data processing ', ' metabolomics ', ' metabonomics ', ' metabolism measurement ', ' data mining ', ' datamining ', ' Data ', ' Disease Pathway ', ' Molecular Target ', ' Classification Scheme ', ' Preparation ', ' Characteristics ', ' Molecular ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' clinical phenotype ', ' disease phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' data integration ', ' Minority ', ' multidisciplinary ', ' early therapy ', ' Early treatment ', ' data space ', ' human disease ', ' next generation diagnostics ', ' new diagnostics ', ' novel diagnostics ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel druggable target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new druggable target ', ' new drug target ', ' new therapeutic target ', ' novel therapy approach ', ' novel therapeutic approach ', ' new therapy approaches ', ' new therapeutic strategies ', ' new therapeutic intervention ', ' new therapeutic approach ', ' novel therapeutic intervention ', ' treatment strategy ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' learning method ', ' learning activity ', ' learning strategy ', ' multi-omics ', ' multiple omics ', ' molecular subsets ', ' molecular sub-types ', ' expression subtypes ', ' molecular subtypes ', ' secondary analysis ', ' Disease stratification ', ' high dimensionality ', ' Expression Profiling ', ' unsupervised machine learning ', ' unsupervised learning ', ' ']",NHLBI,UNIVERSITY OF COLORADO DENVER,R21,2018,117464,CO-06,0.4244675570074906
"INTEGRATIVE GENOMICS OF CLINICAL SUBTYPES IN COPDGENE     DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, which is not captured by the degree of airflow limitation measured by spirometry. One of the goals of the Genetic Epidemiology of COPD Study (COPDGene) is to define meaningful subgroups of COPD, leading to a new disease classification. These clinical and statistical approaches are utilizing the extensive phenotype data collected in COPDGene, including chest CT scans. The ""Integrative Genomics of Clinical Subtypes in COPDGene"" study will use RNA sequencing and miRNA for subtyping, different from the main COPDGene study. The hypothesis is that different COPD subtypes will have distinct pathophysiology, which can be identified through gene expression signatures, miRNA profiling and integrative genomics studies. Genomewide genotyping data can be used to test for associations with the subtypes. However, traditional genomewide association studies may be underpowered to detect subtype effects. Gene expression is an important intermediate phenotype between genotypes and complex traits, and can be easily assayed in peripheral blood. In this proposal, we will use expression quantitative trait locus (eQTL) analysis to identify functional single nucleotide polymorphisms (SNPs) affecting expression of differentially expressed genes and miRNAs. We will address the following Specific Aims: (1) Gene expression profiling in COPD subtypes: We will collect peripheral blood RNA samples from subjects in COPDGene, perform RNA sequencing and miRNA profiling and test for differentially expressed transcripts and miRNAs for two clinical subtype comparisons: (A) emphysema-predominant vs. airway-predominant COPD and (B) frequent vs. infrequent acute exacerbations. We will validate the blood associations by RNA-sequencing in COPD lung tissue samples. (2) Molecular subtypes of COPD: We will use statistical and machine learning methods to define molecular subtypes based on the RNA sequencing and miRNA data. We will validate the molecular subtypes with the clinical, imaging and longitudinal follow-up data. (3) Integrative genomics of COPD subtypes: We will integrate the gene and miRNA expression data with genomewide SNP data to identify eQTL SNPs associated with transcript levels of the differentially expressed and subtype-defining genes and miRNAs from Aims 1 and Aim 2. The eQTL SNPs will be tested for association with the clinical subtypes in the full COPDGene Study population. This proposal will be distinct yet complement the parent COPDGene Study by using mRNA and miRNA expression data to identify genetic influences on COPD subtypes, which could identify biomarkers of disease subtypes or novel pathways and targets, moving towards the goal of precision medicine in COPD. The gene expression, miRNA and eQTL datasets will serve as resources for COPDGene and the community of COPD investigators. PUBLIC HEALTH RELEVANCE: The ""Integrative Genomics of Clinical Subtypes in COPDGene"" study will allow us to find genes that are responsible for the specific type of COPD experienced by a patient. The information we learn may eventually lead to a more personalized approach to the diagnosis and treatment of COPD patients.",INTEGRATIVE GENOMICS OF CLINICAL SUBTYPES IN COPDGENE,9492745,R01HL125583,"['Affect ', ' Rheumatoid Arthritis ', ' rheumatic arthritis ', ' Atrophic Arthritis ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Blood ', ' Blood Reticuloendothelial System ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Communities ', ' Complement ', ' Complement Proteins ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Environmental Exposure ', ' Gene Expression ', ' Genes ', ' Genotype ', ' Goals ', ' Heterogeneity ', ' Recording of previous events ', ' History ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Learning ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Lung diseases ', ' lung disorder ', ' disorder of the lung ', ' disease of the lung ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Parents ', ' Patients ', ' Phenotype ', ' Pulmonary Emphysema ', ' emphysematous ', ' Emphysema ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Respiratory physiology ', ' respiratory function ', ' lung function ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' Messenger RNA ', ' mRNA ', ' Spirometry ', ' Testing ', ' X-Ray Computed Tomography ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' Genetic Variation ', ' Genetic Diversity ', ' Measures ', ' Data Set ', ' Dataset ', ' Guidelines ', ' base ', ' Blood Sample ', ' Blood specimen ', ' improved ', ' Acute ', ' Clinical ', ' Phase ', ' Biological ', ' peripheral blood ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Techniques ', ' experience ', ' Quantitative Trait Loci ', ' QTL ', ' small airways disease ', ' disease natural history ', ' trait ', ' novel ', ' Study Subject ', ' disease classification ', ' nosology ', ' disorder classification ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' Gene Expression Profiling ', ' transcriptional profiling ', ' gene expression assay ', ' gene expression analysis ', ' Transcript Expression Analysis ', ' Transcript Expression Analyses ', ' Gene Expression Pattern Analysis ', ' Gene Expression Monitoring ', ' Structure of parenchyma of lung ', ' Lung Tissue ', ' Lung Parenchyma ', ' Sampling ', ' genetic epidemiology ', ' genetic epidemiologic study ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Genomics ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Tissue Sample ', ' genome sequencing ', ' Address ', ' Symptoms ', ' Data ', ' Subgroup ', ' nonmalignant ', ' Non-Malignant ', ' Transcript ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' transcriptional signature ', ' gene expression signature ', ' gene expression pattern ', ' Expression Signature ', ' Gene Expression Profile ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' bloodstream infection ', ' blood infection ', ' Sepsis ', ' clinical relevance ', ' clinically relevant ', ' public health relevance ', ' therapeutic response ', ' response to treatment ', ' treatment response ', ' molecular phenotype ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' genomewide ', ' genome scale ', ' genome-wide ', ' exomes ', ' exome ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' transcriptome sequencing ', ' rare allele ', ' rare variant ', ' precision-based medicine ', ' precision medicine ', ' transcriptional differences ', ' differentially expressed ', ' differential expression ', ' learning method ', ' learning activity ', ' learning strategy ', ' tailored approach ', ' precision approach ', ' individualized approach ', ' Personalized medical approach ', ' personalized approach ', ' phenotypic data ', ' molecular subsets ', ' molecular sub-types ', ' expression subtypes ', ' molecular subtypes ', ' disease heterogeneity ', ' study population ', ' full genome ', ' entire genome ', ' whole genome ', ' chest CT ', ' chest computed tomography ', ' clinical subtypes ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,R01,2018,860223,MA-07,0.4106033809787729
"Systems Level Causal Discovery in Heterogeneous TOPMed Data SYSTEMS LEVEL CAUSAL DISCOVERY IN HETEROGENEOUS TOPMED DATA ABSTRACT The advent of new technologies for collecting and analyzing multiple heterogeneous data streams from the same individual makes possible the detailed phenotypic characterization of diseases and paves the way for the development of individualized precision therapies. A major bottleneck in this process is the lack of robust, efficient and truly integrative analytic methods for such multi-modal data. This proposal builds on the ongoing efforts of our group in the area of causal learning in biomedicine. The objective of this application is to extend, modify and tailor our causal probabilistic graphical models to data typically collected by TOPMed projects, such as omics data (SNPs, metabolomics, RNA-seq, etc), imaging, patients' history, and clinical data. COPDGene is one of the TOPMed projects and has generated datasets with those modalities for 10,000 patients with chronic obstructive pulmonary disease (COPD), the third leading cause of death and a major cause of disability and health care costs in the US. The prevailing view is that COPD is a syndrome, consisting of multiple diseases with different characteristics. There is currently no satisfactory method for COPD subtyping or prediction of disease progression. In this project we will apply, test and validate our approaches on COPDGene and another large independent COPD cohort. The extension and application of our methods to cross-sectional and longitudinal data will also allow us to investigate a number of important questions and aspects related to COPD. Mechanistically, we will investigate how SNPs, genes and their networks are causally linked to disease phenotypes. In pathology, we will identify conditional biomarkers, which will lead to disease sub-classification and identification of causal components in each subtype. In pathophysiology, we will identify features that are directly linked to lung function decline and outcome. We will make all our algorithms and results available to the community through web and public cloud interfaces. The deliverables will be (1) new probabilistic approaches for integration and analysis of multi-modal cross-sectional and longitudinal data, including SNPs, blood biomarkers, CT scans and clinical data; (2) new cloud-based server to make these approaches available to the research community; (3) results on the mechanism, pathology and pathophysiology of COPD facilitation and progression. To guarantee the success of the project we have assembled a team of experts in genomics, machine learning, cloud computing and COPD. This cross- disciplinary team project will have a positive impact beyond the above deliverables, since the generality of our approaches makes them applicable to any disease. We expect that during this U01 we will have the opportunity to collaborate with other teams in the TOPMed consortium to help them investigate the causes of their corresponding disease phenotypes. We do believe that data integration in a single probabilistic framework will be in the heart of precision medicine strategies in the future, when massive high-throughput data collection will become a routine diagnostic and prognostic procedure in all hospitals. PROJECT NARRATIVE Current technologies for high-throughput biomedical data collection allow the interrogation of multiple modalities from a single patient. New promising analytical methods started emerging, which can analyze those multi-modal data in a holistic way. Chronic obstructive pulmonary disease (COPD) constitutes the third leading cause of death and a major cause of disability and health care costs in the US. The prevailing view is that COPD is a syndrome, consisting of multiple diseases with their own characteristics. There is currently no satisfactory method for COPD subtyping. We will apply, test and validate new probabilistic approaches on two cohorts of COPD patients. We will investigate the mechanisms of disease facilitation; we will identify patient cohorts with specific characteristics (disease subtypes); and investigate risk factors and causal variants for the disease progression in each subtype. ",Systems Level Causal Discovery in Heterogeneous TOPMed Data,9473087,U01HL137159,"['Algorithms ', ' Blood ', ' Blood Reticuloendothelial System ', ' Cause of Death ', ' Classification ', ' Systematics ', ' Communities ', ' Data Collection ', ' Disease ', ' Disorder ', ' Disease susceptibility ', ' liability to disease ', ' Diathesis ', ' Future ', ' Genes ', ' Genotype ', ' Goals ', ' Heart ', ' Recording of previous events ', ' History ', ' Hospitals ', ' Learning ', ' Chronic Obstructive Airway Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' COAD ', ' Methods ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' mortality ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Pathology ', ' Patients ', ' Phenotype ', ' outcome forecast ', ' Prognosis ', ' Pulmonology ', ' Pulmonary Medicine ', ' Pneumonology ', ' Pneumology ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Respiratory physiology ', ' respiratory function ', ' lung function ', ' Risk ', ' Risk Factors ', ' medical schools ', ' school of medicine ', ' medical college ', ' Science ', ' Computer software ', ' Software ', ' Syndrome ', ' Technology ', ' Testing ', ' Tissues ', ' Body Tissues ', ' X-Ray Computed Tomography ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' Universities ', ' Health Care Costs ', ' Healthcare Costs ', ' Health Costs ', ' Outcome Assessment ', ' Data Set ', ' Dataset ', ' analytical method ', ' base ', ' Procedures ', ' Area ', ' Clinical ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Lifting ', ' Link ', ' prognostic ', ' disability ', ' Individual ', ' Disease Progression ', ' Funding ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Morphology ', ' tool ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Computational Biology ', ' computer biology ', ' Stream ', ' System ', ' Visit ', ' success ', ' computer science ', ' cohort ', ' Peripheral Blood Mononuclear Cell ', ' PBMC ', ' novel ', ' Graph ', ' new technology ', ' novel technologies ', ' Disease model ', ' disorder model ', ' Modality ', ' Modeling ', ' high throughput technology ', ' repository ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Genomics ', ' Genetic Determinism ', ' genetic determinant ', ' metabolomics ', ' metabonomics ', ' metabolism measurement ', ' Address ', ' Data ', ' Clinical Data ', ' physiological imaging ', ' Physiologic Imaging ', ' Functional Imaging ', ' Characteristics ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' disease phenotype ', ' data integration ', ' Outcome ', ' cost-effective ', ' cost effective ', ' innovative ', ' innovate ', ' innovation ', ' clinical relevance ', ' clinically relevant ', ' user-friendly ', ' graphic user interface ', ' Graphical interface ', ' graphical user interface ', ' multimodality ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' TCGA ', ' The Cancer Genome Atlas ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' transcriptome sequencing ', ' cloud computer ', ' Cloud Infrastructure ', ' Cloud Computing ', ' cloud based ', ' precision-based medicine ', ' precision medicine ', ' precision treatment ', ' precision therapies ', ' Precision therapeutics ', ' Genomic medicine ', ' precision genomic medicine ', ' patient subtypes ', ' patient subpopulations ', ' patient subgroups ', ' patient subsets ', ' TOPMed ', ' Trans-Omics for Precision Medicine ', ' longitudinal data set ', ' longitudinal dataset ', ' clinical imaging ', ' ']",NHLBI,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,U01,2018,601486,PA-18,0.41662108031881584
"Autoimmunity as a Mechanism for Atherosclerosis in COPD     DESCRIPTION (provided by applicant): This project will facilitate the development of the principal investigator into an independent translational researcher investigating systemic vascular injury in Chronic obstructive pulmonary disease (COPD). This will be accomplished in the rich academic environment at the University of Pittsburgh, under the guidance of a highly accomplished team of mentors, and in the conduct of multidisciplinary research project that will develop autoimmunity as a novel mechanism for atherosclerosis in COPD. The increased risk of atherosclerosis in COPD is not explained by smoking, age, hypertension, and other established vascular disease risk factors. Chronic inflammation has recently been implicated as an atherogenic mechanism in COPD. We and others have reported that chronic inflammation in COPD may be propagated by humoral autoimmunity. Specifically, smokers with COPD have greatly increased levels of circulating autoantibodies that demonstrate in vitro pathogenic effects. Our subsequent studies also show that these autoantibodies target at least 50 different autoantigens and consistently target glucose regulated protein 78 (GRP78), particularly in patients with parenchymal lung destruction, i.e. emphysema. GRP78 is present in the endoplasmic reticulum, where it regulates the unfolded protein response, and is also a multifunction cell surface receptor. Studies in cancer patients suggest that ligation of the N-terminus of cell surface GRP78 by anti-GRP78 IgG transduces pro-inflammatory and pro-proliferative signals by activation of the AKT pathway, followed by NFB activation. Additional in vivo studies have identified anti-GRP78 IgG with affinity for the C-terminus of cell surface GRP78 that produce counteracting anti-inflammatory effects by suppressing AKT activation. Our preliminary work shows that circulating anti-GRP78 IgG in COPD patients binds to macrophages and leads to increased NFB activation and production of atherogenic inflammatory mediators by them. The macrophage is critical in the development of both atherosclerosis and COPD. Also, cross-sectional studies in our cohort find that levels of circulating anti-GRP78 IgG are strongly associated with carotid atherosclerosis in patients with emphysema, independent of established vascular risk factors. Therefore, we hypothesize that autoimmune responses against GRP78 are a mechanism for atherosclerosis in COPD. During this award, we will: (1) Test the hypothesis that elevated levels of circulating anti-GRP78 IgG predict progression of carotid atherosclerosis in patients with emphysema independent of established risk factors over 4 year follow up; (2) Test the hypothesis that anti-GRP78 IgG binds to the N-terminus of cell surface GRP78 and activates the AKT pathway followed by NFB activation and production of inflammatory mediators using a variety of cell function assays, and provide proof of concept for two potential therapeutic strategies; (3) Test the hypothesis that there are other antigen-specific immune responses associated with atherosclerosis in COPD by using machine learning to analyze high-throughput data on a large number of circulating autoantibody levels. PUBLIC HEALTH RELEVANCE: Chronic obstructive pulmonary disease (COPD) is a lung disease caused by smoking that kills more and more Americans each year, and is now the third leading cause of death in the US. Although it is largely viewed as a disease of the lungs, the most common cause of death in patients with COPD are blockages in blood vessels. This research project will investigate why patients with COPD are so prone to develop these blood vessel blockages.",Autoimmunity as a Mechanism for Atherosclerosis in COPD,9668180,K23HL126912,"['Age ', ' ages ', ' Antibodies ', ' Antigens ', ' immunogen ', ' ATGN ', ' Atherosclerosis ', ' atherosclerotic vascular disease ', ' atherosclerotic disease ', ' atheromatosis ', ' Atherosclerotic Cardiovascular Disease ', ' Atheroscleroses ', ' Autoantibodies ', ' self reactive antibody ', ' autoimmune antibody ', ' Autoantigens ', ' Self-Antigens ', ' Autologous Antigens ', ' Autoimmune Diseases ', ' autoimmune disorder ', ' Autoimmune Responses ', ' Autoimmunity ', ' Autoimmune Status ', ' Award ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Blood Vessels ', ' vascular ', ' Western Blotting ', ' protein blotting ', ' Western Immunoblotting ', ' Cause of Death ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Disease Frequency Surveys ', ' Cross-Sectional Survey ', ' Cross-Sectional Analyses ', ' Cross Sectional Analysis ', ' Cross-Sectional Studies ', ' Ergastoplasm ', ' Endoplasmic Reticulum ', ' Environment ', ' ELISA ', ' Enzyme-Linked Immunosorbent Assay ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Flow Cytometry ', ' Modern Man ', ' Human ', ' hypertensive disease ', ' hyperpiesis ', ' hyperpiesia ', ' high blood pressure ', ' Vascular Hypertensive Disorder ', ' Vascular Hypertensive Disease ', ' Hypertension ', ' IgG ', ' 7S Gamma Globulin ', ' Immunoglobulin G ', ' In Vitro ', ' Inflammation ', ' Closure by Ligation ', ' Ligation ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' lung disorder ', ' disorder of the lung ', ' disease of the lung ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Lung diseases ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' Chronic Obstructive Airway Disease ', ' macrophage ', ' Mentors ', ' Mentorship ', ' Morbidity ', ' Morbidity - disease rate ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Patients ', ' Phenotype ', ' Protein Phosphorylation ', ' Phosphorylation ', ' Production ', ' Proteins ', ' emphysematous ', ' Emphysema ', ' Pulmonary Emphysema ', ' Cell Surface Receptors ', ' Risk ', ' Risk Factors ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Smoking ', ' Testing ', ' ultrasound scanning ', ' ultrasound imaging ', ' ultrasound ', ' sound measurement ', ' sonography ', ' sonogram ', ' diagnostic ultrasound ', ' Ultrasound Test ', ' Ultrasound Medical Imaging ', ' Ultrasound Diagnosis ', ' Ultrasonogram ', ' Ultrasonic Imaging ', ' Medical Ultrasound ', ' Echotomography ', ' Echography ', ' Ultrasonography ', ' Universities ', ' vasculopathy ', ' vascular dysfunction ', ' blood vessel disorder ', ' Vascular Disorder ', ' Vascular Diseases ', ' Work ', ' glucose-regulated proteins ', ' Measures ', ' Proto-Oncogene Proteins c-akt ', ' related to A and C-protein ', ' rac protein kinase ', ' proto-oncogene protein akt ', ' proto-oncogene protein RAC ', ' c-akt protein ', ' RAC-PK protein ', ' Protein Kinase B ', ' Akt protein ', ' AKT ', ' Injury ', ' Chronic ', ' Link ', ' Fostering ', ' Interdisciplinary Study ', ' Multidisciplinary Research ', ' Multidisciplinary Collaboration ', ' Interdisciplinary Research ', ' Inflammation Mediators ', ' inflammatory mediator ', ' Funding ', ' Research Project Grants ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Immune response ', ' immunoresponse ', ' host response ', ' Immunological response ', ' Therapeutic ', ' Therapeutic Agents ', ' Exposure to ', ' Inflammatory ', ' Smoker ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Investigation ', ' Event ', ' Carotid Atherosclerotic Disease ', ' Carotid Atheroscleroses ', ' American ', ' cohort ', ' novel ', ' Cell surface ', ' Reporting ', ' Carotid Artery Plaques ', ' carotid plaque ', ' Carotid Artery Plaque ', ' response ', ' Pathogenicity ', ' Molecular Interaction ', ' Binding ', ' preventing ', ' prevent ', ' Affinity ', ' Data ', ' K-Series Research Career Programs ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' in vivo ', ' Antiinflammatory Effect ', ' anti-inflammatory effect ', ' Cancer Patient ', ' Principal Investigator ', ' follow-up ', ' followup ', ' followed up ', ' follow up ', ' active followup ', ' Active Follow-up ', ' Development ', ' developmental ', ' Pathway interactions ', ' pathway ', ' peptidomimetics ', ' peptide mimic ', ' peptide mimetic ', ' public health relevance ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' in vitro testing ', ' vascular risk factor ', ' predictive marker ', ' predictive molecular biomarker ', ' predictive biomarkers ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' cancer clinical trial ', ' translational scientist ', ' translational researcher ', ' translational investigator ', ' atherosclerosis risk ', ' atherosclerotic risk ', ' machine learning algorithm ', ' ']",NHLBI,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,K23,2019,166104,PA-18,0.4664874579589209
"Identifying palliative care needs among hospitalized patients with chronic obstructive pulmonary disease PROJECT SUMMARY Millions of Americans with COPD experience burdensome symptoms, reduced quality of life, and undesirable end-of-life care. Increasing palliative care for this vulnerable population is widely advocated to improve these important patient-centered outcomes. Yet patients with COPD rarely receive palliative care due, in part, to difficulties identifying which patients have unmet palliative care needs and palliative care workforce shortages. The proposed study's core objective is to address the national priority of improving palliative care for patients with COPD by developing an efficient, innovative, and patient-centered method to identify those with unmet palliative care needs. Specifically, the candidate seeks to (1) assess patients with COPD to determine their palliative care needs; (2) develop and validate an electronic health record-based classification model for each domain of palliative care needs; and (3) evaluate the relationship between the probability of having unmet palliative care needs and patient-centered clinical outcomes. The study will involve an in-person cross- sectional survey of 432 hospitalized patients with COPD of any stage. Participants will complete a validated survey to capture a wide variety of palliative care needs, which will be supplemented with expert chart review to identify patients with needs in any of three clinically relevant and actionable domains. These cases will be used as the patient-reported reference standard for development and validation of domain-specific classification models leveraging natural language processing of unstructured clinical text in electronic health records and machine learning methods. Finally, a large, multicenter retrospective cohort study will evaluate the associations between different probabilities of having unmet palliative care needs and several clinical outcomes important to patients, caregivers, and hospitals. This will enable the identification of thresholds of probabilities of unmet needs above which COPD patients' risks of undesirable clinical outcomes increase. Such patients will then be targeted for enrollment in future trials testing interventions to improve these outcomes. Completion of this research will build upon the candidate's past training, which includes a Masters in Health Policy Research obtained with NHLBI T32 support, an F32-supported post-doctoral fellowship, and a career development award from the National Palliative Care Research Center, and will provide the experience, education, and mentorship to allow the candidate to become a fully independent investigator. The candidate's rigorous training plan, focused on obtaining advanced skills in multisite prospective research, patient-centered outcomes research, and advanced bioinformatics methods will allow her to submit successful R01 or PCORI applications testing interventions directly informed by the results of this work. The candidate's primary mentor, collaborators, and advisors will ensure adherence to the proposed timeline and goals and provide a supportive environment for her to develop an independent research career focused on improving the uptake and effectiveness of palliative care for patients with COPD and other cardiopulmonary diseases. PROJECT NARRATIVE Patients with COPD experience burdensome symptoms, reduced quality of life, and low quality end-of-life care. Palliative care may improve such outcomes, yet resources are strained and it is difficult to identify which patients are most in need. The aims of this research are to provide new knowledge regarding the unmet palliative care needs of patients with COPD and to develop a novel and scalable method to identify patients with such needs in order to reduce patients' suffering and improve quality of life.",Identifying palliative care needs among hospitalized patients with chronic obstructive pulmonary disease,9746515,K23HL143181,"['Age ', ' ages ', ' Award ', ' Beds ', ' Calibration ', ' Systematics ', ' Classification ', ' Clinical Study ', ' Clinical Research ', ' co-morbidity ', ' Comorbidity ', ' Disease Frequency Surveys ', ' Cross-Sectional Survey ', ' Cross-Sectional Analyses ', ' Cross Sectional Analysis ', ' Cross-Sectional Studies ', ' data representation ', ' Data Reporting ', ' Data Sources ', ' Death ', ' Cessation of life ', ' Cognitive Discrimination ', ' Discrimination ', ' Disorder ', ' Disease ', ' Educational aspects ', ' Education ', ' Fellowship ', ' Future ', ' Patient Care Delivery ', ' Patient Care ', ' Goals ', ' healthcare policy ', ' health care policy ', ' Health Policy ', ' Hospitals ', ' Inpatients ', ' Intensive Care Units ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' Chronic Obstructive Airway Disease ', ' Manuals ', ' Marital Status ', ' Mentors ', ' Mentorship ', ' Methods ', ' Persons ', ' natural language understanding ', ' Natural Language Processing ', ' nurse ', ' Nurses ', ' comfort care ', ' Palliative Treatment ', ' Palliative Therapy ', ' Palliative Care ', ' Patient Reported Outcomes ', ' Patient Outcomes Assessments ', ' Patients ', ' Physicians ', ' Probability ', ' professional society ', ' professional membership ', ' professional association ', ' Professional Organizations ', ' cardiopulmonary disorder ', ' cardiopulmonary disease ', ' Pulmonary Heart Disorder ', ' Cor pulmonale ', ' Pulmonary Heart Disease ', ' QOL ', ' Quality of life ', ' Reference Standards ', ' Research ', ' study design ', ' Study Type ', ' Research Design ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Risk ', ' social support network ', ' Social support ', ' Social Service ', ' Social Work ', ' Specialty ', ' medical specialties ', ' Survey Instrument ', ' Surveys ', ' Teaching ', ' Educational process of instructing ', ' Testing ', ' Time ', ' Triage ', ' Work ', ' Care Givers ', ' Caregivers ', ' Outcomes Research ', ' TimeLine ', ' Caring ', ' base ', ' career ', ' improved ', ' Site ', ' Clinical ', ' Medical ', ' Ensure ', ' Training ', ' Distress ', ' uptake ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' psychosocial ', ' Visit ', ' Consult ', ' Postdoctoral Fellow ', ' post-doctoral ', ' post-doc ', ' Research Associate ', ' Postdoc ', ' American ', ' experience ', ' Performance ', ' functional status ', ' cohort ', ' Structure ', ' skills ', ' novel ', ' Participant ', ' Reporting ', ' end of life care ', ' Modeling ', ' Sampling ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Vulnerable Populations ', ' vulnerable group ', ' Bioinformatics ', ' Bio-Informatics ', ' Institution ', ' Effectiveness ', ' Address ', ' end of life ', ' end-of-life ', ' Symptoms ', ' Adherence ', ' Advocate ', ' Data ', ' Mentored Patient-Oriented Research Career Development Award ', ' Mentored Patient-Oriented Research Career Development Award (K23) ', ' K23 Program ', ' K23 Mechanism ', ' K23 Award ', ' Policy Research ', ' K-Series Research Career Programs ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' Research Training ', ' Enrollment ', ' enroll ', ' Observational Study ', ' Observational research ', ' Observation study ', ' Observation research ', ' Patient-Focused Outcomes ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Validation ', ' Characteristics ', ' Process ', ' Text ', ' Development ', ' developmental ', ' Electronic Health Record ', ' electronic healthcare record ', ' electronic health care record ', ' National Heart, Lung, and Blood Institute ', ' NHLBI ', ' Outcome ', ' Prevalence ', ' prospective ', ' innovation ', ' innovative ', ' innovate ', ' clinically relevant ', ' clinical relevance ', ' patient oriented ', ' patient centered ', ' randomized trial ', ' Randomization trial ', ' Patient risk ', ' clinically actionable ', ' learning strategy ', ' learning method ', ' learning activity ', ' improved outcome ', ' study population ', ' physical symptom ', ' Retrospective cohort study ', ' recruit ', ' hospital services ', ' readmission rates ', ' rehospitalization rate ', ' re-hospitalization rate ', ' re-admission rates ', ' hospital readmission rate ', ' hospital re-admission rates ', ' supportive environment ', ' supportive atmosphere ', ' enthusiastic environment ', ' enthusiastic atmosphere ', ' ']",NHLBI,UNIVERSITY OF PENNSYLVANIA,K23,2019,174140,PA-03,0.38407516212314335
"Machine Learning Development for Subtyping COPD Project Summary Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by progressive loss of lung function with subsequent increasing breathlessness and worsening quality of life. This heterogeneity makes it difficult to predict health decline and develop targeted treatments for better patient care. To date, researchers have attempted to use standard machine learning methodology to identify more meaningful subtypes of COPD, but these methods often make general assumptions about the data, limiting their ability to penetrate more complex patterns in some data sets. Thus, a meaningful reclassification of COPD subtypes that could lead to more targeted therapies and interventions has been elusive. The applicant introduces a new way of looking at the COPD subtyping problem by recasting it in terms of discovering associations of individuals to disease trajectories  i.e., grouping individuals based on their similarity in response to environmental and/or disease causing variables. The machine learning methods proposed build on the most recent advances in Bayesian nonparametrics, a collection of theoretical ideas and techniques that permit very flexible data representations. In this career development proposal, the applicant hypothesizes that these machine learning methods and extensions thereof  together with data sources not previously leveraged for COPD subtyping  will produce more biologically meaningful sub-groupings of patients, leading to a better understanding of the genetic and biological underpinnings of the disease and ultimately improved patient management. Aim 1 of this application involves evaluating the utility of CT-assessed lung mass  a potentially more discriminative measure of emphysema than conventionally used measures  for defining COPD subtypes using both K-means clustering and our disease trajectory algorithm. The goal of Aim 2 is to evaluate the utility of comorbidity data for defining COPD subtypes using our trajectory clustering algorithm. Novel computed tomography based measures of muscle wasting (cachexia) and pulmonary vascular pruning will be explored to determine their efficacy in subtype determination. Additionally, we will extend and test the trajectory algorithm in order to model discrete outputs (such as physician-diagnosed comorbidities), count data (e.g. exacerbations), and time-to-event data (death). In Aim 3, the applicant will extend our trajectory clustering algorithms to directly incorporate genetic and omics data for subtype discovery. Together, the research proposed in the aims of this award will take full advantage of the comprehensive data set available through the COPDGene study. Execution of the aims in this proposal will be possible through active collaboration with Dr. Ron Kikinis, M.D., a renowned leader in the field of medical image analysis, and Dr. Ed Silverman, an internationally recognized expert in the genetic epidemiology of COPD. Project Narrative Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by progressive loss of lung function with subsequent increasing breathlessness and worsening quality of life. This heterogeneity makes it difficult to predict health decline and develop targeted treatments for better patient care. In carrying out the research outlined in the following proposal, we plan to develop and apply machine learning methods to better identify subpopulations of individuals who have similar forms of COPD, potentially enabling better, targeted therapies.",Machine Learning Development for Subtyping COPD,9704042,K25HL130637,"['Affect ', ' Algorithms ', ' Award ', ' Blood Vessels ', ' vascular ', ' Cachexia ', ' Cachectic ', ' Cause of Death ', ' co-morbidity ', ' Comorbidity ', ' data representation ', ' Data Reporting ', ' Data Sources ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' Disorder ', ' Disease ', ' liability to disease ', ' Diathesis ', ' Disease susceptibility ', ' Breathlessness ', ' Dyspnea ', ' Environment ', ' Patient Care Delivery ', ' Patient Care ', ' Goals ', ' Health ', ' Heterogeneity ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' Chronic Obstructive Airway Disease ', ' Medical Imaging ', ' Methods ', ' Methodology ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' mortality ', ' muscle wasting ', ' muscle loss ', ' muscle deterioration ', ' muscle degradation ', ' muscle breakdown ', ' Muscle Atrophy ', ' Muscular Atrophy ', ' Patients ', ' Physicians ', ' Publishing ', ' emphysematous ', ' Emphysema ', ' Pulmonary Emphysema ', ' QOL ', ' Quality of life ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' respiratory function ', ' lung function ', ' Respiratory physiology ', ' Smoke ', ' Syndrome ', ' Testing ', ' Time ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' X-Ray Computed Tomography ', ' Measures ', ' Lung Mass ', ' Pulmonary Mass ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Image Analysis ', ' image evaluation ', ' Image Analyses ', ' Clinical ', ' Biological ', ' peripheral blood ', ' Failure ', ' Individual ', ' Bayesian Analysis ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian computation ', ' Disease Progression ', ' Collaborations ', ' Descriptor ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Event ', ' Pattern ', ' Techniques ', ' particle ', ' novel ', ' Disease model ', ' disorder model ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Modeling ', ' career development ', ' response ', ' genetic epidemiology ', ' genetic epidemiologic study ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Inflammatory Response ', ' genetic association ', ' Data ', ' Doctor of Medicine ', ' M.D. ', ' International ', ' Subgroup ', ' Collection ', ' Functional Imaging ', ' physiological imaging ', ' Physiologic Imaging ', ' Scheme ', ' Characteristics ', ' Process ', ' Grouping ', ' groupings ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' Output ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' design ', ' designing ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' flexibility ', ' flexible ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' imaging biomarker ', ' imaging-based marker ', ' imaging-based biomarker ', ' imaging-based biological marker ', ' imaging marker ', ' learning strategy ', ' learning method ', ' learning activity ', ' cigarette smoke ', ' machine learning algorithm ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K25,2019,189000,MA-07,0.44476189124601284
"Combined Cardiopulmonary Failure in COPD: SPIROMICS HF The death rate and hospitalizations from chronic obstructive pulmonary disease (COPD) have doubled in the last 50 years. A third of COPD hospitalizations overlap with heart failure, mostly with preserved ejection fraction (HFpEF), yet no large COPD study has ascertained cardiac function. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study was funded to test the endothelial hypothesis of emphysema and examine reduced RV dimensions (cor pulmonale parvus) in COPD. In the MESA COPD Study II, we found that associations of reduced pulmonary microvascular blood flow with emphysema do not appear to be confounded by hypoxic pulmonary vasoconstriction and that emphysema on CT predicted RV regression over 5 years. We also developed methods to further subtype emphysema and COPD and scaled them up to the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS). We used unsupervised machine learning to discover new emphysema subtypes that are common and have molecular origins. Separately, we found that 26% of adults have segmental airway variants, which are associated with COPD and the developmental genes FGF10 and RARA. Both genes affect right heart development. In pilot work, we found one dramatically altered RV strain and the other associated with cor pulmonale parvus. Finally, we found that bronchitic symptomatic smokers, who have hyperinflation from gas trapping, may have increased LV diastolic dysfunction. Hence, cardiac alterations in COPD are complex but recent advances in COPD subtyping may allow their personalized diagnosis and treatment. SPIROMICS is an NHLBI-funded prospective study that recruited smokers with COPD and controls and is re-examining 2,000 participants with gold- standard lung phenotyping including full-lung CT. We propose to add comprehensive echocardiography (echo) with speckle-tracking for cardiac mechanics for 1,000 SPIROMICS participants, with exercise in 700 and cardiopulmonary MRI in 600, to test the following hypotheses: 1) machine-learned subtypes of emphysema on CT are associated with specific alterations in cardiac structure and function, which vary from cor pulmonale to LV diastolic dysfunction; 2) participants with segmental airway variants have abnormal RV structure and function; 3) symptomatic smokers have signs of increased LV afterload and LV diastolic dysfunction. Innovative aspects of the application include the use of novel echo and MRI measures in a large, well- characterized cohort of COPD patients. Confirmation of the hypotheses would define the mechanisms of HFpEF in COPD and identify subsets of patients for targeted treatment of cardiopulmonary dysfunction. The death rate and hospitalizations from chronic obstructive pulmonary disease (COPD) have doubled in the last 50 years. A third of COPD hospitalizations overlap with heart failure, mostly with preserved ejection fraction. The proposed study would be the first large study with gold-standard phenotyping of the heart and lungs and would test highly specific hypothesized based upon recent advances in lung subphenotyping to yield personalized approaches to combined cardiopulmonary disease in COPD.",Combined Cardiopulmonary Failure in COPD: SPIROMICS HF,9819260,R01HL093081,"['Adult ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Affect ', ' Cardiac Output ', ' heart output ', ' heart sonography ', ' Transthoracic Echocardiography ', ' Echocardiogram ', ' Echocardiography ', ' Endothelium ', ' Exercise ', ' Fibrosis ', ' Gases ', ' Genes ', ' Developmental Gene ', ' Gold ', ' Heart ', ' atrium ', ' Cardiac Atrium ', ' Atrial ', ' Heart Atrium ', ' cardiac failure ', ' Heart failure ', ' Hospital Admission ', ' Hospitalization ', ' indexing ', ' Kinetics ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' Chronic Obstructive Airway Disease ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Methods ', ' Pathology ', ' Patients ', ' Phenotype ', ' pressure ', ' Prospective Studies ', ' Pulmonary Artery ', ' Pulmonary artery structure ', ' emphysematous ', ' Emphysema ', ' Pulmonary Emphysema ', ' lung fibrosis ', ' Pulmonary Fibrosis ', ' cardiopulmonary disorder ', ' cardiopulmonary disease ', ' Pulmonary Heart Disorder ', ' Cor pulmonale ', ' Pulmonary Heart Disease ', ' Suggestion ', ' Technology ', ' Testing ', ' vascular constriction ', ' vasoconstriction ', ' Work ', ' Measures ', ' Outcome Measure ', ' Right Ventricular Hypertrophy ', ' base ', ' Apical ', ' Diffuse ', ' Variant ', ' Variation ', ' Death Rate ', ' Right ventricular structure ', ' Right Ventricles ', ' Failure ', ' heart function ', ' function of the heart ', ' cardiac function ', ' Blood flow ', ' Hypoxia ', ' Oxygen Deficiency ', ' Hypoxic ', ' Funding ', ' Functional disorder ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Smoker ', ' Mechanics ', ' mechanical ', ' Dimensions ', ' Complex ', ' EFRAC ', ' Ejection Fraction ', ' Cardiopulmonary ', ' heart preservation ', ' cardiac preservation ', ' interstitial ', ' receptor ', ' Receptor Protein ', ' cohort ', ' Structure ', ' novel ', ' Participant ', ' Code ', ' Coding System ', ' Sampling ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' disorder control ', ' disease control ', ' Drops ', ' Respiratory Failure ', ' respiratory insufficiency/failure ', ' pulmonary failure ', ' heart formation ', ' heart development ', ' cardiogenesis ', ' DRD1 gene ', ' Dopamine Receptor D1 Gene ', ' DRD1 ', ' FGF10 gene ', ' fibroblast growth factor 10 ', ' FGF10 ', ' FGF-10 ', ' RARA gene ', ' Retinoic Acid Receptor Alpha Gene ', ' RARA ', ' NR1B1 ', ' Molecular ', ' Myocardial ', ' Ventricular ', ' Cardiac ', ' National Heart, Lung, and Blood Institute ', ' NHLBI ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' innovation ', ' innovative ', ' innovate ', ' Impairment ', ' novel diagnostics ', ' next generation diagnostics ', ' new diagnostics ', ' novel therapeutic intervention ', ' novel therapy approach ', ' novel therapeutic approach ', ' new therapy approaches ', ' new therapeutic strategies ', ' new therapeutic intervention ', ' new therapeutic approach ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized diagnostics ', ' precision diagnostics ', ' personalized diagnosis ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' Lung CAT Scan ', ' Lung CT scan ', ' Lung CT ', ' CT Lung Screening ', ' personalized approach ', ' tailored approach ', ' precision approach ', ' individualized approach ', ' Personalized medical approach ', ' patient subsets ', ' patient subtypes ', ' patient subpopulations ', ' patient subgroups ', ' Multi-Ethnic Study of Atherosclerosis ', ' recruit ', ' preservation ', ' unsupervised learning ', ' unsupervised machine learning ', ' ']",NHLBI,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2019,2391491,NY-13,0.4741370876605206
"Clinical significance and genetic determinants of novel imaging measures of emphysema distribution in 9,743 smokers PROJECT SUMMARY/ABSTRACT Candidate: Dr. Adel El Boueiz is a pulmonary and critical care physician-scientist completing a period of T32- funded support at the Channing Division of Network Medicine (CDNM) and Harvard Medical School (HMS). He received a Master's of Medical Science in Biomedical Informatics from HMS in May 2016. He will be promoted to Instructor of Medicine at the CDNM and HMS on July 1, 2017. His principal research interests are the genetic epidemiology of chronic obstructive pulmonary disease (COPD) and the translation of genomic discoveries into clinical practice and public health. His long-term goal is to be an independent investigator with expertise in imaging phenotyping, genomics, and predictive analytics of the regional heterogeneity of the various aspects of COPD (emphysema, airway disease, and pulmonary vascular remodeling). Environment: Dr. El Boueiz will continue to pursue his research and career development in the rich and multidisciplinary environment of the CDNM and the Brigham and Women's Hospital Applied Chest Imaging Lab (ACIL). He will be mentored by Drs. Edwin K. Silverman, Peter J. Castaldi, and Ral San Jos Estpar, leaders in the field of COPD quantitative imaging, genetic epidemiology, and predictive analytics with excellent track records of mentoring young investigators towards independent research careers. His career development will also be overseen by an advisory committee with expertise related to key areas of his proposal. Research: COPD is a major cause of morbidity and mortality that is of increasing public health importance. COPD is a heterogeneous disease and this heterogeneity complicates the identification of the predictors of disease progression and consequently, the development of effective therapies. Emphysema distribution is an important COPD-related phenotype that emerged as a strong predictor of the response to lung volume reduction procedures. Despite the availability of advanced texture-based CT quantification methods, global threshold-based quantitative metrics have to date been the cornerstone for the radiological characterization of emphysema distribution with inability to differentiate centrilobular, panlobular, and paraseptal emphysema patterns. In this project, we will apply a texture-based CT quantification method to discover novel imaging biomarkers of the regional heterogeneity of centrilobular, panlobular, and paraseptal emphysema in a large cohort of well-characterized smokers and identify their genetic determinants using whole genome sequencing and integrative genomics analyses. The results will be considered for inclusion along with other rich phenotypic and imaging data in COPD disease progression machine learning predictive models. Relevance: Through improved radiographic phenotyping of emphysema distribution, better understanding of disease pathobiology, and more accurate prediction of disease progression, the proposed work will open new avenues of investigation for the development of personalized and improved COPD therapeutic strategies. PROJECT NARRATIVE Chronic obstructive pulmonary disease (COPD) is a common disease that affects up to 24 million people in the United States, is associated with considerable and increasing morbidity and mortality, and for which there is no available disease-modifying therapy. COPD is associated with significant variation in radiographic, symptomatic and physiologic presentation and exhibits variability in progression. Currently, there is no satisfactory method for progression prediction. This project will identify novel imaging biomarkers of the regional distribution of centrilobular, panlobular, and paraseptal emphysema with particular emphasis on their associations with clinical relevant COPD-related outcomes, their genetic determinants, and their ability to improve prediction of COPD disease progression, above and beyond that provided by the traditional clinical, radiographic, and genetic features. This is an important area of research as predicting those patients who will remain stable from those who will have rapid disease progression is critical in defining prognosis and selecting patients for specific therapeutic interventions.","Clinical significance and genetic determinants of novel imaging measures of emphysema distribution in 9,743 smokers",9672582,K08HL141601,"['Accounting ', ' Affect ', ' Automobile Driving ', ' driving ', ' Clinical Trials ', ' Concurrent Studies ', ' Cohort Studies ', ' co-morbidity ', ' Comorbidity ', ' Computers ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Critical Care ', ' Disorder ', ' Disease ', ' Breathlessness ', ' Dyspnea ', ' Environment ', ' Exhibits ', ' Genes ', ' Clinical genetics ', ' Medical Genetics ', ' Goals ', ' Heterogeneity ', ' Hospitals ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' lung disorder ', ' disorder of the lung ', ' disease of the lung ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Lung diseases ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' Chronic Obstructive Airway Disease ', ' Medicine ', ' Mentors ', ' Mentorship ', ' Methods ', ' Morbidity ', ' Morbidity - disease rate ', ' mortality ', ' Patients ', ' Phenotype ', ' Physicians ', ' polymorphism ', ' Genetic Polymorphism ', ' Prognosis ', ' outcome forecast ', ' Public Health ', ' emphysematous ', ' Emphysema ', ' Pulmonary Emphysema ', ' Radiology ', ' General Radiology ', ' Radiology Specialty ', ' Records ', ' Research ', ' R&D ', ' R & D ', ' Development and Research ', ' research and development ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' respiratory function ', ' lung function ', ' Respiratory physiology ', ' school of medicine ', ' medical college ', ' medical schools ', ' Science ', ' Technology ', ' Testing ', ' Body Tissues ', ' Tissues ', ' tomography ', ' Translations ', ' United States ', ' Woman ', ' Work ', ' X-Ray Medical Imaging ', ' X-Ray Imaging ', ' Roentgenography ', ' Radiography ', ' Diagnostic X-Ray Radiology ', ' Diagnostic X-Ray ', ' Diagnostic Radiology ', ' Conventional X-Ray ', ' Diagnostic radiologic examination ', ' Generations ', ' Measures ', ' Medical Research ', ' Walking ', ' Advisory Committees ', ' advisory team ', ' Task Forces ', ' base ', ' career ', ' improved ', ' Procedures ', ' Area ', ' Clinical ', ' Variant ', ' Variation ', ' Physiological ', ' Physiologic ', ' Medical ', ' Evaluation ', ' prognostic ', ' Visual ', ' Disease Progression ', ' Funding ', ' Biological Process ', ' Biological Function ', ' Therapeutic ', ' Genetic ', ' Smoker ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Scientist ', ' Investigation ', ' Complex ', ' Texture ', ' Pattern ', ' respiratory ', ' Lung Volume Reductions ', ' interest ', ' instructor ', ' Quantitative Trait Loci ', ' QTL ', ' cohort ', ' attenuation ', ' novel ', ' disorder risk ', ' disease risk ', ' Positioning Attribute ', ' Position ', ' Lobe ', ' lobes ', ' Therapeutic Intervention ', ' intervention therapy ', ' Chest ', ' Thorax ', ' Thoracic ', ' Thorace ', ' Structure of parenchyma of lung ', ' Lung Tissue ', ' Lung Parenchyma ', ' Pulmonary Function Test/Forced Expiratory Volume 1 ', ' PFT/FEV1 ', ' Forced Expiratory Volume in 1 Second ', ' Forced Expiratory Volume 1 Test ', ' FEV1%VC ', ' FEV1 ', ' Modeling ', ' career development ', ' genetic epidemiology ', ' genetic epidemiologic study ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Genomics ', ' Genetic Determinism ', ' genetic determinant ', ' Bioinformatics ', ' Bio-Informatics ', ' datamining ', ' data mining ', ' genetic association ', ' genome sequencing ', ' Type IB Gene Activin A Receptor ', ' Activin Receptor-Like Kinase 4 Gene ', ' Activin A Receptor, Type II-Like Kinase 4 Gene ', ' ALK4 Gene ', ' ACVRLK4 Gene ', ' ACVR1B ', ' ACVR1B gene ', ' Data ', ' Detection ', ' Subgroup ', ' Clinical/Radiologic ', ' Collection ', ' Pathologic ', ' Lobar ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' disease phenotype ', ' biomedical informatics ', ' biomed informatics ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' Outcome ', ' Vascular remodeling ', ' clinically relevant ', ' clinical relevance ', ' clinically significant ', ' clinical significance ', ' multidisciplinary ', ' effective therapy ', ' effective treatment ', ' genome-wide ', ' genomewide ', ' genome scale ', ' clinical practice ', ' rare variant ', ' rare allele ', ' genetic predictors ', ' personalized care ', ' personalized patient care ', ' individualized patient care ', ' individualized care ', ' Precision care ', ' Genomic approach ', ' genomic strategy ', ' genomic effort ', ' quantitative imaging ', ' imaging biomarker ', ' imaging-based marker ', ' imaging-based biomarker ', ' imaging-based biological marker ', ' imaging marker ', ' learning strategy ', ' learning method ', ' learning activity ', ' Predictive Analytics ', ' predicting response ', ' response prediction ', ' predictor of response ', ' predictive response ', ' prediction of response ', ' disease heterogeneity ', ' whole genome ', ' full genome ', ' entire genome ', ' genomic predictors ', ' imaging genetics ', ' Airway Disease ', ' genetic architecture ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K08,2019,170639,MA-07,0.37436875921610646
"Identification of immune cell-cell communication networks and inflammatory pulmonary microenvironments associated with the progression of COPD PROJECT SUMMARY Chronic obstructive pulmonary disease (COPD) is a fatal lung disease that is the fourth leading cause of death in the U.S. Despite an estimated $50 billion in yearly healthcare costs, it has no current cure and only palliat- ive treatments. COPD is clearly characterized by chronic lung inflammation that likely arises from dysregulat- ion of complex networks of immune factors and cells across multiple tissue compartments. Although multiple individual genes and proteins have been associated with COPD risk and progression, global mechanistic understanding of its pathophysiology is lacking, particularly regarding the marked heterogeneity in COPD phenotypes. The overall objective of our study is to gain systems-level insight into complex inflammatory and immune mechanisms underlying COPD, by applying data-driven (also called machine learning) modeling approaches to clinical samples collected from human pulmonary microenvironments and matched immune cell networks from peripheral blood. Our central hypothesis is that immune networks will be more predictive of COPD phenotype, progression, and exacerbation than individual factors. We will test this hypothesis in three Specific Aims, using matched brochoalveolar lavage (BAL) and blood samples collected in SPIROMICS I and II clinical trials. Aim 1 will identify changes in immune cell-cell communication networks, by high-throughput cytokine measurements from stimulated systems of peripheral blood immune cells from smokers with and without COPD and never-smoking controls (collected from the upcoming SPIROMICS II visit; n=150). Aim 2 will determine systems-level changes that occur in the inflamed lung microenvironment, using high-throughput cytokine measurements in BAL samples (both archival from SPIROMICS I, n=200, and collected during upcoming SPIROMICS II bronchoscopies) from smokers with and without COPD and never-smoking controls. We will identify networks associated with longitudinal clinical progression and exacerbation frequency. Aim 3 will integrate measurements across lung and blood tissue compartments to define key combinatorial relationships associated with progression and exacerbation events. Overall, this project will provide systems- level insight into COPD pathogenesis and progression, and create a new paradigm for the study of other pulmonary conditions involving chronic inflammation, including idiopathic pulmonary fibrosis, asthma, and lung transplant. Results will aid in the future development of new non-invasive diagnostic assays and will guide systems-level mechanistic studies that could result in new combinatorial therapies. PROJECT NARRATIVE The goal of this proposal is to gain new systems-level insight into chronic obstructive pulmonary disease (COPD), which is the third leading cause of death worldwide and an enormous cost burden in the U.S. yearly (~50 billion). Despite progress in identifying individual immune factors associated with COPD, there are only palliative treatment options and no cure. New insight generated by this project into how immune cell communication networks and inflammatory pulmonary microenvironments are altered in COPD could be used to identify diagnostic biomarkers and to guide the design of combinatorial therapies.",Identification of immune cell-cell communication networks and inflammatory pulmonary microenvironments associated with the progression of COPD,9640679,R01HL144849,"['Accounting ', ' Archives ', ' Asthma ', ' Bronchial Asthma ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Blood ', ' Blood Reticuloendothelial System ', ' Bronchoscopy ', ' Cause of Death ', ' Cell-to-Cell Interaction ', ' Cell Interaction ', ' Cell Communication ', ' Cell Body ', ' Cells ', ' Clinical Trials ', ' Concurrent Studies ', ' Cohort Studies ', ' Death Records ', ' Disorder ', ' Disease ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Flow Cytometry ', ' Future ', ' Goals ', ' Heterogeneity ', ' Modern Man ', ' Human ', ' immunological substance ', ' immunologic substance ', ' Immunological Factors ', ' Immunologic Factors ', ' In Vitro ', ' Inflammation ', ' other than vaginal Irrigation ', ' other than vaginal Douching ', ' lavage therapy ', ' irrigation therapy ', ' Nonvaginal lavage ', ' Nonvaginal irrigation ', ' Lavage ', ' Irrigation ', ' longterm study ', ' long-term study ', ' Longitudinal Studies ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' lung disorder ', ' disorder of the lung ', ' disease of the lung ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Lung diseases ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' Chronic Obstructive Airway Disease ', ' lung transplant ', ' Lung Grafting ', ' Lung Transplantation ', ' Methods ', ' Mucosal Tissue ', ' Mucosa ', ' Mucous Membrane ', ' comfort care ', ' Palliative Treatment ', ' Palliative Therapy ', ' Palliative Care ', ' Patients ', ' Radiology ', ' General Radiology ', ' Radiology Specialty ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Risk ', ' Spirometry ', ' Testing ', ' Body Tissues ', ' Tissues ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' X-Ray Computed Tomography ', ' visual function ', ' Sight ', ' Vision ', ' cytokine ', ' Measures ', ' Healthcare Costs ', ' Health Costs ', ' Health Care Costs ', ' health care ', ' Healthcare ', ' Outcome Measure ', ' population diversity ', ' heterogeneous population ', ' diverse populations ', ' Population Heterogeneity ', ' Caring ', ' Blood specimen ', ' Blood Sample ', ' detector ', ' Bronchoalveolar Lavage ', ' bronchopulmonary lavage therapy ', ' Lung Lavage ', ' Bronchopulmonary Lavage ', ' Bronchioalveolar Lavage ', ' Chronic ', ' Clinical ', ' Physiological ', ' Physiologic ', ' prognostic ', ' Epithelial ', ' peripheral blood ', ' insight ', ' Individual ', ' Measurement ', ' Disease Progression ', ' Funding ', ' noninvasive diagnosis ', ' noninvasive diagnostic ', ' non-invasive diagnostic ', ' non-invasive diagnosis ', ' Functional disorder ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Inflammatory ', ' Smoker ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Immune ', ' Immunes ', ' Severities ', ' Complex ', ' Event ', ' System ', ' Visit ', ' experience ', ' cohort ', ' Participant ', ' disorder risk ', ' disease risk ', ' Pathogenesis ', ' Positioning Attribute ', ' Position ', ' Gene Proteins ', ' Protein Gene Products ', ' Proteome ', ' Modeling ', ' Sampling ', ' Data ', ' Clinical Data ', ' Enrollment ', ' enroll ', ' Process ', ' follow-up ', ' followup ', ' followed up ', ' follow up ', ' active followup ', ' Active Follow-up ', ' Development ', ' developmental ', ' disease phenotype ', ' cost ', ' design ', ' designing ', ' adjudicate ', ' Outcome ', ' Lung Inflammation ', ' prospective ', ' combinatorial ', ' clinically relevant ', ' clinical relevance ', ' new therapeutic target ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel druggable target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new druggable target ', ' new drug target ', ' novel therapeutic intervention ', ' novel therapy approach ', ' novel therapeutic approach ', ' new therapy approaches ', ' new therapeutic strategies ', ' new therapeutic intervention ', ' new therapeutic approach ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' diagnostic assay ', ' diagnostic biomarker ', ' diagnostic marker ', ' idiopathic pulmonary fibrosis ', ' diffuse interstitial pulmonary fibrosis ', ' never smoking ', ' ']",NHLBI,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2019,322937,MI-12,0.37207459114546343
"Multi-omic Subtyping of Chronic Obstructive Pulmonary Disease PROJECT SUMMARY/ABSTRACT Chronic obstructive pulmonary disease (COPD) is the leading cause of respiratory mortality in the United States. COPD is a highly heterogeneous disease and some COPD therapies are only applied to specific clinically defined subtypes. With the advent of multiple high-throughput biological assays and machine learning approaches, data-driven subtypes are increasingly being recognized. We hypothesize that such subtypes exist in COPD and that they can be identified using an integrative, multi-'omic approach. To accomplish this goal, we first propose to complement existing RNA and whole genome sequencing data in the well-phenotyped COPDGene study with peripheral blood microRNA sequencing. We will study the relationship of microRNA to genetic variation and gene expression in COPD. Next, we will apply a patient-based network similarity method to these three data types to identify COPD molecular subtypes. Finally, we will associate these subtypes with important clinical phenotypes and outcomes, and validate these subtypes in an independent subset of subjects. Our analysis targets a key clinical problem in COPD management, and will allow the mentee to become an independent investigator, applying bioinformatic and machine learning methods to genomic data in respiratory diseases. PROJECT NARRATIVE Chronic obstructive pulmonary disease (COPD) is a leading cause of death in the United States. Patients with COPD may have very similar lung function but differ in many other characteristics. We propose to use multiple types of biologic data to identify different COPD subtypes, which may be important for disease prognosis and treatment.",Multi-omic Subtyping of Chronic Obstructive Pulmonary Disease,9729808,K08HL136928,"['Affect ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Blood ', ' Blood Reticuloendothelial System ', ' Cause of Death ', ' Complement Proteins ', ' Complement ', ' Disorder ', ' Disease ', ' Gene Expression ', ' Genes ', ' Goals ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' lung disorder ', ' disorder of the lung ', ' disease of the lung ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Lung diseases ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' Chronic Obstructive Airway Disease ', ' Methods ', ' mortality ', ' muscle wasting ', ' muscle loss ', ' muscle deterioration ', ' muscle degradation ', ' muscle breakdown ', ' Muscle Atrophy ', ' Muscular Atrophy ', ' Patients ', ' Phenotype ', ' Prognosis ', ' outcome forecast ', ' emphysematous ', ' Emphysema ', ' Pulmonary Emphysema ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' respiratory function ', ' lung function ', ' Respiratory physiology ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' Spirometry ', ' Testing ', ' United States ', ' Genetic Diversity ', ' Genetic Variation ', ' X-Ray Medical Imaging ', ' X-Ray Imaging ', ' Roentgenography ', ' Radiography ', ' Diagnostic X-Ray Radiology ', ' Diagnostic X-Ray ', ' Diagnostic Radiology ', ' Conventional X-Ray ', ' Diagnostic radiologic examination ', ' Measures ', ' base ', ' Chronic ', ' Clinical ', ' Biological ', ' Training ', ' peripheral blood ', ' Individual ', ' Genetic ', ' Lung volume reduction surgery ', ' LVRS ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Disease Management ', ' Disorder Management ', ' programs ', ' Severities ', ' Complex ', ' respiratory ', ' cohort ', ' Expert Opinion ', ' novel ', ' Participant ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Genomics ', ' Genetic Determinism ', ' genetic determinant ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Bioinformatics ', ' Bio-Informatics ', ' genome sequencing ', ' Data ', ' Molecular Profiling ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Genetic Risk ', ' Principal Investigator ', ' Characteristics ', ' Molecular ', ' Pathway interactions ', ' pathway ', ' clinical phenotype ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' Outcome ', ' Impairment ', ' transcriptomics ', ' clinically relevant ', ' clinical relevance ', ' Network-based ', ' exome ', ' exomes ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' quantitative imaging ', ' miRNA expression profiling ', ' microRNA sequencing ', ' micro RNA expression profiling ', ' miRNA-seq ', ' miRNA sequencing ', ' global miRNA profiling ', ' MicroRNA Expression Profiling ', ' learning strategy ', ' learning method ', ' learning activity ', ' personalized approach ', ' tailored approach ', ' precision approach ', ' individualized approach ', ' Personalized medical approach ', ' multiple omics ', ' multiomics ', ' SNP array ', ' SNP chip ', ' molecular subtypes ', ' molecular subsets ', ' molecular sub-types ', ' expression subtypes ', ' whole genome ', ' full genome ', ' entire genome ', ' patient subsets ', ' patient subtypes ', ' patient subpopulations ', ' patient subgroups ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' Trans-Omics for Precision Medicine ', ' TOPMed ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' Multiomic Data ', ' multiple omic data ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K08,2019,172800,MA-07,0.4806416259634665
"An Integrative Radiogenomic Approach to Design Genetically-Informed Image Biomarker for Characterizing COPD ! Abstract  Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of death worldwide with a devastating socio-economic burden impacting more than three million individuals per year in the US. The primary environmental risk factor in the susceptible population is smoking, which causes an exaggerated inflammatory response. However, many factors including several genetic risk variants substantially influence the susceptibility. Twin-based studies show that families with emphysema have a higher risk for the disease. The two different major phenotypes of COPD are small airway remodeling (airway disease) and alveolar destruction (emphysema). Although these two major phenotypes result in a similar deficiency in global lung function, the relationship between them is complicated and likely involves feedback mechanisms. Developing an objective method to characterize lung phenotypes is critical since treatment candidates vary based on phenotype. Measurements from High-Resolution Computed Tomography (HRCT) images are increasingly used to describe COPD since they can quantitatively describe the contribution of the phenotypes. To discover the genetic risk variants, Genome-Association Studies (GWAS) have focused on either the physiological lung function or a simple threshold-based measurement from lung CT, neither of which fully characterizes phenotypic subtypes or the distribution pattern of disease. The proposed studies will take advantage of the rich image and genetic data jointly to build a genetically-informed imaging biomarker to characterize each patient. For each patient, our method summarizes the CT image to a vector representation that accurately describes the severity of the disease. Also, a method to link the representation back to the genetic risk variants will be developed. If successful, these methods can be used to monitor the efficacy of treatment or progression of the disease using imaging data. Successful execution of the second aim will result in better understanding of the etiology of different disease subtypes and discovery of novel genetic pathways that could be used as potential drug targets. Furthermore, the patient representation enables the use of image data to construct a more powerful model to predict the so-called acute exacerbation event. Predicting the exacerbations is clinically important since they cause further damage to the lung.  In Aim 1, we develop and implement a novel image biomarker that is mutually informed by imaging and genetic data from each patient. Our statistical method in Aim 2 elucidates the underlying genetic pathways behind the abnormal anatomical variations explained by the biomarker. We validate our method on data from 10,300 patients in the COPDGene dataset. ! Narrative  Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of death worldwide with a devastating socio-economic burden impacting more than three million individuals per year in the US. Measurements from High-Resolution Computed Tomography (HRCT) images are increasingly used to describe COPD. Many factors including several genetic risk variants substantially influence the susceptibility. We propose to take advantage of the rich image and genetic data jointly to understand the underlying biological causes of the disease and discovery of novel genetic pathways that could be used as potential drug targets.",An Integrative Radiogenomic Approach to Design Genetically-Informed Image Biomarker for Characterizing COPD,9692778,R01HL141813,"['Affect ', ' airway obstruction ', ' obstructed airway ', ' obstructed airflow ', ' airflow obstruction ', "" Alzheimer's Disease "", ' senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', ' Anatomy ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Back ', ' Dorsum ', ' Cause of Death ', ' Chronic Bronchitis ', ' Computers ', ' Disorder ', ' Disease ', ' Disease Vectors ', ' Family ', ' Feedback ', ' Genes ', ' genetic biomarker ', ' Genetic Markers ', ' Genome ', ' Genotype ', ' Goals ', ' Joints ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' Chronic Obstructive Airway Disease ', ' Math ', ' Mathematics ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Patients ', ' Phenotype ', ' emphysematous ', ' Emphysema ', ' Pulmonary Emphysema ', ' respiratory function ', ' lung function ', ' Respiratory physiology ', ' Risk Factors ', ' Smoking ', ' Spirometry ', ' Time ', ' tomography ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' X-Ray Computed Tomography ', ' Twins ', ' Twin Multiple Birth ', ' Measures ', ' Dataset ', ' Data Set ', ' Caring ', ' base ', ' Image Analysis ', ' image evaluation ', ' Image Analyses ', ' Area ', ' Acute ', ' Clinical ', ' Variant ', ' Variation ', ' Biological ', ' Physiological ', ' Physiologic ', ' Link ', ' Predisposition ', ' Susceptibility ', ' lung lobe ', ' Individual ', ' Measurement ', ' Disease Progression ', ' Descriptor ', ' Deformity ', ' Anatomical Abnormality ', ' Anatomic Abnormality ', ' Genetic ', ' clinical Diagnosis ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Pollution ', ' Dimensions ', ' Complex ', ' Event ', ' Pattern ', ' Severity of illness ', ' disease severity ', ' small airways disease ', ' attenuation ', ' novel ', ' economic cost ', ' disorder risk ', ' disease risk ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Reporting ', ' Statistical Methods ', ' Pulmonary Function Test/Forced Expiratory Volume 1 ', ' PFT/FEV1 ', ' Forced Expiratory Volume in 1 Second ', ' Forced Expiratory Volume 1 Test ', ' FEV1%VC ', ' FEV1 ', ' Modeling ', ' drug development ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Pathogenicity ', ' Inflammatory Response ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' Address ', ' Data ', ' Economic Burden ', ' High Resolution Computed Tomography ', ' high resolution CT ', ' Resolution ', ' Genetic Risk ', ' Pathologic ', ' Monitor ', ' Process ', ' follow-up ', ' followup ', ' followed up ', ' follow up ', ' active followup ', ' Active Follow-up ', ' socioeconomics ', ' socioeconomically ', ' socio-economically ', ' socio-economic ', ' Image ', ' imaging ', ' Pathway interactions ', ' pathway ', ' vector ', ' design ', ' designing ', ' airway remodeling ', ' Treatment Efficacy ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Population ', ' alveolar destruction ', ' Heritability ', ' endophenotype ', ' high risk ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' Drug Targeting ', ' Radiogenomics ', ' non-invasive imaging ', ' noninvasive imaging ', ' Lung CAT Scan ', ' Lung CT scan ', ' Lung CT ', ' CT Lung Screening ', ' imaging biomarker ', ' imaging-based marker ', ' imaging-based biomarker ', ' imaging-based biological marker ', ' imaging marker ', ' genotyped patients ', ' imaging genetics ', ' high dimensionality ', ' Airway Disease ', ' deep learning ', ' convolutional neural network ', ' convolutional neural nets ', ' ConvNet ', ' ']",NHLBI,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,R01,2019,564472,PA-18,0.281208006586705
"Systems Level Causal Discovery in Heterogeneous TOPMed Data SYSTEMS LEVEL CAUSAL DISCOVERY IN HETEROGENEOUS TOPMED DATA ABSTRACT The advent of new technologies for collecting and analyzing multiple heterogeneous data streams from the same individual makes possible the detailed phenotypic characterization of diseases and paves the way for the development of individualized precision therapies. A major bottleneck in this process is the lack of robust, efficient and truly integrative analytic methods for such multi-modal data. This proposal builds on the ongoing efforts of our group in the area of causal learning in biomedicine. The objective of this application is to extend, modify and tailor our causal probabilistic graphical models to data typically collected by TOPMed projects, such as omics data (SNPs, metabolomics, RNA-seq, etc), imaging, patients' history, and clinical data. COPDGene is one of the TOPMed projects and has generated datasets with those modalities for 10,000 patients with chronic obstructive pulmonary disease (COPD), the third leading cause of death and a major cause of disability and health care costs in the US. The prevailing view is that COPD is a syndrome, consisting of multiple diseases with different characteristics. There is currently no satisfactory method for COPD subtyping or prediction of disease progression. In this project we will apply, test and validate our approaches on COPDGene and another large independent COPD cohort. The extension and application of our methods to cross-sectional and longitudinal data will also allow us to investigate a number of important questions and aspects related to COPD. Mechanistically, we will investigate how SNPs, genes and their networks are causally linked to disease phenotypes. In pathology, we will identify conditional biomarkers, which will lead to disease sub-classification and identification of causal components in each subtype. In pathophysiology, we will identify features that are directly linked to lung function decline and outcome. We will make all our algorithms and results available to the community through web and public cloud interfaces. The deliverables will be (1) new probabilistic approaches for integration and analysis of multi-modal cross-sectional and longitudinal data, including SNPs, blood biomarkers, CT scans and clinical data; (2) new cloud-based server to make these approaches available to the research community; (3) results on the mechanism, pathology and pathophysiology of COPD facilitation and progression. To guarantee the success of the project we have assembled a team of experts in genomics, machine learning, cloud computing and COPD. This cross- disciplinary team project will have a positive impact beyond the above deliverables, since the generality of our approaches makes them applicable to any disease. We expect that during this U01 we will have the opportunity to collaborate with other teams in the TOPMed consortium to help them investigate the causes of their corresponding disease phenotypes. We do believe that data integration in a single probabilistic framework will be in the heart of precision medicine strategies in the future, when massive high-throughput data collection will become a routine diagnostic and prognostic procedure in all hospitals. PROJECT NARRATIVE Current technologies for high-throughput biomedical data collection allow the interrogation of multiple modalities from a single patient. New promising analytical methods started emerging, which can analyze those multi-modal data in a holistic way. Chronic obstructive pulmonary disease (COPD) constitutes the third leading cause of death and a major cause of disability and health care costs in the US. The prevailing view is that COPD is a syndrome, consisting of multiple diseases with their own characteristics. There is currently no satisfactory method for COPD subtyping. We will apply, test and validate new probabilistic approaches on two cohorts of COPD patients. We will investigate the mechanisms of disease facilitation; we will identify patient cohorts with specific characteristics (disease subtypes); and investigate risk factors and causal variants for the disease progression in each subtype. ",Systems Level Causal Discovery in Heterogeneous TOPMed Data,9678366,U01HL137159,"['Algorithms ', ' Blood ', ' Blood Reticuloendothelial System ', ' Cause of Death ', ' Systematics ', ' Classification ', ' Communities ', ' Data Collection ', ' Disorder ', ' Disease ', ' liability to disease ', ' Diathesis ', ' Disease susceptibility ', ' Future ', ' Genes ', ' Genotype ', ' Goals ', ' Heart ', ' History ', ' Recording of previous events ', ' Hospitals ', ' Learning ', ' Chronic Obstructive Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' COPD ', ' Chronic Obstructive Airway Disease ', ' Methods ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' mortality ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Pathology ', ' Patients ', ' Phenotype ', ' Prognosis ', ' outcome forecast ', ' Pulmonary Medicine ', ' Pneumonology ', ' Pneumology ', ' Pulmonology ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' respiratory function ', ' lung function ', ' Respiratory physiology ', ' Risk ', ' Risk Factors ', ' school of medicine ', ' medical college ', ' medical schools ', ' Science ', ' Software ', ' Computer software ', ' Syndrome ', ' Technology ', ' Testing ', ' Body Tissues ', ' Tissues ', ' computerized tomography ', ' computerized axial tomography ', ' computed axial tomography ', ' catscan ', ' Xray Computed Tomography ', ' X-Ray Computerized Tomography ', ' X-Ray CAT Scan ', ' Tomodensitometry ', ' EMI scan ', ' Computed Tomography ', ' CT scan ', ' CT imaging ', ' CT X Ray ', ' CAT scan ', ' X-Ray Computed Tomography ', ' Universities ', ' Healthcare Costs ', ' Health Costs ', ' Health Care Costs ', ' Outcome Assessment ', ' Dataset ', ' Data Set ', ' analytical method ', ' base ', ' Procedures ', ' Area ', ' Clinical ', ' Physiological ', ' Physiologic ', ' Lifting ', ' Link ', ' prognostic ', ' disability ', ' Individual ', ' Disease Progression ', ' Funding ', ' Functional disorder ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Collaborations ', ' Morphology ', ' tool ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Computational Biology ', ' computer biology ', ' Stream ', ' System ', ' Visit ', ' success ', ' computer science ', ' cohort ', ' Peripheral Blood Mononuclear Cell ', ' PBMC ', ' novel ', ' Graph ', ' new technology ', ' novel technologies ', ' Disease model ', ' disorder model ', ' Modality ', ' Modeling ', ' high throughput technology ', ' repository ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Genomics ', ' Genetic Determinism ', ' genetic determinant ', ' metabonomics ', ' metabolism measurement ', ' metabolomics ', ' Address ', ' Data ', ' Clinical Data ', ' Functional Imaging ', ' physiological imaging ', ' Physiologic Imaging ', ' Characteristics ', ' Molecular ', ' Process ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' disease phenotype ', ' data integration ', ' Outcome ', ' cost effective ', ' innovation ', ' innovative ', ' innovate ', ' clinically relevant ', ' clinical relevance ', ' user-friendly ', ' graphical user interface ', ' graphic user interface ', ' Graphical interface ', ' multimodality ', ' multi-modality ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' The Cancer Genome Atlas ', ' TCGA ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' Cloud Computing ', ' cloud computer ', ' Cloud Infrastructure ', ' cloud based ', ' precision medicine ', ' precision-based medicine ', ' Precision therapeutics ', ' precision treatment ', ' precision therapies ', ' Genomic medicine ', ' precision genomic medicine ', ' patient subsets ', ' patient subtypes ', ' patient subpopulations ', ' patient subgroups ', ' Trans-Omics for Precision Medicine ', ' TOPMed ', ' longitudinal dataset ', ' longitudinal data set ', ' clinical imaging ', ' multimodal data ', ' multi-modal data ', ' causal variant ', ' causative variant ', ' causative mutation ', ' causal mutation ', ' causal gene ', ' causal allele ', ' ']",NHLBI,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,U01,2019,602448,PA-18,0.41662108031881584
"Clinical feasibility of a non-invasive, low-cost wearable for measuring air trapping in COPD ABSTRACT  Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of hospitalization in the US. Exacerbations - a worsening or flare up of symptoms - cause most COPD hospitalizations. Since most exacerbations can be treated with changes of inhalers and/or oral medications, at-home detection of lung function deterioration may facilitate earlier intervention and help delay or prevent hospitalizations. The Standards of Care for monitoring lung function are spirometry, plethysmography, and CT scan. However, these are expensive methods and unsuited for continuous monitoring or at-home use. Various patient self-monitoring approaches have been tried, for example, pulse oximetry, respiratory rate monitoring, and peak flow metering, but their efficacy in reducing hospitalizations has been limited.  A common finding for all forms of COPD is air trapping, defined, as an abnormal increase in the volume of air remaining in the lungs after exhalation is complete. A body of evidence definitively shows that air trapping increases during exacerbations and decreases when exacerbations resolve. Recent reports show that air trapping is an earlier harbinger of deteriorating lung function than spirometric changes, and can be measured by low-frequency ultrasound (1-40 kHz). Acoustic monitoring of air trapping could provide clinicians with a non- invasive tool when medical intervention is needed to avoid unnecessary ER visits and hospitalizations.  Respira Labs has developed a low-cost, non-invasive, acoustic-based wearable device that can continually monitor lung resonance: Sylvee. The device uses known acoustic-based technology with machine- learning algorithms to detect minor changes in lung resonance, which our preliminary results suggest correspond to changes in air trapping. The overall objective of this project is to validate Sylvee's air trapping algorithms in a cohort of 20 healthy controls and 40 COPD patients with and without air trapping, respectively. In Aims 1 and 2, we will miniaturize and add sensors to the Sylvee device and develop a user interface (UI) and a mobile application. In Aims 3 and 4, we will create an Air Trapping Index Report and validate it in a cross-sectional study vis--vis whole body plethysmography as a control. Results of this project provide a go/no-go development decision based on device function. We can apply these results in STTR Phase II, in a larger clinical study to evaluate Sylvee as an at-home monitoring system, with a goal of reducing hospitalizations by at least 30%. Ultimately, Sylvee will allow physicians to remotely monitor their patients' lung function and adjust their medications to reduce healthcare costs and improve patients' quality of life. PROJECT NARRATIVE More than 12 million Americans have been diagnosed with COPD, and another 17 million may have COPD, but are unaware of it. By 2020, the costs associated with COPD are estimated to be $72B billion per year, of which with ~50% are the costs of spent on ER visits and hospitalizations. The goal of this proposal is to establish and validate a seamless and non-obtrusive wearable that measures abnormal air trapping via a novel acoustic technology, which would reduce hospitalizations through at-home monitoring of lung function.","Clinical feasibility of a non-invasive, low-cost wearable for measuring air trapping in COPD",10080272,R41HL152769,"['Acoustics ', ' Acoustic ', ' Activities of Daily Living ', ' Activities of everyday life ', ' daily living functionality ', ' functional ability ', ' functional capacity ', ' Adult ', ' 21+ years old ', ' Adult Human ', ' adulthood ', ' Air ', ' Algorithms ', ' Asthma ', ' Bronchial Asthma ', ' Chronic Bronchitis ', ' Clinical Research ', ' Clinical Study ', ' Clinical Trials ', ' Cross-Sectional Studies ', ' Cross Sectional Analysis ', ' Cross-Sectional Analyses ', ' Cross-Sectional Survey ', ' Disease Frequency Surveys ', ' Data Analyses ', ' Data Analysis ', ' data interpretation ', ' Diagnosis ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Dyspnea ', ' Breathlessness ', ' Edema ', ' Dropsy ', ' Hydrops ', ' Future ', ' Goals ', ' Health ', ' Heart Rate ', ' Cardiac Chronotropism ', ' Hospitalization ', ' Hospital Admission ', ' Hospitals ', ' General Hospitals ', ' Humidity ', ' indexing ', ' Inhalators ', ' Inhaler ', ' Laboratories ', ' Lung ', ' Lung Respiratory System ', ' pulmonary ', ' Chronic Obstructive Airway Disease ', ' COPD ', ' Chronic Obstruction Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Pulmonary function tests ', ' Lung Function Tests ', ' Respiratory Function Tests ', ' Methods ', ' Military Personnel ', ' Armed Forces Personnel ', ' Military ', ' Miniaturization ', ' Miniaturisations ', ' Minor ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Mucous body substance ', ' Mucus ', ' mucous ', ' Noise ', ' Patients ', ' Physicians ', ' Physiology ', ' Plethysmography ', ' Whole Body Plethysmography ', ' Pulmonary Emphysema ', ' Emphysema ', ' emphysematous ', ' Pulse Oximetry ', ' Quality of life ', ' QOL ', ' Questionnaires ', ' Respiratory Muscles ', ' Ventilatory Muscles ', ' Respiratory physiology ', ' lung function ', ' respiratory function ', ' Risk ', ' Running ', ' San Francisco ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Computer software ', ' Software ', ' Spirometry ', ' Standardization ', ' Technology ', ' Temperature ', ' Testing ', ' Time ', ' X-Ray Computed Tomography ', ' CAT scan ', ' CT X Ray ', ' CT Xray ', ' CT imaging ', ' CT scan ', ' Computed Tomography ', ' Tomodensitometry ', ' X-Ray CAT Scan ', ' X-Ray Computerized Tomography ', ' Xray CAT scan ', ' Xray Computed Tomography ', ' Xray computerized tomography ', ' catscan ', ' computed axial tomography ', ' computer tomography ', ' computerized axial tomography ', ' computerized tomography ', ' Translating ', ' Ultrasonography ', ' Echography ', ' Echotomography ', ' Medical Ultrasound ', ' Ultrasonic Imaging ', ' Ultrasonogram ', ' Ultrasound Diagnosis ', ' Ultrasound Medical Imaging ', ' Ultrasound Test ', ' diagnostic ultrasound ', ' sonogram ', ' sonography ', ' sound measurement ', ' ultrasound ', ' ultrasound imaging ', ' ultrasound scanning ', ' Veterans ', ' Bronchoconstriction ', ' Bronchial Constriction ', ' Measures ', ' Health Care Costs ', ' Health Costs ', ' Healthcare Costs ', ' Device Designs ', ' Caring ', ' base ', ' sensor ', ' improved ', ' Clinical ', ' Refractory ', ' Phase ', ' Medical ', ' Individual ', ' O3 exposure ', ' ozone exposure ', ' Measurement ', ' Disease Progression ', ' Early Intervention ', ' Personal Medical History ', ' Personal Medical History Epidemiology ', ' Medical History ', ' Dysfunction ', ' Physiopathology ', ' pathophysiology ', ' Functional disorder ', ' Exposure to ', ' tool ', ' Smoker ', ' machine learned ', ' Machine Learning ', ' Frequencies ', ' Oral ', ' Home ', ' Home environment ', ' Clinic ', ' Exhaling ', ' Respiratory Expiration ', ' Exhalation ', ' System ', ' Particulate ', ' meter ', ' respiratory ', ' Oximetry ', ' Oxygen saturation measurement ', ' Medical center ', ' American ', ' experience ', ' success ', ' cohort ', ' novel ', ' Devices ', ' Reporting ', ' intervention therapy ', ' Therapeutic Intervention ', ' Deterioration ', ' develop software ', ' developing computer software ', ' software development ', ' miniaturize ', ' Intervention Strategies ', ' interventional strategy ', ' Intervention ', ' air monitoring ', ' Cell Phone ', ' Cellular Telephone ', ' iPhone ', ' smart phone ', ' smartphone ', ' Cellular Phone ', ' preventing ', ' prevent ', ' Symptoms ', ' Data ', ' Detection ', ' Regulatory Pathway ', ' Clinical Data ', ' Flare ', ' STTR ', ' Small Business Technology Transfer Research ', ' wireless ', ' Wireless Technology ', ' Monitor ', ' developmental ', ' Development ', ' cost ', ' designing ', ' design ', ' Population ', ' user-friendly ', ' usability ', ' prototype ', ' Secure ', ' screening ', ' Algorithmic Analyses ', ' Analyses of Algorithms ', ' Analysis of Algorithms ', ' Algorithmic Analysis ', ' mobile app ', ' mobile application ', ' cloud based ', ' ED visit ', ' ER visit ', ' Emergency care visit ', ' Emergency hospital visit ', ' Emergency room visit ', ' Emergency department visit ', ' accurate diagnosis ', ' recruit ', ' Android App ', ' Android Application ', ' Cell Phone Application ', ' Cell phone App ', ' Cellular Phone App ', ' Cellular Phone Application ', ' Smart Phone App ', ' Smart Phone Application ', ' Smartphone App ', ' iOS app ', ' iOS application ', ' iPhone App ', ' iPhone Application ', ' smartphone Application ', ' Bluetooth ', ' wearable electronics ', ' wearable technology ', ' wearable device ', ' microphone ', ' machine learned algorithm ', ' machine learning algorithm ', ' ']",NHLBI,"RESPIRA LABS, LLC",R41,2020,350000,CA-18,0.23492473815537812
"Machine Learning Development for Subtyping COPD Project Summary Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by progressive loss of lung function with subsequent increasing breathlessness and worsening quality of life. This heterogeneity makes it difficult to predict health decline and develop targeted treatments for better patient care. To date, researchers have attempted to use standard machine learning methodology to identify more meaningful subtypes of COPD, but these methods often make general assumptions about the data, limiting their ability to penetrate more complex patterns in some data sets. Thus, a meaningful reclassification of COPD subtypes that could lead to more targeted therapies and interventions has been elusive. The applicant introduces a new way of looking at the COPD subtyping problem by recasting it in terms of discovering associations of individuals to disease trajectories  i.e., grouping individuals based on their similarity in response to environmental and/or disease causing variables. The machine learning methods proposed build on the most recent advances in Bayesian nonparametrics, a collection of theoretical ideas and techniques that permit very flexible data representations. In this career development proposal, the applicant hypothesizes that these machine learning methods and extensions thereof  together with data sources not previously leveraged for COPD subtyping  will produce more biologically meaningful sub-groupings of patients, leading to a better understanding of the genetic and biological underpinnings of the disease and ultimately improved patient management. Aim 1 of this application involves evaluating the utility of CT-assessed lung mass  a potentially more discriminative measure of emphysema than conventionally used measures  for defining COPD subtypes using both K-means clustering and our disease trajectory algorithm. The goal of Aim 2 is to evaluate the utility of comorbidity data for defining COPD subtypes using our trajectory clustering algorithm. Novel computed tomography based measures of muscle wasting (cachexia) and pulmonary vascular pruning will be explored to determine their efficacy in subtype determination. Additionally, we will extend and test the trajectory algorithm in order to model discrete outputs (such as physician-diagnosed comorbidities), count data (e.g. exacerbations), and time-to-event data (death). In Aim 3, the applicant will extend our trajectory clustering algorithms to directly incorporate genetic and omics data for subtype discovery. Together, the research proposed in the aims of this award will take full advantage of the comprehensive data set available through the COPDGene study. Execution of the aims in this proposal will be possible through active collaboration with Dr. Ron Kikinis, M.D., a renowned leader in the field of medical image analysis, and Dr. Ed Silverman, an internationally recognized expert in the genetic epidemiology of COPD. Project Narrative Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by progressive loss of lung function with subsequent increasing breathlessness and worsening quality of life. This heterogeneity makes it difficult to predict health decline and develop targeted treatments for better patient care. In carrying out the research outlined in the following proposal, we plan to develop and apply machine learning methods to better identify subpopulations of individuals who have similar forms of COPD, potentially enabling better, targeted therapies.",Machine Learning Development for Subtyping COPD,9948018,K25HL130637,"['Affect ', ' airway obstruction ', ' airflow limitation ', ' airflow obstruction ', ' airway limitation ', ' obstructed airflow ', ' obstructed airway ', ' Algorithms ', ' Award ', ' Blood Vessels ', ' vascular ', ' Cachexia ', ' Cachectic ', ' Cause of Death ', ' comorbidity ', ' co-morbid ', ' co-morbidity ', ' Data Reporting ', ' data representation ', ' Data Sources ', ' Cessation of life ', ' Death ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Disease susceptibility ', ' Diathesis ', ' liability to disease ', ' Dyspnea ', ' Breathlessness ', ' Environment ', ' Patient Care ', ' Patient Care Delivery ', ' Goals ', ' Health ', ' Heterogeneity ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Lung ', ' Lung Respiratory System ', ' pulmonary ', ' Chronic Obstructive Airway Disease ', ' COPD ', ' Chronic Obstruction Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Medical Imaging ', ' Methods ', ' Methodology ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' mortality ', ' Muscular Atrophy ', ' Muscle Atrophy ', ' muscle breakdown ', ' muscle degradation ', ' muscle deterioration ', ' muscle loss ', ' muscle wasting ', ' Patients ', ' Physicians ', ' Publishing ', ' Pulmonary Emphysema ', ' Emphysema ', ' emphysematous ', ' Quality of life ', ' QOL ', ' Research ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Respiratory physiology ', ' lung function ', ' respiratory function ', ' Smoke ', ' Syndrome ', ' Testing ', ' Time ', ' X-Ray Computed Tomography ', ' CAT scan ', ' CT X Ray ', ' CT Xray ', ' CT imaging ', ' CT scan ', ' Computed Tomography ', ' Tomodensitometry ', ' X-Ray CAT Scan ', ' X-Ray Computerized Tomography ', ' Xray CAT scan ', ' Xray Computed Tomography ', ' Xray computerized tomography ', ' catscan ', ' computed axial tomography ', ' computer tomography ', ' computerized axial tomography ', ' computerized tomography ', ' Measures ', ' Lung Mass ', ' Pulmonary Mass ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Image Analyses ', ' image evaluation ', ' image interpretation ', ' Image Analysis ', ' Clinical ', ' Biological ', ' peripheral blood ', ' Failure ', ' Individual ', ' Bayesian computation ', ' Bayesian inference ', ' Bayesian network analysis ', ' Bayesian spatial analysis ', ' Bayesian statistical analysis ', ' Bayesian statistical inference ', ' Bayesian statistics ', ' Bayesian Analysis ', ' Disease Progression ', ' Collaborations ', ' Descriptor ', ' Genetic ', ' machine learned ', ' Machine Learning ', ' Complex ', ' Event ', ' Pattern ', ' Techniques ', ' particle ', ' novel ', ' disorder model ', ' Disease model ', ' Environmental Factor ', ' environmental risk ', ' Environmental Risk Factor ', ' Modeling ', ' career development ', ' response ', ' genetic epidemiologic study ', ' genetic epidemiology ', ' disease subgroups ', ' disease subtype ', ' disorder subtype ', ' Intervention Strategies ', ' interventional strategy ', ' Intervention ', ' Inflammatory Response ', ' genetic association ', ' Data ', ' M.D. ', ' Doctor of Medicine ', ' International ', ' Subgroup ', ' Collection ', ' Physiologic Imaging ', ' physiological imaging ', ' Functional Imaging ', ' Scheme ', ' Characteristics ', ' Process ', ' groupings ', ' Grouping ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' Output ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' designing ', ' design ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' flexible ', ' flexibility ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' imaging marker ', ' imaging-based biological marker ', ' imaging-based biomarker ', ' imaging-based marker ', ' imaging biomarker ', ' cigarette smoke ', ' machine learned algorithm ', ' machine learning algorithm ', ' machine learning method ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K25,2020,189000,MA-07,0.44476189124601284
"Multi-omic Subtyping of Chronic Obstructive Pulmonary Disease PROJECT SUMMARY/ABSTRACT Chronic obstructive pulmonary disease (COPD) is the leading cause of respiratory mortality in the United States. COPD is a highly heterogeneous disease and some COPD therapies are only applied to specific clinically defined subtypes. With the advent of multiple high-throughput biological assays and machine learning approaches, data-driven subtypes are increasingly being recognized. We hypothesize that such subtypes exist in COPD and that they can be identified using an integrative, multi-'omic approach. To accomplish this goal, we first propose to complement existing RNA and whole genome sequencing data in the well-phenotyped COPDGene study with peripheral blood microRNA sequencing. We will study the relationship of microRNA to genetic variation and gene expression in COPD. Next, we will apply a patient-based network similarity method to these three data types to identify COPD molecular subtypes. Finally, we will associate these subtypes with important clinical phenotypes and outcomes, and validate these subtypes in an independent subset of subjects. Our analysis targets a key clinical problem in COPD management, and will allow the mentee to become an independent investigator, applying bioinformatic and machine learning methods to genomic data in respiratory diseases. PROJECT NARRATIVE Chronic obstructive pulmonary disease (COPD) is a leading cause of death in the United States. Patients with COPD may have very similar lung function but differ in many other characteristics. We propose to use multiple types of biologic data to identify different COPD subtypes, which may be important for disease prognosis and treatment.",Multi-omic Subtyping of Chronic Obstructive Pulmonary Disease,9975882,K08HL136928,"['Affect ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Blood ', ' Blood Reticuloendothelial System ', ' Cause of Death ', ' Complement ', ' Complement Proteins ', ' Disease ', ' Disorder ', ' Gene Expression ', ' Genes ', ' Goals ', ' Lung ', ' Lung Respiratory System ', ' pulmonary ', ' Lung diseases ', ' Pulmonary Diseases ', ' Pulmonary Disorder ', ' Respiratory Disease ', ' Respiratory System Disease ', ' Respiratory System Disorder ', ' disease of the lung ', ' disorder of the lung ', ' lung disorder ', ' Chronic Obstructive Airway Disease ', ' COPD ', ' Chronic Obstruction Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Methods ', ' mortality ', ' Muscular Atrophy ', ' Muscle Atrophy ', ' muscle breakdown ', ' muscle degradation ', ' muscle deterioration ', ' muscle loss ', ' muscle wasting ', ' Patients ', ' Phenotype ', ' outcome forecast ', ' Prognosis ', ' Pulmonary Emphysema ', ' Emphysema ', ' emphysematous ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Respiratory physiology ', ' lung function ', ' respiratory function ', ' RNA ', ' Non-Polyadenylated RNA ', ' RNA Gene Products ', ' Ribonucleic Acid ', ' Spirometry ', ' Testing ', ' United States ', ' Genetic Variation ', ' Genetic Diversity ', ' Diagnostic radiologic examination ', ' Conventional X-Ray ', ' Diagnostic Radiology ', ' Diagnostic X-Ray ', ' Diagnostic X-Ray Radiology ', ' Radiography ', ' Roentgenography ', ' X-Ray Imaging ', ' X-Ray Medical Imaging ', ' Xray imaging ', ' Xray medical imaging ', ' conventional Xray ', ' diagnostic Xray ', ' diagnostic Xray radiology ', ' Measures ', ' base ', ' Chronic ', ' Clinical ', ' Biological ', ' Training ', ' peripheral blood ', ' Individual ', ' Genetic ', ' LVRS ', ' Lung volume reduction surgery ', ' machine learned ', ' Machine Learning ', ' Disorder Management ', ' Disease Management ', ' programs ', ' Severities ', ' Complex ', ' respiratory ', ' cohort ', ' Expert Opinion ', ' novel ', ' Participant ', ' disease subgroups ', ' disease subtype ', ' disorder subtype ', ' Genomics ', ' genetic determinant ', ' Genetic Determinism ', ' Micro RNA ', ' miRNA ', ' miRNAs ', ' MicroRNAs ', ' Bio-Informatics ', ' Bioinformatics ', ' genome sequencing ', ' Data ', ' Molecular Fingerprinting ', ' molecular profile ', ' molecular signature ', ' Molecular Profiling ', ' Genetic Risk ', ' Principal Investigator ', ' Characteristics ', ' Molecular ', ' pathway ', ' Pathway interactions ', ' clinical phenotype ', ' GWA study ', ' GWAS ', ' genome wide association ', ' genome wide association scan ', ' genome wide association studies ', ' genomewide association scan ', ' genomewide association studies ', ' genomewide association study ', ' whole genome association analysis ', ' whole genome association studies ', ' whole genome association study ', ' genome wide association study ', ' Outcome ', ' Impairment ', ' transcriptomics ', ' clinical relevance ', ' clinically relevant ', ' Network-based ', ' exomes ', ' exome ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' NGS Method ', ' NGS system ', ' next gen sequencing ', ' nextgen sequencing ', ' next generation sequencing ', ' Risk-associated variant ', ' risk allele ', ' risk gene ', ' risk genotype ', ' risk loci ', ' risk locus ', ' risk variant ', ' quantitative imaging ', ' MicroRNA Expression Profiling ', ' global miRNA profiling ', ' miRNA sequencing ', ' miRNA-seq ', ' micro RNA expression profiling ', ' microRNA sequencing ', ' miRNA expression profiling ', ' Personalized medical approach ', ' individualized approach ', ' precision approach ', ' tailored approach ', ' personalized approach ', ' multiomics ', ' multiple omics ', ' SNP chip ', ' single nucleotide polymorphism array ', ' single nucleotide polymorphism chip ', ' SNP array ', ' expression subtypes ', ' molecular sub-types ', ' molecular subsets ', ' molecular subtypes ', ' entire genome ', ' full genome ', ' whole genome ', ' patient subgroups ', ' patient subpopulations ', ' patient subtypes ', ' patient subsets ', ' genomic data-set ', ' genomic dataset ', ' genomic data ', ' TOPMed ', ' Trans-Omics for Precision Medicine ', ' genetic condition ', ' genetic disorder ', ' Genetic Diseases ', ' multiple omic data ', ' Multiomic Data ', ' machine learning method ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K08,2020,172800,MA-07,0.4806416259634665
"Enhancing the I AM GOLD study with single-cell deep phenotyping and machine learning meta-analysis Project Summary/Abstract Patients with HIV are at increased risk for chronic obstructive pulmonary disease (COPD), the third leading cause of death worldwide. In this proposal, our long-term goal is to identify the mechanisms underlying the increased risk of COPD with HIV infection. Our central hypothesis is that enhanced Th17 driven inflammation and chronic Gammaproteobacteria-dominated airway microbiota interact to contribute to obstructive lung disease in HIV+ individuals. This hypothesis is based on the following evidence. First, we have found in HIV- uninfected COPD patients that a genomic signature of Th17 driven airway inflammation marks a COPD subgroup with functional small airway disease, which is thought to precede emphysema. Second, Th17 driven inflammation, a pathway classically thought to defend against bacteria, is enhanced in the airways of HIV+ patients. Third, our group has shown that amongst Ugandan HIV+ patients with pneumonia, a population at higher risk for lung function decline, there are subgroups characterized by distinct lower airway microbial communities with differing immune responses. One subgroup had Pseudomonadaceae-dominated airway microbiota and inflammatory gene expression. Gammaproteobacteria, which includes Pseudomonas, are commonly found in COPD and, as with Th17 inflammation, are associated with emphysema. Thus, the Pseudomonadaceae-dominant pneumonia subgroup may be at higher risk for developing chronic disease in the setting of continued dysbiosis and low level Th17 driven chronic inflammation. Our proposed specific aims will use existing and newly collected samples from our international multi-center study of HIV-associated COPD, I AM OLD (Inflammation, Aging, Microbes and Obstructive Lung Disease), in which HIV+ participants in Uganda and San Francisco are enrolled at the time of acute pneumonia and followed longitudinally. Aim 1 will identify the airway microbial communities and inflammatory gene expression markers at the time of acute infection that are associated with subsequent incident COPD and lung function decline in HIV. Aim 2 will identify the airway microbial communities and inflammatory gene expression markers during chronic stable disease that are enhanced in HIV+COPD compared to participants without COPD (HIV+COPD-). In Aim 3 we will perform integrative analyses of the airway microbiome, microbial and human transcriptome, metabolome and lung radiographic changes in HIV+COPD. We anticipate the following outcomes: 1) identification of the predominant airway microbiome-host response interactions associated with HIV+COPD in two international at- risk populations, 2) identification of metabolome alterations associated with specific microbial communities and inflammatory responses in HIV+COPD, 3) delineation of the range of radiographic abnormalities associated with microbiome-host response interactions in HIV+COPD. We expect these outcomes to have a positive impact, providing a new understanding of the biology underlying the enhanced risk for COPD amongst the HIV- infected population which could direct therapeutic interventions. Project Narrative In this proposal, our long-term goal is to identify the mechanisms underlying the increased risk of COPD with HIV infection. Our central hypothesis is that enhanced Th17 driven inflammation and chronic Gammaproteobacteria-dominated airway microbiota interact to contribute to obstructive lung disease in HIV+ individuals. We will test this hypothesis in an ongoing international multi-center study of HIV-associated COPD in which HIV+ participants in Uganda and San Francisco are enrolled at the time of acute pneumonia, characterized comprehensively for airway infection and the associated inflammatory response, and followed longitudinally.",Enhancing the I AM GOLD study with single-cell deep phenotyping and machine learning meta-analysis,10177730,R01HL143998,"['Aging ', ' Bacteria ', ' Biology ', ' Cause of Death ', ' Cells ', ' Cell Body ', ' Chronic Disease ', ' Chronic Illness ', ' chronic disorder ', ' Gene Expression ', ' Goals ', ' HIV ', ' AIDS Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' Acquired Immunodeficiency Syndrome Virus ', ' Human Immunodeficiency Viruses ', ' LAV-HTLV-III ', ' Lymphadenopathy-Associated Virus ', ' Virus-HIV ', ' HIV Infections ', ' HTLV-III Infections ', ' HTLV-III-LAV Infections ', ' Human T-Lymphotropic Virus Type III Infections ', ' Human ', ' Modern Man ', ' Infection ', ' Inflammation ', ' Chronic Obstructive Airway Disease ', ' COPD ', ' Chronic Obstruction Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Patients ', ' Phenotype ', ' Pneumonia ', ' Pseudomonadaceae ', ' Pseudomonas ', ' Chrysemonas ', ' Flavimonas ', ' Pulmonary Emphysema ', ' Emphysema ', ' emphysematous ', ' Respiratory physiology ', ' lung function ', ' respiratory function ', ' Risk ', ' San Francisco ', ' Testing ', ' Thoracic Radiography ', ' CXR ', ' chest X ray ', ' chest Xray ', ' chest radiography ', ' lung radiography ', ' radiographic chest image ', ' radiographic lung image ', ' thoracic radiogram ', ' thorax radiography ', ' Time ', ' Uganda ', ' Diagnostic radiologic examination ', ' Conventional X-Ray ', ' Diagnostic Radiology ', ' Diagnostic X-Ray ', ' Diagnostic X-Ray Radiology ', ' Radiography ', ' Roentgenography ', ' X-Ray Imaging ', ' X-Ray Medical Imaging ', ' Xray imaging ', ' Xray medical imaging ', ' conventional Xray ', ' diagnostic Xray ', ' diagnostic Xray radiology ', ' base ', ' Chronic ', ' Individual ', ' Populations at Risk ', ' Multi-center studies ', ' Multicenter Studies ', ' Immunological response ', ' host response ', ' immunoresponse ', ' Immune response ', ' Inflammatory ', ' machine learned ', ' Machine Learning ', ' small airways disease ', ' microbial ', ' obstructive airway disease ', ' respiratory airway obstruction ', ' Obstructive Lung Diseases ', ' Stable Disease ', ' Participant ', ' Acute Pneumonia ', ' gamma Proteobacteria ', ' -Proteobacteria ', ' Gammaproteobacteria ', ' intervention therapy ', ' Therapeutic Intervention ', ' Sampling ', ' disease subgroups ', ' disease subtype ', ' disorder subtype ', ' Meta-Analysis ', ' Inflammatory Response ', ' International ', ' Subgroup ', ' enroll ', ' Enrollment ', ' pathway ', ' Pathway interactions ', ' decline in function ', ' decline in functional status ', ' functional status decline ', ' functional decline ', ' airway epithelium inflammation ', ' airway inflammation ', ' Outcome ', ' Population ', ' community microbes ', ' microbial community ', ' Microbe ', ' high risk ', ' global gene expression ', ' global transcription profile ', ' transcriptome ', ' metabonome ', ' metabolome ', ' genomic classifier ', ' genomic signature ', ' acute infection ', ' dysbacteriosis ', ' dysbiotic ', ' microbial imbalance ', ' dysbiosis ', ' airway microbial community ', ' airway microbiota ', ' respiratory microbiota ', ' airway microbiome ', ' respiratory tract microbiome ', ' respiratory microbiome ', ' host microbiome ', ' ']",NHLBI,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",R01,2020,89962,CA-12,0.2697900461807553
"An Integrative Radiogenomic Approach to Design Genetically-Informed Image Biomarker for Characterizing COPD ! Abstract  Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of death worldwide with a devastating socio-economic burden impacting more than three million individuals per year in the US. The primary environmental risk factor in the susceptible population is smoking, which causes an exaggerated inflammatory response. However, many factors including several genetic risk variants substantially influence the susceptibility. Twin-based studies show that families with emphysema have a higher risk for the disease. The two different major phenotypes of COPD are small airway remodeling (airway disease) and alveolar destruction (emphysema). Although these two major phenotypes result in a similar deficiency in global lung function, the relationship between them is complicated and likely involves feedback mechanisms. Developing an objective method to characterize lung phenotypes is critical since treatment candidates vary based on phenotype. Measurements from High-Resolution Computed Tomography (HRCT) images are increasingly used to describe COPD since they can quantitatively describe the contribution of the phenotypes. To discover the genetic risk variants, Genome-Association Studies (GWAS) have focused on either the physiological lung function or a simple threshold-based measurement from lung CT, neither of which fully characterizes phenotypic subtypes or the distribution pattern of disease. The proposed studies will take advantage of the rich image and genetic data jointly to build a genetically-informed imaging biomarker to characterize each patient. For each patient, our method summarizes the CT image to a vector representation that accurately describes the severity of the disease. Also, a method to link the representation back to the genetic risk variants will be developed. If successful, these methods can be used to monitor the efficacy of treatment or progression of the disease using imaging data. Successful execution of the second aim will result in better understanding of the etiology of different disease subtypes and discovery of novel genetic pathways that could be used as potential drug targets. Furthermore, the patient representation enables the use of image data to construct a more powerful model to predict the so-called acute exacerbation event. Predicting the exacerbations is clinically important since they cause further damage to the lung.  In Aim 1, we develop and implement a novel image biomarker that is mutually informed by imaging and genetic data from each patient. Our statistical method in Aim 2 elucidates the underlying genetic pathways behind the abnormal anatomical variations explained by the biomarker. We validate our method on data from 10,300 patients in the COPDGene dataset. ! Narrative  Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of death worldwide with a devastating socio-economic burden impacting more than three million individuals per year in the US. Measurements from High-Resolution Computed Tomography (HRCT) images are increasingly used to describe COPD. Many factors including several genetic risk variants substantially influence the susceptibility. We propose to take advantage of the rich image and genetic data jointly to understand the underlying biological causes of the disease and discovery of novel genetic pathways that could be used as potential drug targets.",An Integrative Radiogenomic Approach to Design Genetically-Informed Image Biomarker for Characterizing COPD,9934266,R01HL141813,"['Affect ', ' Air Movements ', ' air flow ', ' airflow ', ' airway obstruction ', ' airflow limitation ', ' airflow obstruction ', ' airway limitation ', ' obstructed airflow ', ' obstructed airway ', "" Alzheimer's Disease "", ' AD dementia ', ' Alzheimer ', ' Alzheimer Type Dementia ', ' Alzheimer disease ', ' Alzheimer sclerosis ', ' Alzheimer syndrome ', "" Alzheimer's "", "" Alzheimer's disease dementia "", ' Alzheimers Dementia ', ' Alzheimers disease ', ' Primary Senile Degenerative Dementia ', ' dementia of the Alzheimer type ', ' primary degenerative dementia ', ' senile dementia of the Alzheimer type ', ' Anatomy ', ' Anatomic ', ' Anatomic Sites ', ' Anatomic structures ', ' Anatomical Sciences ', ' Back ', ' Dorsum ', ' Cause of Death ', ' Chronic Bronchitis ', ' Disease ', ' Disorder ', ' Disease Vectors ', ' Family ', ' Feedback ', ' Genes ', ' Genetic Markers ', ' genetic biomarker ', ' Genome ', ' Genotype ', ' Goals ', ' Joints ', ' Lung ', ' Lung Respiratory System ', ' pulmonary ', ' Chronic Obstructive Airway Disease ', ' COPD ', ' Chronic Obstruction Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Mathematics ', ' Math ', ' Methods ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Patients ', ' Phenotype ', ' Pulmonary Emphysema ', ' Emphysema ', ' emphysematous ', ' Respiratory physiology ', ' lung function ', ' respiratory function ', ' Risk Factors ', ' Smoking ', ' Spirometry ', ' Time ', ' X-Ray Computed Tomography ', ' CAT scan ', ' CT X Ray ', ' CT Xray ', ' CT imaging ', ' CT scan ', ' Computed Tomography ', ' Tomodensitometry ', ' X-Ray CAT Scan ', ' X-Ray Computerized Tomography ', ' Xray CAT scan ', ' Xray Computed Tomography ', ' Xray computerized tomography ', ' catscan ', ' computed axial tomography ', ' computer tomography ', ' computerized axial tomography ', ' computerized tomography ', ' Twin Multiple Birth ', ' Twins ', ' Measures ', ' Dataset ', ' Data Set ', ' Caring ', ' base ', ' Area ', ' Acute ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Physiologic ', ' Physiological ', ' Link ', ' Susceptibility ', ' Predisposition ', ' lung lobe ', ' Individual ', ' Measurement ', ' Disease Progression ', ' Descriptor ', ' Anatomic Abnormality ', ' Anatomical Abnormality ', ' Deformity ', ' Genetic ', ' clinical Diagnosis ', ' machine learned ', ' Machine Learning ', ' Pollution ', ' Dimensions ', ' Complex ', ' Event ', ' Pattern ', ' disease severity ', ' Severity of illness ', ' small airways disease ', ' attenuation ', ' novel ', ' economic cost ', ' disease risk ', ' disorder risk ', ' Environmental Factor ', ' environmental risk ', ' Environmental Risk Factor ', ' Reporting ', ' Statistical Methods ', ' FEV1 ', ' FEV1%VC ', ' Forced Expiratory Volume 1 Test ', ' Forced Expiratory Volume in 1 Second ', ' PFT/FEV1 ', ' Pulmonary Function Test/Forced Expiratory Volume 1 ', ' Modeling ', ' drug development ', ' disease subgroups ', ' disease subtype ', ' disorder subtype ', ' Pathogenicity ', ' Inflammatory Response ', ' Causality ', ' causation ', ' disease causation ', ' Etiology ', ' Address ', ' Data ', ' Economic Burden ', ' high resolution CT ', ' High Resolution Computed Tomography ', ' Resolution ', ' Genetic Risk ', ' Pathologic ', ' Monitor ', ' Process ', ' Active Follow-up ', ' active followup ', ' follow up ', ' followed up ', ' followup ', ' follow-up ', ' socio-economic ', ' socio-economically ', ' socioeconomically ', ' socioeconomics ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' vector ', ' designing ', ' design ', ' airway remodeling ', ' intervention efficacy ', ' therapeutic efficacy ', ' therapeutically effective ', ' therapy efficacy ', ' Treatment Efficacy ', ' Population ', ' alveolar destruction ', ' Heritability ', ' endophenotype ', ' high risk ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' Risk-associated variant ', ' risk allele ', ' risk gene ', ' risk genotype ', ' risk loci ', ' risk locus ', ' risk variant ', ' Drug Targeting ', ' Radiogenomics ', ' noninvasive imaging ', ' non-invasive imaging ', ' CT Lung Screening ', ' Lung CT ', ' Lung CT scan ', ' computerized tomography lung screening ', ' lung computerized axial tomography scan ', ' lung computerized tomography ', ' lung computerized tomography scan ', ' Lung CAT Scan ', ' imaging marker ', ' imaging-based biological marker ', ' imaging-based biomarker ', ' imaging-based marker ', ' imaging biomarker ', ' genotyped patients ', ' imaging genetics ', ' high dimensionality ', ' Airway Disease ', ' deep learning ', ' ConvNet ', ' convolutional network ', ' convolutional neural nets ', ' convolutional neural network ', ' ']",NHLBI,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,R01,2020,564472,PA-18,0.281208006586705
"Identification of immune cell-cell communication networks and inflammatory pulmonary microenvironments associated with the progression of COPD PROJECT SUMMARY Chronic obstructive pulmonary disease (COPD) is a fatal lung disease that is the fourth leading cause of death in the U.S. Despite an estimated $50 billion in yearly healthcare costs, it has no current cure and only palliat- ive treatments. COPD is clearly characterized by chronic lung inflammation that likely arises from dysregulat- ion of complex networks of immune factors and cells across multiple tissue compartments. Although multiple individual genes and proteins have been associated with COPD risk and progression, global mechanistic understanding of its pathophysiology is lacking, particularly regarding the marked heterogeneity in COPD phenotypes. The overall objective of our study is to gain systems-level insight into complex inflammatory and immune mechanisms underlying COPD, by applying data-driven (also called machine learning) modeling approaches to clinical samples collected from human pulmonary microenvironments and matched immune cell networks from peripheral blood. Our central hypothesis is that immune networks will be more predictive of COPD phenotype, progression, and exacerbation than individual factors. We will test this hypothesis in three Specific Aims, using matched brochoalveolar lavage (BAL) and blood samples collected in SPIROMICS I and II clinical trials. Aim 1 will identify changes in immune cell-cell communication networks, by high-throughput cytokine measurements from stimulated systems of peripheral blood immune cells from smokers with and without COPD and never-smoking controls (collected from the upcoming SPIROMICS II visit; n=150). Aim 2 will determine systems-level changes that occur in the inflamed lung microenvironment, using high-throughput cytokine measurements in BAL samples (both archival from SPIROMICS I, n=200, and collected during upcoming SPIROMICS II bronchoscopies) from smokers with and without COPD and never-smoking controls. We will identify networks associated with longitudinal clinical progression and exacerbation frequency. Aim 3 will integrate measurements across lung and blood tissue compartments to define key combinatorial relationships associated with progression and exacerbation events. Overall, this project will provide systems- level insight into COPD pathogenesis and progression, and create a new paradigm for the study of other pulmonary conditions involving chronic inflammation, including idiopathic pulmonary fibrosis, asthma, and lung transplant. Results will aid in the future development of new non-invasive diagnostic assays and will guide systems-level mechanistic studies that could result in new combinatorial therapies. PROJECT NARRATIVE The goal of this proposal is to gain new systems-level insight into chronic obstructive pulmonary disease (COPD), which is the third leading cause of death worldwide and an enormous cost burden in the U.S. yearly (~50 billion). Despite progress in identifying individual immune factors associated with COPD, there are only palliative treatment options and no cure. New insight generated by this project into how immune cell communication networks and inflammatory pulmonary microenvironments are altered in COPD could be used to identify diagnostic biomarkers and to guide the design of combinatorial therapies.",Identification of immune cell-cell communication networks and inflammatory pulmonary microenvironments associated with the progression of COPD,9888409,R01HL144849,"['Accounting ', ' Archives ', ' Asthma ', ' Bronchial Asthma ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Blood ', ' Blood Reticuloendothelial System ', ' Bronchoscopy ', ' Cause of Death ', ' Cell Communication ', ' Cell Interaction ', ' Cell-to-Cell Interaction ', ' Cells ', ' Cell Body ', ' Clinical Trials ', ' Cohort Studies ', ' Concurrent Studies ', ' Death Records ', ' Disease ', ' Disorder ', ' Epithelium ', ' Epithelium Part ', ' Flow Cytometry ', ' Flow Cytofluorometries ', ' Flow Cytofluorometry ', ' Flow Microfluorimetry ', ' Flow Microfluorometry ', ' flow cytophotometry ', ' Future ', ' Goals ', ' Heterogeneity ', ' Human ', ' Modern Man ', ' Immunologic Factors ', ' Immunological Factors ', ' immunologic substance ', ' immunological substance ', ' In Vitro ', ' Inflammation ', ' Irrigation ', ' Lavage ', ' Nonvaginal irrigation ', ' Nonvaginal lavage ', ' irrigation therapy ', ' lavage therapy ', ' other than vaginal Douching ', ' other than vaginal Irrigation ', ' Longitudinal Studies ', ' long-term study ', ' longitudinal outcome studies ', ' longterm study ', ' Lung ', ' Lung Respiratory System ', ' pulmonary ', ' Lung diseases ', ' Pulmonary Diseases ', ' Pulmonary Disorder ', ' Respiratory Disease ', ' Respiratory System Disease ', ' Respiratory System Disorder ', ' disease of the lung ', ' disorder of the lung ', ' lung disorder ', ' Chronic Obstructive Airway Disease ', ' COPD ', ' Chronic Obstruction Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Lung Transplantation ', ' Lung Grafting ', ' lung transplant ', ' Methods ', ' Mucous Membrane ', ' Mucosa ', ' Mucosal Tissue ', ' Palliative Care ', ' Palliative Therapy ', ' Palliative Treatment ', ' comfort care ', ' Patients ', ' Radiology Specialty ', ' General Radiology ', ' Radiology ', ' Research ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Risk ', ' Spirometry ', ' Testing ', ' Tissues ', ' Body Tissues ', ' X-Ray Computed Tomography ', ' CAT scan ', ' CT X Ray ', ' CT Xray ', ' CT imaging ', ' CT scan ', ' Computed Tomography ', ' Tomodensitometry ', ' X-Ray CAT Scan ', ' X-Ray Computerized Tomography ', ' Xray CAT scan ', ' Xray Computed Tomography ', ' Xray computerized tomography ', ' catscan ', ' computed axial tomography ', ' computer tomography ', ' computerized axial tomography ', ' computerized tomography ', ' Vision ', ' Sight ', ' visual function ', ' cytokine ', ' Measures ', ' Health Care Costs ', ' Health Costs ', ' Healthcare Costs ', ' health care ', ' Healthcare ', ' Outcome Measure ', ' diverse populations ', ' heterogeneous population ', ' population diversity ', ' Population Heterogeneity ', ' Caring ', ' Blood Sample ', ' Blood specimen ', ' detector ', ' Bronchioalveolar Lavage ', ' Bronchopulmonary Lavage ', ' Lung Lavage ', ' bronchopulmonary lavage therapy ', ' Bronchoalveolar Lavage ', ' Chronic ', ' Clinical ', ' Physiologic ', ' Physiological ', ' prognostic ', ' Epithelial ', ' peripheral blood ', ' insight ', ' Individual ', ' Measurement ', ' Disease Progression ', ' Funding ', ' non-invasive diagnosis ', ' non-invasive diagnostic ', ' noninvasive diagnostic ', ' noninvasive diagnosis ', ' Dysfunction ', ' Physiopathology ', ' pathophysiology ', ' Functional disorder ', ' Inflammatory ', ' Smoker ', ' Diagnostic ', ' machine learned ', ' Machine Learning ', ' Frequencies ', ' Immunes ', ' Immune ', ' Severities ', ' Complex ', ' Event ', ' System ', ' Visit ', ' experience ', ' cohort ', ' Participant ', ' disease risk ', ' disorder risk ', ' Pathogenesis ', ' Position ', ' Positioning Attribute ', ' Protein Gene Products ', ' Gene Proteins ', ' Proteome ', ' Modeling ', ' Sampling ', ' Data ', ' Clinical Data ', ' enroll ', ' Enrollment ', ' Process ', ' Active Follow-up ', ' active followup ', ' follow up ', ' followed up ', ' followup ', ' follow-up ', ' developmental ', ' Development ', ' disease phenotype ', ' cost ', ' designing ', ' design ', ' adjudicate ', ' Outcome ', ' Lung Inflammation ', ' prospective ', ' combinatorial ', ' clinical relevance ', ' clinically relevant ', ' new drug target ', ' new druggable target ', ' new pharmacotherapy target ', ' new therapy target ', ' novel drug target ', ' novel druggable target ', ' novel pharmacotherapy target ', ' novel therapeutic target ', ' novel therapy target ', ' new therapeutic target ', ' new therapeutic approach ', ' new therapeutic intervention ', ' new therapeutic strategies ', ' new therapy approaches ', ' novel therapeutic approach ', ' novel therapy approach ', ' novel therapeutic intervention ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' prognostic ability ', ' prognostic power ', ' prognostic utility ', ' prognostic value ', ' diagnostic assay ', ' diagnostic marker ', ' diagnostic biomarker ', ' diffuse interstitial pulmonary fibrosis ', ' idiopathic pulmonary fibrosis ', ' never smoking ', ' ']",NHLBI,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2020,319844,MI-12,0.37207459114546343
"Clinical significance and genetic determinants of novel imaging measures of emphysema distribution in 9,743 smokers PROJECT SUMMARY/ABSTRACT Candidate: Dr. Adel El Boueiz is a pulmonary and critical care physician-scientist completing a period of T32- funded support at the Channing Division of Network Medicine (CDNM) and Harvard Medical School (HMS). He received a Master's of Medical Science in Biomedical Informatics from HMS in May 2016. He will be promoted to Instructor of Medicine at the CDNM and HMS on July 1, 2017. His principal research interests are the genetic epidemiology of chronic obstructive pulmonary disease (COPD) and the translation of genomic discoveries into clinical practice and public health. His long-term goal is to be an independent investigator with expertise in imaging phenotyping, genomics, and predictive analytics of the regional heterogeneity of the various aspects of COPD (emphysema, airway disease, and pulmonary vascular remodeling). Environment: Dr. El Boueiz will continue to pursue his research and career development in the rich and multidisciplinary environment of the CDNM and the Brigham and Women's Hospital Applied Chest Imaging Lab (ACIL). He will be mentored by Drs. Edwin K. Silverman, Peter J. Castaldi, and Ral San Jos Estpar, leaders in the field of COPD quantitative imaging, genetic epidemiology, and predictive analytics with excellent track records of mentoring young investigators towards independent research careers. His career development will also be overseen by an advisory committee with expertise related to key areas of his proposal. Research: COPD is a major cause of morbidity and mortality that is of increasing public health importance. COPD is a heterogeneous disease and this heterogeneity complicates the identification of the predictors of disease progression and consequently, the development of effective therapies. Emphysema distribution is an important COPD-related phenotype that emerged as a strong predictor of the response to lung volume reduction procedures. Despite the availability of advanced texture-based CT quantification methods, global threshold-based quantitative metrics have to date been the cornerstone for the radiological characterization of emphysema distribution with inability to differentiate centrilobular, panlobular, and paraseptal emphysema patterns. In this project, we will apply a texture-based CT quantification method to discover novel imaging biomarkers of the regional heterogeneity of centrilobular, panlobular, and paraseptal emphysema in a large cohort of well-characterized smokers and identify their genetic determinants using whole genome sequencing and integrative genomics analyses. The results will be considered for inclusion along with other rich phenotypic and imaging data in COPD disease progression machine learning predictive models. Relevance: Through improved radiographic phenotyping of emphysema distribution, better understanding of disease pathobiology, and more accurate prediction of disease progression, the proposed work will open new avenues of investigation for the development of personalized and improved COPD therapeutic strategies. PROJECT NARRATIVE Chronic obstructive pulmonary disease (COPD) is a common disease that affects up to 24 million people in the United States, is associated with considerable and increasing morbidity and mortality, and for which there is no available disease-modifying therapy. COPD is associated with significant variation in radiographic, symptomatic and physiologic presentation and exhibits variability in progression. Currently, there is no satisfactory method for progression prediction. This project will identify novel imaging biomarkers of the regional distribution of centrilobular, panlobular, and paraseptal emphysema with particular emphasis on their associations with clinical relevant COPD-related outcomes, their genetic determinants, and their ability to improve prediction of COPD disease progression, above and beyond that provided by the traditional clinical, radiographic, and genetic features. This is an important area of research as predicting those patients who will remain stable from those who will have rapid disease progression is critical in defining prognosis and selecting patients for specific therapeutic interventions.","Clinical significance and genetic determinants of novel imaging measures of emphysema distribution in 9,743 smokers",9975215,K08HL141601,"['Accounting ', ' Affect ', ' Automobile Driving ', ' driving ', ' Clinical Trials ', ' Cohort Studies ', ' Concurrent Studies ', ' comorbidity ', ' co-morbid ', ' co-morbidity ', ' Computing Methodologies ', ' computational methodology ', ' computational methods ', ' computer based method ', ' computer methods ', ' computing method ', ' Critical Care ', ' Disease ', ' Disorder ', ' Dyspnea ', ' Breathlessness ', ' Environment ', ' Exhibits ', ' Genes ', ' Medical Genetics ', ' Clinical genetics ', ' Goals ', ' Heterogeneity ', ' Hospitals ', ' Lung ', ' Lung Respiratory System ', ' pulmonary ', ' Lung diseases ', ' Pulmonary Diseases ', ' Pulmonary Disorder ', ' Respiratory Disease ', ' Respiratory System Disease ', ' Respiratory System Disorder ', ' disease of the lung ', ' disorder of the lung ', ' lung disorder ', ' Chronic Obstructive Airway Disease ', ' COPD ', ' Chronic Obstruction Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Medicine ', ' Mentors ', ' Mentorship ', ' Methods ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Patients ', ' Phenotype ', ' Physicians ', ' Genetic Polymorphism ', ' polymorphism ', ' outcome forecast ', ' Prognosis ', ' Public Health ', ' Pulmonary Emphysema ', ' Emphysema ', ' emphysematous ', ' Radiology Specialty ', ' General Radiology ', ' Radiology ', ' Records ', ' Research ', ' research and development ', ' Development and Research ', ' R & D ', ' R&D ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Resources ', ' Research Resources ', ' Respiratory physiology ', ' lung function ', ' respiratory function ', ' medical schools ', ' medical college ', ' school of medicine ', ' Science ', ' Technology ', ' Testing ', ' Tissues ', ' Body Tissues ', ' X-Ray Computed Tomography ', ' CAT scan ', ' CT X Ray ', ' CT Xray ', ' CT imaging ', ' CT scan ', ' Computed Tomography ', ' Tomodensitometry ', ' X-Ray CAT Scan ', ' X-Ray Computerized Tomography ', ' Xray CAT scan ', ' Xray Computed Tomography ', ' Xray computerized tomography ', ' catscan ', ' computed axial tomography ', ' computer tomography ', ' computerized axial tomography ', ' computerized tomography ', ' Translations ', ' United States ', ' Woman ', ' Work ', ' Diagnostic radiologic examination ', ' Conventional X-Ray ', ' Diagnostic Radiology ', ' Diagnostic X-Ray ', ' Diagnostic X-Ray Radiology ', ' Radiography ', ' Roentgenography ', ' X-Ray Imaging ', ' X-Ray Medical Imaging ', ' Xray imaging ', ' Xray medical imaging ', ' conventional Xray ', ' diagnostic Xray ', ' diagnostic Xray radiology ', ' Generations ', ' Measures ', ' Medical Research ', ' Walking ', ' Task Forces ', ' advisory team ', ' Advisory Committees ', ' base ', ' career ', ' improved ', ' Procedures ', ' Area ', ' Clinical ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Medical ', ' Evaluation ', ' prognostic ', ' Visual ', ' Disease Progression ', ' Funding ', ' Biological Function ', ' Biological Process ', ' Therapeutic ', ' Genetic ', ' Smoker ', ' Nature ', ' machine learned ', ' Machine Learning ', ' Scientist ', ' Investigation ', ' Complex ', ' Texture ', ' Pattern ', ' respiratory ', ' Lung Volume Reductions ', ' interest ', ' instructor ', ' QTL ', ' Quantitative Trait Loci ', ' cohort ', ' attenuation ', ' novel ', ' disease risk ', ' disorder risk ', ' Position ', ' Positioning Attribute ', ' lobes ', ' Lobe ', ' intervention therapy ', ' Therapeutic Intervention ', ' Thorace ', ' Thoracic ', ' Thorax ', ' Chest ', ' Lung Parenchyma ', ' Lung Tissue ', ' Structure of parenchyma of lung ', ' FEV1 ', ' FEV1%VC ', ' Forced Expiratory Volume 1 Test ', ' Forced Expiratory Volume in 1 Second ', ' PFT/FEV1 ', ' Pulmonary Function Test/Forced Expiratory Volume 1 ', ' Modeling ', ' career development ', ' genetic epidemiologic study ', ' genetic epidemiology ', ' disease subgroups ', ' disease subtype ', ' disorder subtype ', ' Genomics ', ' genetic determinant ', ' Genetic Determinism ', ' Bio-Informatics ', ' Bioinformatics ', ' datamining ', ' data mining ', ' genetic association ', ' genome sequencing ', ' ACVR1B ', ' ACVRLK4 Gene ', ' ALK4 Gene ', ' Activin A Receptor, Type II-Like Kinase 4 Gene ', ' Activin Receptor-Like Kinase 4 Gene ', ' Type IB Gene Activin A Receptor ', ' ACVR1B gene ', ' Data ', ' Detection ', ' Subgroup ', ' Clinical/Radiologic ', ' Collection ', ' Pathologic ', ' Lobar ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' disease phenotype ', ' biomed informatics ', ' biomedical informatics ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' Outcome ', ' Vascular remodeling ', ' clinical relevance ', ' clinically relevant ', ' clinical significance ', ' clinically significant ', ' multidisciplinary ', ' effective treatment ', ' effective therapy ', ' genome scale ', ' genomewide ', ' genome-wide ', ' clinical practice ', ' rare allele ', ' rare variant ', ' genetic predictors ', ' Precision care ', ' individualized care ', ' individualized patient care ', ' personalized patient care ', ' personalized care ', ' genomic effort ', ' genomic strategy ', ' Genomic approach ', ' quantitative imaging ', ' imaging marker ', ' imaging-based biological marker ', ' imaging-based biomarker ', ' imaging-based marker ', ' imaging biomarker ', ' Predictive Analytics ', ' prediction of response ', ' predictive response ', ' predictor of response ', ' response prediction ', ' predicting response ', ' disease heterogeneity ', ' entire genome ', ' full genome ', ' whole genome ', ' genomic predictors ', ' imaging genetics ', ' Airway Disease ', ' genetic architecture ', ' machine learning method ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,K08,2020,170639,MA-07,0.37436875921610646
"Identifying palliative care needs among hospitalized patients with chronic obstructive pulmonary disease PROJECT SUMMARY Millions of Americans with COPD experience burdensome symptoms, reduced quality of life, and undesirable end-of-life care. Increasing palliative care for this vulnerable population is widely advocated to improve these important patient-centered outcomes. Yet patients with COPD rarely receive palliative care due, in part, to difficulties identifying which patients have unmet palliative care needs and palliative care workforce shortages. The proposed study's core objective is to address the national priority of improving palliative care for patients with COPD by developing an efficient, innovative, and patient-centered method to identify those with unmet palliative care needs. Specifically, the candidate seeks to (1) assess patients with COPD to determine their palliative care needs; (2) develop and validate an electronic health record-based classification model for each domain of palliative care needs; and (3) evaluate the relationship between the probability of having unmet palliative care needs and patient-centered clinical outcomes. The study will involve an in-person cross- sectional survey of 432 hospitalized patients with COPD of any stage. Participants will complete a validated survey to capture a wide variety of palliative care needs, which will be supplemented with expert chart review to identify patients with needs in any of three clinically relevant and actionable domains. These cases will be used as the patient-reported reference standard for development and validation of domain-specific classification models leveraging natural language processing of unstructured clinical text in electronic health records and machine learning methods. Finally, a large, multicenter retrospective cohort study will evaluate the associations between different probabilities of having unmet palliative care needs and several clinical outcomes important to patients, caregivers, and hospitals. This will enable the identification of thresholds of probabilities of unmet needs above which COPD patients' risks of undesirable clinical outcomes increase. Such patients will then be targeted for enrollment in future trials testing interventions to improve these outcomes. Completion of this research will build upon the candidate's past training, which includes a Masters in Health Policy Research obtained with NHLBI T32 support, an F32-supported post-doctoral fellowship, and a career development award from the National Palliative Care Research Center, and will provide the experience, education, and mentorship to allow the candidate to become a fully independent investigator. The candidate's rigorous training plan, focused on obtaining advanced skills in multisite prospective research, patient-centered outcomes research, and advanced bioinformatics methods will allow her to submit successful R01 or PCORI applications testing interventions directly informed by the results of this work. The candidate's primary mentor, collaborators, and advisors will ensure adherence to the proposed timeline and goals and provide a supportive environment for her to develop an independent research career focused on improving the uptake and effectiveness of palliative care for patients with COPD and other cardiopulmonary diseases. PROJECT NARRATIVE Patients with COPD experience burdensome symptoms, reduced quality of life, and low quality end-of-life care. Palliative care may improve such outcomes, yet resources are strained and it is difficult to identify which patients are most in need. The aims of this research are to provide new knowledge regarding the unmet palliative care needs of patients with COPD and to develop a novel and scalable method to identify patients with such needs in order to reduce patients' suffering and improve quality of life.",Identifying palliative care needs among hospitalized patients with chronic obstructive pulmonary disease,10004708,K23HL143181,"['Age ', ' ages ', ' Award ', ' Beds ', ' Calibration ', ' Classification ', ' Systematics ', ' Clinical Research ', ' Clinical Study ', ' comorbidity ', ' co-morbid ', ' co-morbidity ', ' Cross-Sectional Studies ', ' Cross Sectional Analysis ', ' Cross-Sectional Analyses ', ' Cross-Sectional Survey ', ' Disease Frequency Surveys ', ' Data Reporting ', ' data representation ', ' Data Sources ', ' Cessation of life ', ' Death ', ' Discrimination ', ' Cognitive Discrimination ', ' Disease ', ' Disorder ', ' Education ', ' Educational aspects ', ' Fellowship ', ' Future ', ' Patient Care ', ' Patient Care Delivery ', ' Goals ', ' Health Policy ', ' health care policy ', ' healthcare policy ', ' Hospitals ', ' Inpatients ', ' Intensive Care Units ', ' Chronic Obstructive Airway Disease ', ' COPD ', ' Chronic Obstruction Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Manuals ', ' Marital Status ', ' Mentors ', ' Mentorship ', ' Methods ', ' Persons ', ' Natural Language Processing ', ' natural language understanding ', ' Nurses ', ' nurse ', ' Palliative Care ', ' Palliative Therapy ', ' Palliative Treatment ', ' comfort care ', ' Patient Outcomes Assessments ', ' Patient Reported Measures ', ' Patient Reported Outcomes ', ' Patients ', ' Physicians ', ' Probability ', ' Professional Organizations ', ' professional association ', ' professional membership ', ' professional society ', ' Pulmonary Heart Disease ', ' Cor pulmonale ', ' Pulmonary Heart Disorder ', ' cardiopulmonary disease ', ' cardiopulmonary disorder ', ' Quality of life ', ' QOL ', ' Reference Standards ', ' Research ', ' Research Design ', ' Study Type ', ' study design ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Resources ', ' Research Resources ', ' Risk ', ' Social support ', ' social support network ', ' Social Work ', ' Social Service ', ' medical specialties ', ' Specialty ', ' Surveys ', ' Survey Instrument ', ' Educational process of instructing ', ' Teaching ', ' Testing ', ' Time ', ' Triage ', ' Work ', ' Caregivers ', ' Care Givers ', ' Outcomes Research ', ' TimeLine ', ' Caring ', ' base ', ' career ', ' improved ', ' Site ', ' Clinical ', ' Medical ', ' Ensure ', ' Training ', ' Distress ', ' uptake ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' psychosocial ', ' Visit ', ' Consult ', ' Postdoc ', ' Research Associate ', ' post-doc ', ' post-doctoral ', ' Postdoctoral Fellow ', ' American ', ' experience ', ' Performance ', ' functional status ', ' cohort ', ' Structure ', ' skills ', ' novel ', ' Participant ', ' Reporting ', ' end of life care ', ' Modeling ', ' Sampling ', ' Intervention Strategies ', ' interventional strategy ', ' Intervention ', ' vulnerable group ', ' Vulnerable Populations ', ' Bio-Informatics ', ' Bioinformatics ', ' Institution ', ' Effectiveness ', ' Address ', ' end-of-life ', ' end of life ', ' Symptoms ', ' Adherence ', ' Advocate ', ' Data ', ' K23 Award ', ' K23 Mechanism ', ' K23 Program ', ' Mentored Patient-Oriented Research Career Development Award (K23) ', ' Mentored Patient-Oriented Research Career Development Award ', ' Policy Research ', ' Career Development Awards ', ' Career Development Awards and Programs ', ' Career Development Programs K-Series ', ' K-Awards ', ' Research Career Program ', ' K-Series Research Career Programs ', ' Research Training ', ' enroll ', ' Enrollment ', ' Observation research ', ' Observation study ', ' Observational research ', ' Observational Study ', ' Patient outcome ', ' Patient-Centered Outcomes ', ' Patient-Focused Outcomes ', ' Validation ', ' Characteristics ', ' Process ', ' Text ', ' developmental ', ' Development ', ' electronic health care record ', ' electronic healthcare record ', ' Electronic Health Record ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' Outcome ', ' Prevalence ', ' prospective ', ' innovate ', ' innovative ', ' innovation ', ' clinical relevance ', ' clinically relevant ', ' patient centered ', ' patient oriented ', ' Randomization trial ', ' randomized trial ', ' Patient risk ', ' clinically actionable ', ' improved outcome ', ' study population ', ' physical symptom ', ' Retrospective cohort study ', ' recruit ', ' hospital services ', ' hospital re-admission rates ', ' hospital readmission rate ', ' re-admission rates ', ' re-hospitalization rate ', ' rehospitalization rate ', ' readmission rates ', ' enthusiastic atmosphere ', ' enthusiastic environment ', ' supportive atmosphere ', ' supportive environment ', ' unstructured data ', ' machine learning method ', ' clinical center ', ' ']",NHLBI,UNIVERSITY OF PENNSYLVANIA,K23,2020,173628,PA-03,0.38407516212314335
"Multi-omic networks associated with COPD progression in TOPMed Cohorts PROJECT SUMMARY Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the US. Although COPD occurs predominantly in smokers, it is unknown why only a minority of smokers (~20-40%) develop chronic airflow limitation or destruction of distal airspaces (emphysema). The difference susceptibility to tobacco smoke could be explained by differences in genetics or environment, which lead to activation or repression of pathways that are important in the pathogenesis and progression of COPD. Recent advances in high throughput omics (whole genome sequencing, DNA methylation, RNA-Seq, proteomics and metabolomics) applied to NHLBI cohorts now permits a comprehensive assessment of the molecular profiles of susceptible patients. This proposal will use sparse multiple canonical correlation network analysis (SmCCNet) to integrate these existing -omics data from three NHLBI cohorts: COPDGene, Jackson Heart Study, and SPIROMICS. The three independent cohorts will allow replication of specific molecular networks which can be used to target new therapies or more precise prognostic information to individuals (i.e., precision medicine). The first two of these cohorts have large numbers of African American subjects, who are underrepresented in omics studies. We will perform population specific analyses, which will allow us to determine which molecular signatures and pathways might be specific to African Americans. PROJECT NARRATIVE Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the US. To help identify why only some smokers develop COPD, this proposal will integrate recently collected extensive molecular profiles from three NHLBI cohorts (COPDGene, Jackson Heart Study, and SPIROMICS) to discover molecular networks that are important in both diagnosis and progression. In addition to non- Hispanic Whites, by focusing on African Americans, which are highly underrepresented in these types of studies, we expect that there are specific molecular network differences that may lead to specific therapies (i.e., precision medicine) based on race/ethnicity.",Multi-omic networks associated with COPD progression in TOPMed Cohorts,9998187,R01HL152735,"['airway obstruction ', ' airflow limitation ', ' airflow obstruction ', ' airway limitation ', ' obstructed airflow ', ' obstructed airway ', ' alpha 1-Antitrypsin ', ' A1PI ', ' alpha 1 Antiprotease ', ' alpha 1-Antiproteinase ', ' alpha 1-Antitrypsin Trypsin Inhibitor ', ' alpha 1-Protease Inhibitor ', ' alpha 1-Proteinase Inhibitor ', ' 1-Antitrypsin ', ' 1-Proteinase Inhibitor ', ' Biology ', ' Cause of Death ', ' Computers ', ' Diagnosis ', ' Environment ', ' Genetic Markers ', ' genetic biomarker ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Lung ', ' Lung Respiratory System ', ' pulmonary ', ' Chronic Obstructive Airway Disease ', ' COPD ', ' Chronic Obstruction Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Methods ', ' Patients ', ' Phenotype ', ' Publications ', ' Scientific Publication ', ' Pulmonary Emphysema ', ' Emphysema ', ' emphysematous ', ' Race ', ' Racial Group ', ' Racial Stocks ', ' Repression ', ' Research ', ' Research Design ', ' Study Type ', ' study design ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Spirometry ', ' Technology ', ' X-Ray Computed Tomography ', ' CAT scan ', ' CT X Ray ', ' CT Xray ', ' CT imaging ', ' CT scan ', ' Computed Tomography ', ' Tomodensitometry ', ' X-Ray CAT Scan ', ' X-Ray Computerized Tomography ', ' Xray CAT scan ', ' Xray Computed Tomography ', ' Xray computerized tomography ', ' catscan ', ' computed axial tomography ', ' computer tomography ', ' computerized axial tomography ', ' computerized tomography ', ' Work ', ' Afro American ', ' Afroamerican ', ' Black Populations ', ' black American ', ' African American ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Distal ', ' Susceptibility ', ' Predisposition ', ' prognostic ', ' Individual ', ' Sample Size ', ' Disease Progression ', ' Ethnicity ', ' Ethnic Origin ', ' Genetic ', ' Smoker ', ' DNA Methylation ', ' Knowledge ', ' Scientist ', ' Investigation ', ' Complex ', ' Tobacco smoke ', ' Scanning ', ' System ', ' QTL ', ' Quantitative Trait Loci ', ' cohort ', ' novel ', ' Pathogenesis ', ' Network Analysis ', ' Pathway Analysis ', ' Proteomics ', ' single molecule ', ' metabolism measurement ', ' metabonomics ', ' metabolomics ', ' genome sequencing ', ' Data ', ' Molecular Fingerprinting ', ' molecular profile ', ' molecular signature ', ' Molecular Profiling ', ' Epidemiologist ', ' Epigenetic ', ' Epigenetic Change ', ' Epigenetic Mechanism ', ' Epigenetic Process ', ' Non-Hispanic ', ' Nonhispanic ', ' Not Hispanic or Latino ', ' Transcript ', ' Underrepresented Ethnic Minority ', ' under-representation of minorities ', ' underrepresentation of minorities ', ' Underrepresented Minority ', ' Characteristics ', ' Molecular ', ' developmental ', ' Development ', ' chronic airflow limitation ', ' chronic airway obstruction ', ' chronic airflow obstruction ', ' pathway ', ' Pathway interactions ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' protein metabolite ', ' clinical phenotype ', ' disease phenotype ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' Minority ', ' Population ', ' transcriptomics ', ' multidisciplinary ', ' new diagnostics ', ' next generation diagnostics ', ' novel diagnostics ', ' new drug target ', ' new druggable target ', ' new pharmacotherapy target ', ' new therapy target ', ' novel drug target ', ' novel druggable target ', ' novel pharmacotherapy target ', ' novel therapeutic target ', ' novel therapy target ', ' new therapeutic target ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' Jackson Heart Study ', ' precision-based medicine ', ' precision medicine ', ' multiomics ', ' multiple omics ', ' entire genome ', ' full genome ', ' whole genome ', ' TOPMed ', ' Trans-Omics for Precision Medicine ', ' Molecular Disease ', ' unsupervised machine learning ', ' unsupervised learning ', ' sRAGE ', ' soluble RAGE ', ' ']",NHLBI,UNIVERSITY OF COLORADO DENVER,R01,2020,824479,CO-06,0.3711650393550677
"Prognostic Markers of Emphysema Progression Project Summary/Abstract Chronic Obstructive Pulmonary Disease (COPD) affects up to 24 million people in the United States and is projected to be the 3rd leading cause of death worldwide by 2020 with a total cost of $50 billion. COPD has been traditionally dichotomized into the clinical phenotypes of emphysema and chronic bronchitis, but its underlying mechanisms are poorly understood. In particular, emphysema is defined as abnormal, permanent dilation of the distal airspaces. The development and progression of this pathologic process are associated with a decline in lung function and progressive clinical impairment. Computed tomographic (CT) imaging of the chest is increasingly being leveraged to quantify the disease and its progression objectively. Current approaches to quantify emphysema progression are limited and discard most of the spatial and temporal information in CT scans obtained at inspiration and expiration. In this proposal, we plan on developing computational components to prognosticate emphysema progression that builds upon image density markers and lung mechanical strain characteristics conditioned on their underlying emphysema subtypes. This proposal leverages our previous experience in computational emphysema subtyping to discover, validate and translate a novel panel of prognostic markers tailored around the postulated mechanisms of emphysema progression: inflammation injury and mechanical strain. To reach this goals, we will (1) develop an advanced emphysema subtyping approach using novel deep learning architectures, (2) develop a fast mass preserving large displacement registration approach to enable the discovery of local elastic properties of lung tissue between inspiratory and expiration CT scans, (3) discover new subtype-specific biomarker features based on image density relations and mechanical properties using unsupervised deep learning techniques within a common statistical framework, and (4) validate the prognostic value of the proposed biomarkers and their association with decline end-points and clinical outcomes to enable its clinical interpretation and translation. In addition to that, will be explored alternative prognostic models based on advanced machine learning techniques and performed a model comparison study to define the most prognostic model for emphysema progression. Our analysis will process 12,300 scans corresponding to 5,517 subjects with baseline and follow-up data from the COPDGene cohort one of the largest cohort in COPD containing CT images at inspiration and expiration, respiratory and genetic measurements. The proposed methodology will provide reproducible, automatic and low-cost prognostic in-vivo biomarkers of emphysema progression that may enable the discovery of new therapies and translate them into clinical practice. Project Narrative Computed tomographic assessments of emphysema progression based on emphysema subtyping and lung mechanical strain biomarkers in the COPDGene study may provide insight into its prognostication. This may in turn lead to new therapies for patients with COPD.",Prognostic Markers of Emphysema Progression,9865706,R01HL149877,"['Affect ', ' Architecture ', ' Engineering / Architecture ', ' Breathing ', ' Respiratory Aspiration ', ' Respiratory Inspiration ', ' inspiration ', ' Cause of Death ', ' Chronic Bronchitis ', ' Complement ', ' Complement Proteins ', ' Connective Tissue ', ' Disease ', ' Disorder ', ' Fracture ', ' bone fracture ', ' Medical Genetics ', ' Clinical genetics ', ' Goals ', ' Inflammation ', ' Joints ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Lung ', ' Lung Respiratory System ', ' pulmonary ', ' Chronic Obstructive Airway Disease ', ' COPD ', ' Chronic Obstruction Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Maps ', ' Methodology ', ' Pathologic Processes ', ' Pathological Processes ', ' Patients ', ' Plasma ', ' Blood Plasma ', ' Plasma Serum ', ' Reticuloendothelial System, Serum, Plasma ', ' Pulmonary Emphysema ', ' Emphysema ', ' emphysematous ', ' Radiology Specialty ', ' General Radiology ', ' Radiology ', ' Regression Analysis ', ' Regression Analyses ', ' Regression Diagnostics ', ' Statistical Regression ', ' Research ', ' Respiratory physiology ', ' lung function ', ' respiratory function ', ' Risk ', ' Mechanical Stress ', ' Supervision ', ' Tissues ', ' Body Tissues ', ' X-Ray Computed Tomography ', ' CAT scan ', ' CT X Ray ', ' CT Xray ', ' CT imaging ', ' CT scan ', ' Computed Tomography ', ' Tomodensitometry ', ' X-Ray CAT Scan ', ' X-Ray Computerized Tomography ', ' Xray CAT scan ', ' Xray Computed Tomography ', ' Xray computerized tomography ', ' catscan ', ' computed axial tomography ', ' computer tomography ', ' computerized axial tomography ', ' computerized tomography ', ' Translating ', ' Translations ', ' United States ', ' Mediating ', ' injuries ', ' Injury ', ' base ', ' density ', ' improved ', ' Distal ', ' Chronic ', ' Clinical ', ' Histologically ', ' Histologic ', ' Logistic Regressions ', ' Susceptibility ', ' Predisposition ', ' prognostic ', ' Alveolar wall ', ' expiration ', ' insight ', ' Measurement ', ' Disease Progression ', ' Therapeutic ', ' Genetic ', ' Staging ', ' Inflammatory ', ' Deposit ', ' Deposition ', ' Smoker ', ' LVRS ', ' Lung volume reduction surgery ', ' machine learned ', ' Machine Learning ', ' mechanical ', ' Mechanics ', ' Investigation ', ' Tobacco smoke ', ' Scanning ', ' Pattern ', ' Techniques ', ' respiratory ', ' experience ', ' cohort ', ' novel ', ' Reporting ', ' Appearance ', ' Thorace ', ' Thoracic ', ' Thorax ', ' Chest ', ' Lung Parenchyma ', ' Lung Tissue ', ' Structure of parenchyma of lung ', ' Modeling ', ' Property ', ' response ', ' genetic association ', ' Address ', ' Data ', ' Multicellular Inflammation Process ', ' Inflammation Process ', ' Molecular Marker of Prognosis ', ' Prognosis Marker ', ' prognostic biomarker ', ' prognostic indicator ', ' Prognostic Marker ', ' Reproducibility ', ' in vivo ', ' Validation ', ' Characteristics ', ' Process ', ' Active Follow-up ', ' active followup ', ' follow up ', ' followed up ', ' followup ', ' follow-up ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' clinical phenotype ', ' decline in function ', ' decline in functional status ', ' functional status decline ', ' functional decline ', ' cost ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' injury response ', ' response to injury ', ' Outcome ', ' prospective ', ' Impairment ', ' clinical applicability ', ' clinical application ', ' new drug treatments ', ' new drugs ', ' new therapeutics ', ' new therapy ', ' next generation therapeutics ', ' novel drug treatments ', ' novel drugs ', ' novel therapy ', ' novel therapeutics ', ' inclusion criteria ', ' progression biomarker ', ' progression marker ', ' inflammation marker ', ' inflammatory marker ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' clinical practice ', ' Patient risk ', ' prognostic ability ', ' prognostic power ', ' prognostic utility ', ' prognostic value ', ' stratified patient ', ' patient stratification ', ' specific biomarkers ', ' alleviate symptom ', ' ameliorating symptom ', ' decrease symptom ', ' fewer symptoms ', ' relieves symptoms ', ' symptom alleviation ', ' symptom reduction ', ' symptom relief ', ' reduce symptoms ', ' mechanical properties ', ' Risk stratification ', ' Clinical stratification ', ' preservation ', ' deep learning ', ' ConvNet ', ' convolutional network ', ' convolutional neural nets ', ' convolutional neural network ', ' tissue stress ', ' ']",NHLBI,BRIGHAM AND WOMEN'S HOSPITAL,R01,2020,730139,MA-07,0.13166684487005975
"Prediction of COPD Progression by PRM PROJECT ABSTRACT  Chronic obstructive pulmonary disease (COPD) is a highly prevalent and heterogeneous disorder that afflicts nearly 30 million Americans. Current disease staging and therapy is based primarily on spirometry and clinical characteristics. Due to limitations in the standard phenotyping approaches, patients with similarly staged COPD may exhibit strikingly different progression patterns. Small airways disease (SAD), a treatable but occult component of COPD, is a significant contributor to airflow obstruction manifesting early in COPD. In recent years, SAD has been has been implicated as a precursor to the irreversible destruction of lung parenchyma, i.e. emphysema. The ability to predict if and when SAD will lead to emphysema would have an immediate clinical impact on the care of COPD patients. In 2012 we reported on the Parametric Response Map (PRM) analytical technique that when applied to paired inspiratory and expiratory CT scans is capable of simultaneously visualizing and quantifying the extent of functional SAD (fSAD) and emphysema in a single COPD patient. Since then we have made three key advances: first, PRM-derived fSAD is predictive of spirometric decline in COPD patients and emphysema development; second, we have validated in human lung samples that PRM- derived fSAD is a measure of small airway narrowing and loss; and finally, applying techniques to capture regional variation of fSAD within the lung, we have enhanced PRM (topological PRM [tPRM]) to provide a more sensitive measure of local disease severity than what is possible with the original PRM concept. Based on our findings, we postulate that PRM, or its advanced form tPRM, has the potential to predict long-term patient progression. The goal of this proposal will be to use baseline, Year 5 and recently available Year 10 COPDGene data to determine the ability of PRM to predict disease progression through three Specific Aims: 1) Characterize PRM-derived fSAD progression patterns over a 5 and 10 year period; 2) Determine how regional differences in disease distribution, as determined by tPRM, identify regional onset of local emphysema; and 3) Apply machine learning strategies to PRM/tPRM and other clinical metrics to develop models that predict patient disease trajectories. It is our expectation that PRM metrics will identify COPD patients at risk for more rapid disease progression but that utilizing regional information and machine learning strategies will further enhance our approach. The results of such analyses could both identify patients appropriate for more intense, targeted therapy at an early disease stage and contribute to our understanding of the progression of small airways disease and emphysema in COPD. PROJECT NARRATIVE  COPD is a highly prevalent but heterogeneous disorder with rising morbidity and mortality with efforts to develop effective treatments have been hampered by an inability to predict disease progression. This study proposes to apply statistical and deep learning strategies to evaluate novel CT-based analytic techniques as predictors of disease course in a COPD patient cohort. The successful outcome of this study will aid physicians in identifying patients for targeted therapies.",Prediction of COPD Progression by PRM,9865565,R01HL150023,"['airway obstruction ', ' airflow limitation ', ' airflow obstruction ', ' airway limitation ', ' obstructed airflow ', ' obstructed airway ', ' Architecture ', ' Engineering / Architecture ', ' Cohort Studies ', ' Concurrent Studies ', ' Decision Trees ', ' Disease ', ' Disorder ', ' Exhibits ', ' Goals ', ' Heterogeneity ', ' Human ', ' Modern Man ', ' Lung ', ' Lung Respiratory System ', ' pulmonary ', ' Chronic Obstructive Airway Disease ', ' COPD ', ' Chronic Obstruction Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Maps ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Patients ', ' Phenotype ', ' Physicians ', ' Pulmonary Emphysema ', ' Emphysema ', ' emphysematous ', ' Research ', ' Respiratory physiology ', ' lung function ', ' respiratory function ', ' Risk ', ' Sensitivity and Specificity ', ' Spirometry ', ' Testing ', ' X-Ray Computed Tomography ', ' CAT scan ', ' CT X Ray ', ' CT Xray ', ' CT imaging ', ' CT scan ', ' Computed Tomography ', ' Tomodensitometry ', ' X-Ray CAT Scan ', ' X-Ray Computerized Tomography ', ' Xray CAT scan ', ' Xray Computed Tomography ', ' Xray computerized tomography ', ' catscan ', ' computed axial tomography ', ' computer tomography ', ' computerized axial tomography ', ' computerized tomography ', ' Diagnostic radiologic examination ', ' Conventional X-Ray ', ' Diagnostic Radiology ', ' Diagnostic X-Ray ', ' Diagnostic X-Ray Radiology ', ' Radiography ', ' Roentgenography ', ' X-Ray Imaging ', ' X-Ray Medical Imaging ', ' Xray imaging ', ' Xray medical imaging ', ' conventional Xray ', ' diagnostic Xray ', ' diagnostic Xray radiology ', ' Measures ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Variation ', ' Variant ', ' Histologically ', ' Histologic ', ' Lesion ', ' Individual ', ' Disease Progression ', ' Funding ', ' Staging ', ' Smoker ', ' machine learned ', ' Machine Learning ', ' Scanning ', ' Pattern ', ' Techniques ', ' 3-D ', ' 3D ', ' three dimensional ', ' 3-Dimensional ', ' disease severity ', ' Severity of illness ', ' Outcome Study ', ' Visit ', ' American ', ' small airways disease ', ' cohort ', ' expectation ', ' novel ', ' regional difference ', ' disease risk ', ' disorder risk ', ' Reporting ', ' Thorace ', ' Thoracic ', ' Thorax ', ' Chest ', ' Lung Parenchyma ', ' Lung Tissue ', ' Structure of parenchyma of lung ', ' Sampling ', ' Connectionist Models ', ' Neural Network Models ', ' Perceptrons ', ' Neural Network Simulation ', ' response ', ' Diameter ', ' Caliber ', ' Symptoms ', ' Data ', ' Disease Marker ', ' Clinical Data ', ' Pathologic ', ' Characteristics ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' image registration ', ' Outcome ', ' Chronic Care ', ' analytical tool ', ' effective treatment ', ' effective therapy ', ' information model ', ' noninvasive imaging ', ' non-invasive imaging ', ' Therapeutic Trials ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' imaging marker ', ' imaging-based biological marker ', ' imaging-based biomarker ', ' imaging-based marker ', ' imaging biomarker ', ' concept maps ', ' concept mapping ', ' learning activity ', ' learning method ', ' learning strategy ', ' deep learning ', ' ConvNet ', ' convolutional network ', ' convolutional neural nets ', ' convolutional neural network ', ' statistical learning ', ' ']",NHLBI,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2020,700225,MI-12,0.4319816424057508
"Combined Cardiopulmonary Failure in COPD: SPIROMICS HF The death rate and hospitalizations from chronic obstructive pulmonary disease (COPD) have doubled in the last 50 years. A third of COPD hospitalizations overlap with heart failure, mostly with preserved ejection fraction (HFpEF), yet no large COPD study has ascertained cardiac function. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study was funded to test the endothelial hypothesis of emphysema and examine reduced RV dimensions (cor pulmonale parvus) in COPD. In the MESA COPD Study II, we found that associations of reduced pulmonary microvascular blood flow with emphysema do not appear to be confounded by hypoxic pulmonary vasoconstriction and that emphysema on CT predicted RV regression over 5 years. We also developed methods to further subtype emphysema and COPD and scaled them up to the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS). We used unsupervised machine learning to discover new emphysema subtypes that are common and have molecular origins. Separately, we found that 26% of adults have segmental airway variants, which are associated with COPD and the developmental genes FGF10 and RARA. Both genes affect right heart development. In pilot work, we found one dramatically altered RV strain and the other associated with cor pulmonale parvus. Finally, we found that bronchitic symptomatic smokers, who have hyperinflation from gas trapping, may have increased LV diastolic dysfunction. Hence, cardiac alterations in COPD are complex but recent advances in COPD subtyping may allow their personalized diagnosis and treatment. SPIROMICS is an NHLBI-funded prospective study that recruited smokers with COPD and controls and is re-examining 2,000 participants with gold- standard lung phenotyping including full-lung CT. We propose to add comprehensive echocardiography (echo) with speckle-tracking for cardiac mechanics for 1,000 SPIROMICS participants, with exercise in 700 and cardiopulmonary MRI in 600, to test the following hypotheses: 1) machine-learned subtypes of emphysema on CT are associated with specific alterations in cardiac structure and function, which vary from cor pulmonale to LV diastolic dysfunction; 2) participants with segmental airway variants have abnormal RV structure and function; 3) symptomatic smokers have signs of increased LV afterload and LV diastolic dysfunction. Innovative aspects of the application include the use of novel echo and MRI measures in a large, well- characterized cohort of COPD patients. Confirmation of the hypotheses would define the mechanisms of HFpEF in COPD and identify subsets of patients for targeted treatment of cardiopulmonary dysfunction. The death rate and hospitalizations from chronic obstructive pulmonary disease (COPD) have doubled in the last 50 years. A third of COPD hospitalizations overlap with heart failure, mostly with preserved ejection fraction. The proposed study would be the first large study with gold-standard phenotyping of the heart and lungs and would test highly specific hypothesized based upon recent advances in lung subphenotyping to yield personalized approaches to combined cardiopulmonary disease in COPD.",Combined Cardiopulmonary Failure in COPD: SPIROMICS HF,10020427,R01HL093081,"['Adult ', ' 21+ years old ', ' Adult Human ', ' adulthood ', ' Affect ', ' Cardiac Output ', ' heart output ', ' Echocardiography ', ' Echocardiogram ', ' Transthoracic Echocardiography ', ' heart sonography ', ' Endothelium ', ' Exercise ', ' Fibrosis ', ' Gases ', ' Genes ', ' Developmental Gene ', ' Gold ', ' Heart ', ' Heart Atrium ', ' Atrial ', ' Cardiac Atrium ', ' atrium ', ' Heart failure ', ' cardiac failure ', ' Hospitalization ', ' Hospital Admission ', ' indexing ', ' Kinetics ', ' Lung ', ' Lung Respiratory System ', ' pulmonary ', ' Chronic Obstructive Airway Disease ', ' COPD ', ' Chronic Obstruction Pulmonary Disease ', ' Chronic Obstructive Lung Disease ', ' Chronic Obstructive Pulmonary Disease ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' Methods ', ' Pathology ', ' Patients ', ' Phenotype ', ' pressure ', ' Prospective Studies ', ' Pulmonary artery structure ', ' Pulmonary Artery ', ' Pulmonary Emphysema ', ' Emphysema ', ' emphysematous ', ' Pulmonary Fibrosis ', ' lung fibrosis ', ' Pulmonary Heart Disease ', ' Cor pulmonale ', ' Pulmonary Heart Disorder ', ' cardiopulmonary disease ', ' cardiopulmonary disorder ', ' Suggestion ', ' Technology ', ' Testing ', ' vasoconstriction ', ' vascular constriction ', ' Work ', ' Measures ', ' Outcome Measure ', ' Right Ventricular Hypertrophy ', ' base ', ' Apical ', ' Diffuse ', ' Variation ', ' Variant ', ' Death Rate ', ' Right Ventricles ', ' Right ventricular structure ', ' Failure ', ' cardiac function ', ' function of the heart ', ' heart function ', ' Blood flow ', ' Funding ', ' Dysfunction ', ' Physiopathology ', ' pathophysiology ', ' Functional disorder ', ' Smoker ', ' machine learned ', ' Machine Learning ', ' mechanical ', ' Mechanics ', ' Dimensions ', ' Complex ', ' Ejection Fraction ', ' EFRAC ', ' Cardiopulmonary ', ' cardiac preservation ', ' heart preservation ', ' interstitial ', ' Receptor Protein ', ' receptor ', ' pulmonary hypoxia ', ' lung hypoxia ', ' cohort ', ' Structure ', ' novel ', ' Participant ', ' Coding System ', ' Code ', ' Sampling ', ' disease subgroups ', ' disease subtype ', ' disorder subtype ', ' disease control ', ' disorder control ', ' Drops ', ' pulmonary failure ', ' respiratory insufficiency/failure ', ' Respiratory Failure ', ' heart development ', ' heart formation ', ' cardiogenesis ', ' DRD1 ', ' Dopamine Receptor D1 Gene ', ' DRD1 gene ', ' FGF-10 ', ' FGF10 ', ' fibroblast growth factor 10 ', ' FGF10 gene ', ' NR1B1 ', ' RARA ', ' Retinoic Acid Receptor Alpha Gene ', ' RARA gene ', ' Molecular ', ' Myocardial ', ' Ventricular ', ' Cardiac ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' innovate ', ' innovative ', ' innovation ', ' Impairment ', ' new diagnostics ', ' next generation diagnostics ', ' novel diagnostics ', ' new therapeutic approach ', ' new therapeutic intervention ', ' new therapeutic strategies ', ' new therapy approaches ', ' novel therapeutic approach ', ' novel therapy approach ', ' novel therapeutic intervention ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' personalized diagnosis ', ' precise diagnostics ', ' precision diagnostics ', ' personalized diagnostics ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' CT Lung Screening ', ' Lung CT ', ' Lung CT scan ', ' computerized tomography lung screening ', ' lung computerized axial tomography scan ', ' lung computerized tomography ', ' lung computerized tomography scan ', ' Lung CAT Scan ', ' Personalized medical approach ', ' individualized approach ', ' precision approach ', ' tailored approach ', ' personalized approach ', ' patient subgroups ', ' patient subpopulations ', ' patient subtypes ', ' patient subsets ', ' Multi-Ethnic Study of Atherosclerosis ', ' recruit ', ' preservation ', ' unsupervised machine learning ', ' unsupervised learning ', ' ']",NHLBI,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2020,2331272,NY-13,0.4741370876605206
